

517 333

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 December 2003 (18.12.2003)

PCT

(10) International Publication Number
WO 03/104458 A1

(51) International Patent Classification⁷: C12N 15/11

(21) International Application Number: PCT/US03/18003

(22) International Filing Date: 9 June 2003 (09.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/167,034 10 June 2002 (10.06.2002) US

(71) Applicant (for all designated States except US): **ISIS PHARMACEUTICALS, INC.** [US/US]; 2292 Faraday Avenue, Carlsbad, CA 92008 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BAKER, Brenda, F.** [US/US]; 2147 Avenida Toronja, Carlsbad, CA 92009 (US). **FREIER, Susan, M.** [US/US]; 2946 Renault Street, San Diego, CA 92112 (US). **DOBIE, Kenneth, W.** [GB/US]; 703 Stratford Court, #4, Del Mar, CA 92014 (US).

(74) Agents: **CALDWELL, John, W.** et al.; Woodcock Washburn LLP, One Liberty Place - 46th Floor, Philadelphia, PA 19103 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-1 EXPRESSION

(57) Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of IL-1 receptor-associated kinase-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding IL-1 receptor-associated kinase-1. Methods of using these compounds for modulation of IL-1 receptor-associated kinase-1 expression and for treatment of diseases associated with expression of IL-1 receptor-associated kinase-1 are provided.



WO 03/104458 A1

Rec'd FCT/PTC 09 DEC 2004

- 1 -

5 ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-1
EXPRESSION

10 FIELD OF THE INVENTION

The present invention provides compositions and methods for modulating the expression of IL-1 receptor-associated kinase-1. In particular, this invention relates to compounds, particularly oligonucleotides, specifically hybridizable with nucleic acids encoding IL-1 receptor-associated kinase-1. Such compounds have been shown to modulate the expression of IL-1 receptor-associated kinase-1.

BACKGROUND OF THE INVENTION

20 The proinflammatory cytokine interleukin-1 (IL-1) is a
central regulator in immune and inflammatory responses,
involved in generating systemic and local response to
infection, injury, and immunologic challenges. IL-1 is
produced mainly by activated macrophages and monocytes, and
25 participates in lymphocyte activation, induction of fever,
leukocyte trafficking, the acute phase response, and
cartilage remodeling. The expression of more than 90 genes is
affected by IL-1, including genes that encode other
cytokines, cytokine receptors, acute-phase reactants, growth
30 factors, tissue-remodeling enzymes, extracellular matrix
components, and cell adhesion molecules. IL-1 is a critical

-2-

cytokine in the pathogenesis of viral infections and inflammatory diseases such as rheumatoid arthritis (O'Neill and Greene, *J. Leukoc. Biol.*, **1998**, 63, 650-657).

Cellular responses are transduced through the type I IL-1 receptor (IL-1RI), located on the plasma membrane of a variety of IL-1-responsive cells. Binding of IL-1 to IL-1RI ultimately triggers activation of transcription factors in the NF- κ B family, which are bound by inhibitory proteins (IkBs) and remain anchored in the cytoplasm until the inhibitory proteins are degraded. In response to IL-1, tumor necrosis factor (TNF), or other extracellular stimuli such as lipopolysaccharides, double-stranded RNA, or oxidative stress, and once unbound and activated, NF- κ B is then transported to the nucleus, where it influences the activity of many genes (O'Neill and Greene, *J. Leukoc. Biol.*, **1998**, 63, 650-657).

A family of proteins has been described that share significant homology with the type I IL-1 receptor in their signaling domains. This family includes IL-1 receptor accessory protein (IL1-RAcP), which does not bind IL-1, but is essential for IL-1 signaling; a *Drosophila* receptor protein, Toll; a number of human Toll-like receptors (hTLRs); the interferon- γ -inducing factor/IL-1 γ / IL-18 receptor-related protein (IL-1Rrp), a number of plant proteins, and the IL-1 receptor-associated kinases (IRAK-1, IRAK-2, and IRAK-M). All members of this family appear to be involved in host responses to injury and infection (O'Neill and Greene, *J. Leukoc. Biol.*, **1998**, 63, 650-657; Wesche et al., *J. Biol. Chem.*, **1999**, 274, 19403-19410).

IL-1 receptor-associated kinase-1 (also known as interleukin 1 receptor-associated kinase 1, IRAK1, IRAK-1, Illrak, mouse Pelle -like kinase, and mPLK) was purified from human embryonic kidney epithelial cell line 293, and its

-3-

amino acid sequence was determined by micropeptide sequencing. PCR was then used to amplify a probe, and the gene was cloned from a human teratocarcinoma cDNA library. The IL-1 receptor-associated kinase-1 gene encodes a 3.5-kb mRNA that was detected in all tissues examined (Cao et al.,
5 *Science*, **1996**, 271, 1128-1131). The IL-1 receptor-associated kinase-1 gene has been mapped to the human X chromosome region q28, and a homologous region XA7-C on mouse chromosome X (Reichwald et al., *Mamm. Genome*, **2000**, 11, 182-190).

10 The IL-1 signaling pathway in mammals is analogous to the Toll pathway in *Drosophila melanogaster*. Homologues of IL-1 receptor-associated kinase-1 are found in *D. melanogaster* (Pelle) and in plants (Pto), and in these systems, the kinases have been shown to be components of a
15 signal transduction system leading to the activation of NF- κ B. In fact, because of their homology to several components of the NF- κ B signaling pathway in *D. melanogaster*, new mammalian proteins of the IL-1RI signaling system and their functions are being elucidated (Burns et al., *Nat. Cell*
20 *Biol.*, **2000**, 2, 346-351; O'Neill and Greene, *J. Leukoc. Biol.*, **1998**, 63, 650-657; Vig et al., *J. Biol. Chem.*, **2001**, 276, 7859-7866). A novel signaling molecule that associates with the mouse Pelle-like kinase, SIMPL, was recently identified in mice, and found to bind to IL-1 receptor
25 associated kinase (Vig et al., *J. Biol. Chem.*, **2001**, 276, 7859-7866). Additionally, a novel protein, Tollip, was found to associate with the activated IL-1RI/IL-1RAcP complex (Burns et al., *Nat. Cell Biol.*, **2000**, 2, 346-351).

When cells receive the extracellular IL-1 signal, a
30 complex between IL-1RI and IL-1RAcP is formed (Huang et al., *Proc. Natl. Acad. Sci. U. S. A.*, **1997**, 94, 12829-12832), the cytosolic adapter protein MyD88 interacts with IL-1RAcP in the receptor complex (Burns et al., *J. Biol. Chem.*, **1998**,

-4-

273, 12203-12209), and MyD88 rapidly recruits IL-1 receptor-associated kinase-1 into the complex. Tollip also interacts with IL-1RAcP and is believed to block autophosphorylation of the IL-1 receptor-associated kinase-1 or its association with another kinase; thus, the association of Tollip with IL-1 receptor-associated kinase-1 is inhibitory (Burns et al., *Nat. Cell Biol.*, **2000**, 2, 346-351). At some point after its IL-1-dependent association with the receptor complex, IL-1 receptor-associated kinase-1 is extensively phosphorylated and its own serine/threonine kinase catalytic activity becomes activated (Cao et al., *Science*, **1996**, 271, 1128-1131). IL-1 receptor-associated kinase-1 then interacts with an adapter protein, TRAF6, a protein critical for IL-1-dependent activation of NF- κ B, which dissociates from the receptor complex. TRAF6 relays a signal via NF- κ B-inducing kinase (NIK) to two I- κ B kinases (IKK-1 and -2), culminating in activation of NF- κ B (Bacher et al., *FEBS Lett.*, **2001**, 497, 153-158; Jefferies et al., *Mol. Cell. Biol.*, **2001**, 21, 4544-4552; O'Neill and Greene, *J. Leukoc. Biol.*, **1998**, 63, 650-657).

Cellular trafficking and nuclear importation may play a role in the timing and/or activity of IL-1 receptor-associated kinase-1 mediated signaling. Association of IL-1 receptor-associated kinase-1 with the receptor complex is detectable 30 seconds after IL-1 stimulation of human umbilical cord vein ECV 304 cells, and significant levels of IL-1 receptor-associated kinase-1 accumulate in the nucleus within 30 minutes (Bol et al., *FEBS Lett.*, **2000**, 477, 73-78).

There is evidence that hyperphosphorylation of IL-1 receptor-associated kinase-1 is regulatory and results in proteolytic degradation. A nonspecific kinase inhibitor blocks proteolysis of IL-1 receptor-associated kinase-1 as well as its phosphorylation, and the translocation of IL-1

-5-

receptor-associated kinase-1 to the IL-1RI/IL-1RAcP complex is independent of this treatment. Degradation of the IL-1 receptor-associated kinase-1 component of this signaling pathway may explain why some IL-1 responses are transient

5 (Yamin and Miller, *J. Biol. Chem.*, **1997**, 272, 21540-21547).

IL-1 receptor-associated kinase-1 plays a role in regulation of multiple signaling pathways. In addition to transducing the IL-1 signal, IL-1 receptor-associated kinase-1 also transduces a signal initiated by binding of tumor

10 necrosis factor (TNF)- α to its receptor, again leading to activation of NF- κ B (Vig et al., *J. Biol. Chem.*, **1999**, 274, 13077-13084; Vig et al., *J. Biol. Chem.*, **2001**, 276, 7859-7866). In another signal transduction pathway separate from its activation of NF- κ B, IL-1 receptor-associated kinase-1

15 has also been implicated in activation of the Jun amino-terminal kinase (JNK) and the transcription factor AP-1 (Bacher et al., *FEBS Lett.*, **2001**, 497, 153-158).

The IL-1 receptor-associated kinase-1 gene has been disrupted in mice. Upon IL-1 treatment, IL-1 receptor-

20 associated kinase-1-deficient embryonic fibroblasts derived from these mice are defective in activation of JNK, p38 MAP kinase, and NF- κ B (Kanakaraj et al., *J. Exp. Med.*, **1998**, 187, 2073-2079). Furthermore, in T helper cell type 1 (Th1) cells from the IL-1 receptor-associated kinase-1 null mice, IL-18-

25 induced production of interferon (IFN)- γ was substantially reduced, proliferation of the Th1 cells was decreased, activation of natural killer (NK) cells was defective, and these defects resulted in an impaired immune response to murine cytomegalovirus (MCMV) infection (Kanakaraj et al., *J.*

30 *Exp. Med.*, **1999**, 189, 1129-1138).

In a separate study, IL-1 receptor-associated kinase-1-deficient mice and fibroblasts were generated, and it was further demonstrated that IL-1 receptor-associated kinase-1

-6-

null mice retain a normal response to *Listeria monocytogenes* infection (Thomas et al., *J. Immunol.*, **1999**, 163, 978-984).

The pharmacological modulation of IL-1 receptor-associated kinase-1 activity and/or expression is therefore
5 believed to be an appropriate point of therapeutic intervention in pathological conditions such as viral infections, rheumatoid arthritis, and other inflammatory disease and immune disorders.

To date, investigative strategies aimed at studying the
10 localization and function of IL-1 receptor-associated kinase-1 have involved the use of antibodies, transgenic animals and IL-1 receptor-associated kinase-1-deficient cell lines, and an antisense oligonucleotide.

Disclosed and claimed in US Patent 5,654,397 are nucleic
15 acids which encode IL-1 receptor-associated kinase-1 and methods for screening chemical libraries and identifying lead compounds to be used as pharmacological agents in the diagnosis and treatment of disease associated with interleukin-1 signal transduction (Cao et al., **1997**).

IL-1 receptor-associated kinase-1 specific antibodies
20 have been raised and used to study IL-1 receptor-associated kinase-1 (Cao et al., *Science*, **1996**, 271, 1128-1131) and its interactions with the IL-1RI/IL-1RAcP complex (Volpe et al., *FEBS Lett.*, **1997**, 419, 41-44) and to demonstrate that the phosphorylated form of IL-1 receptor-associated kinase-1 is
25 degraded (Yamin and Miller, *J. Biol. Chem.*, **1997**, 272, 21540-21547).

A phosphorothioate antisense oligonucleotide, 18
nucleotides in length, targeted to a region from nucleotide -
30 6 to nucleotide 12 of the mRNA encoding the human IL-1 receptor-associated kinase-1 and spanning the translation initiation site, was used to show that inhibition of expression of IL-1 receptor-associated kinase-1 blocks

3/

-7-

activation of NF- κ B (Guo and Wu, *Immunopharmacology*, 2000, 49, 241-246).

Disclosed and claimed in US Patent 6,166,289 is a transgenic mouse whose somatic and germ cells comprise a
5 disruption in an endogenous IL-1 receptor-associated kinase-1 gene, wherein the disruption is generated by targeted replacement with a non-functional IL-1 receptor-associated kinase-1 gene, and wherein said disruption results in IL-1 receptor-associated kinase-1-deficient cells from said mouse
10 having a decrease in activation of JNK, activation of p38, and induction of IL-6 in response to IL-1 as compared to wild-type mice, as well as a method for producing this transgenic mouse (Harris et al., 2000).

Disclosed and claimed in US Patent 6,127,176 is a mutant
15 cell that lacks a functional IL-1 receptor-associated kinase-1 and comprise an HSV thymidine kinase gene operatively linked to an IL-1 promoter and zeomycin resistance gene operatively linked to an IL-1 promoter, as well as a method of making a mutant mammalian cell that lacks a functional
20 component of the IL-1 signaling pathway and the TNF signaling pathways (Stark and Li, 2000).

Disclosed and claimed in US Patent 5,817,479 are polynucleotides which identify and encode novel protein kinases expressed in various human cells and tissues, wherein
25 one of the kinases is IL-1 receptor-associated kinase-1. Further claimed are expression vectors, host cells, and methods for the production of purified kinase peptides, antibodies capable of binding the kinases, and inhibitors of the kinases as well as antisense sequences and
30 oligonucleotides designed from the polynucleotides or their complements (Au-Young et al., 1998).

Currently, there are no known therapeutic agents which effectively inhibit the synthesis of IL-1 receptor-associated

-8-

kinase-1. Consequently, there remains a long felt need for agents capable of effectively inhibiting IL-1 receptor-associated kinase-1 function.

Antisense technology is emerging as an effective means
5 for reducing the expression of specific gene products and may therefore prove to be uniquely useful in a number of therapeutic, diagnostic, and research applications for the modulation of IL-1 receptor-associated kinase-1 expression.

The present invention provides compositions and methods
10 for modulating IL-1 receptor-associated kinase-1 expression.

SUMMARY OF THE INVENTION

The present invention is directed to compounds,
15 particularly antisense oligonucleotides, which are targeted to a nucleic acid encoding IL-1 receptor-associated kinase-1, and which modulate the expression of IL-1 receptor-associated kinase-1. Pharmaceutical and other compositions comprising the compounds of the invention are also provided. Further
20 provided are methods of modulating the expression of IL-1 receptor-associated kinase-1 in cells or tissues comprising contacting said cells or tissues with one or more of the antisense compounds or compositions of the invention. Further provided are methods of treating an animal,
25 particularly a human, suspected of having or being prone to a disease or condition associated with expression of IL-1 receptor-associated kinase-1 by administering a therapeutically or prophylactically effective amount of one or more of the antisense compounds or compositions of the
30 invention.

DETAILED DESCRIPTION OF THE INVENTION

The present invention employs oligomeric compounds,

-9-

particularly antisense oligonucleotides, for use in modulating the function of nucleic acid molecules encoding IL-1 receptor-associated kinase-1, ultimately modulating the amount of IL-1 receptor-associated kinase-1 produced. This is accomplished by providing antisense compounds which specifically hybridize with one or more nucleic acids encoding IL-1 receptor-associated kinase-1. As used herein, the terms "target nucleic acid" and "nucleic acid encoding IL-1 receptor-associated kinase-1" encompass DNA encoding IL-1 receptor-associated kinase-1, RNA (including pre-mRNA and mRNA) transcribed from such DNA, and also cDNA derived from such RNA. The specific hybridization of an oligomeric compound with its target nucleic acid interferes with the normal function of the nucleic acid. This modulation of function of a target nucleic acid by compounds which specifically hybridize to it is generally referred to as "antisense". The functions of DNA to be interfered with include replication and transcription. The functions of RNA to be interfered with include all vital functions such as, for example, translocation of the RNA to the site of protein translation, translocation of the RNA to sites within the cell which are distant from the site of RNA synthesis, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA. The overall effect of such interference with target nucleic acid function is modulation of the expression of IL-1 receptor-associated kinase-1. In the context of the present invention, "modulation" means either an increase (stimulation) or a decrease (inhibition) in the expression of a gene. In the context of the present invention, inhibition is the preferred form of modulation of gene expression and mRNA is a preferred target.

-10-

It is preferred to target specific nucleic acids for antisense. "Targeting" an antisense compound to a particular nucleic acid, in the context of this invention, is a multistep process. The process usually begins with the

5 identification of a nucleic acid sequence whose function is to be modulated. This may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent. In the

10 present invention, the target is a nucleic acid molecule encoding IL-1 receptor-associated kinase-1. The targeting process also includes determination of a site or sites within this gene for the antisense interaction to occur such that the desired effect, e.g., detection or modulation of

15 expression of the protein, will result. Within the context of the present invention, a preferred intragenic site is the region encompassing the translation initiation or termination codon of the open reading frame (ORF) of the gene. Since, as is known in the art, the translation initiation codon is

20 typically 5'-AUG (in transcribed mRNA molecules; 5'-ATG in the corresponding DNA molecule), the translation initiation codon is also referred to as the "AUG codon," the "start codon" or the "AUG start codon". A minority of genes have a translation initiation codon having the RNA sequence 5'-GUG,

25 5'-UUG or 5'-CUG, and 5'-AUA, 5'-ACG and 5'-CUG have been shown to function *in vivo*. Thus, the terms "translation initiation codon" and "start codon" can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or

30 formylmethionine (in prokaryotes). It is also known in the art that eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in a

-11-

particular cell type or tissue, or under a particular set of conditions. In the context of the invention, "start codon" and "translation initiation codon" refer to the codon or codons that are used *in vivo* to initiate translation of an mRNA molecule transcribed from a gene encoding IL-1 receptor-associated kinase-1, regardless of the sequence(s) of such codons.

It is also known in the art that a translation termination codon (or "stop codon") of a gene may have one of three sequences, i.e., 5'-UAA, 5'-UAG and 5'-UGA (the corresponding DNA sequences are 5'-TAA, 5'-TAG and 5'-TGA, respectively). The terms "start codon region" and "translation initiation codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation initiation codon. Similarly, the terms "stop codon region" and "translation termination codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation termination codon.

The open reading frame (ORF) or "coding region," which is known in the art to refer to the region between the translation initiation codon and the translation termination codon, is also a region which may be targeted effectively. Other target regions include the 5' untranslated region (5'UTR), known in the art to refer to the portion of an mRNA in the 5' direction from the translation initiation codon, and thus including nucleotides between the 5' cap site and the translation initiation codon of an mRNA or corresponding nucleotides on the gene, and the 3' untranslated region (3'UTR), known in the art to refer to the portion of an mRNA in the 3' direction from the translation termination codon,

-12-

and thus including nucleotides between the translation termination codon and 3' end of an mRNA or corresponding nucleotides on the gene. The 5' cap of an mRNA comprises an N7-methylated guanosine residue joined to the 5'-most residue of the mRNA via a 5'-5' triphosphate linkage. The 5' cap region of an mRNA is considered to include the 5' cap structure itself as well as the first 50 nucleotides adjacent to the cap. The 5' cap region may also be a preferred target region.

Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions, known as "introns," which are excised from a transcript before it is translated. The remaining (and therefore translated) regions are known as "exons" and are spliced together to form a continuous mRNA sequence. mRNA splice sites, i.e., intron-exon junctions, may also be preferred target regions, and are particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular mRNA splice product is implicated in disease.

Aberrant fusion junctions due to rearrangements or deletions are also preferred targets. mRNA transcripts produced via the process of splicing of two (or more) mRNAs from different gene sources are known as "fusion transcripts". It has also been found that introns can be effective, and therefore preferred, target regions for antisense compounds targeted, for example, to DNA or pre-mRNA.

It is also known in the art that alternative RNA transcripts can be produced from the same genomic region of DNA. These alternative transcripts are generally known as "variants". More specifically, "pre-mRNA variants" are transcripts produced from the same genomic DNA that differ from other transcripts produced from the same genomic DNA in

-13-

either their start or stop position and contain both intronic and extronic regions.

Upon excision of one or more exon or intron regions or portions thereof during splicing, pre-mRNA variants produce smaller "mRNA variants". Consequently, mRNA variants are processed pre-mRNA variants and each unique pre-mRNA variant must always produce a unique mRNA variant as a result of splicing. These mRNA variants are also known as "alternative splice variants". If no splicing of the pre-mRNA variant occurs then the pre-mRNA variant is identical to the mRNA variant.

It is also known in the art that variants can be produced through the use of alternative signals to start or stop transcription and that pre-mRNAs and mRNAs can possess more than one start codon or stop codon. Variants that originate from a pre-mRNA or mRNA that use alternative start codons are known as "alternative start variants" of that pre-mRNA or mRNA. Those transcripts that use an alternative stop codon are known as "alternative stop variants" of that pre-mRNA or mRNA. One specific type of alternative stop variant is the "polyA variant" in which the multiple transcripts produced result from the alternative selection of one of the "polyA stop signals" by the transcription machinery, thereby producing transcripts that terminate at unique polyA sites.

Once one or more target sites have been identified, oligonucleotides are chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired effect.

In the context of this invention, "hybridization" means hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases. For example, adenine and

-14-

thymine are complementary nucleobases which pair through the formation of hydrogen bonds. "Complementary," as used herein, refers to the capacity for precise pairing between two nucleotides. For example, if a nucleotide at a certain position of an oligonucleotide is capable of hydrogen bonding with a nucleotide at the same position of a DNA or RNA molecule, then the oligonucleotide and the DNA or RNA are considered to be complementary to each other at that position. The oligonucleotide and the DNA or RNA are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides which can hydrogen bond with each other. Thus, "specifically hybridizable" and "complementary" are terms which are used to indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the oligonucleotide and the DNA or RNA target. It is understood in the art that the sequence of an antisense compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable.

An antisense compound is specifically hybridizable when binding of the compound to the target DNA or RNA molecule interferes with the normal function of the target DNA or RNA to cause a loss of activity, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, and in the case of in vitro assays, under conditions in which the assays are performed. It is preferred that the antisense compounds of the present invention comprise at least 80% sequence complementarity to a target region within the target nucleic acid, moreover that

-15-

they comprise 90% sequence complementarity and even more comprise 95% sequence complementarity to the target region within the target nucleic acid sequence to which they are targeted. For example, an antisense compound in which 18 of
5 20 nucleobases of the antisense compound are complementary, and would therefore specifically hybridize, to a target region would represent 90 percent complementarity. Percent complementarity of an antisense compound with a region of a target nucleic acid can be determined routinely using basic
10 local alignment search tools (BLAST programs) (Altschul et al., *J. Mol. Biol.*, **1990**, 215, 403-410; Zhang and Madden, *Genome Res.*, **1997**, 7, 649-656).

Antisense and other compounds of the invention, which hybridize to the target and inhibit expression of the target,
15 are identified through experimentation, and representative sequences of these compounds are hereinbelow identified as preferred embodiments of the invention. The sites to which these preferred antisense compounds are specifically hybridizable are hereinbelow referred to as "preferred target
20 regions" and are therefore preferred sites for targeting. As used herein the term "preferred target region" is defined as at least an 8-nucleobase portion of a target region to which an active antisense compound is targeted. While not wishing to be bound by theory, it is presently believed that these
25 target regions represent regions of the target nucleic acid which are accessible for hybridization.

While the specific sequences of particular preferred target regions are set forth below, one of skill in the art will recognize that these serve to illustrate and describe
30 particular embodiments within the scope of the present invention. Additional preferred target regions may be identified by one having ordinary skill.

-16-

Target regions 8-80 nucleobases in length comprising a stretch of at least eight (8) consecutive nucleobases selected from within the illustrative preferred target regions are considered to be suitable preferred target regions as well.

Exemplary good preferred target regions include DNA or RNA sequences that comprise at least the 8 consecutive nucleobases from the 5'-terminus of one of the illustrative preferred target regions (the remaining nucleobases being a consecutive stretch of the same DNA or RNA beginning immediately upstream of the 5'-terminus of the target region and continuing until the DNA or RNA contains about 8 to about 80 nucleobases). Similarly good preferred target regions are represented by DNA or RNA sequences that comprise at least the 8 consecutive nucleobases from the 3'-terminus of one of the illustrative preferred target regions (the remaining nucleobases being a consecutive stretch of the same DNA or RNA beginning immediately downstream of the 3'-terminus of the target region and continuing until the DNA or RNA contains about 8 to about 80 nucleobases). One having skill in the art, once armed with the empirically-derived preferred target regions illustrated herein will be able, without undue experimentation, to identify further preferred target regions. In addition, one having ordinary skill in the art will also be able to identify additional compounds, including oligonucleotide probes and primers, that specifically hybridize to these preferred target regions using techniques available to the ordinary practitioner in the art.

Antisense compounds are commonly used as research reagents and diagnostics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used by those of ordinary skill to elucidate the function of particular genes.

-17-

Antisense compounds are also used, for example, to distinguish between functions of various members of a biological pathway. Antisense modulation has, therefore, been harnessed for research use.

5 For use in kits and diagnostics, the antisense compounds of the present invention, either alone or in combination with other antisense compounds or therapeutics, can be used as tools in differential and/or combinatorial analyses to elucidate expression patterns of a portion or the entire
10 complement of genes expressed within cells and tissues.

 Expression patterns within cells or tissues treated with one or more antisense compounds are compared to control cells or tissues not treated with antisense compounds and the patterns produced are analyzed for differential levels of
15 gene expression as they pertain, for example, to disease association, signaling pathway, cellular localization, expression level, size, structure or function of the genes examined. These analyses can be performed on stimulated or unstimulated cells and in the presence or absence of other
20 compounds which affect expression patterns.

 Examples of methods of gene expression analysis known in the art include DNA arrays or microarrays (Brazma and Vilo, *FEBS Lett.*, **2000**, 480, 17-24; Celis, et al., *FEBS Lett.*, **2000**, 480, 2-16), SAGE (serial analysis of gene
25 expression) (Madden, et al., *Drug Discov. Today*, **2000**, 5, 415-425), READS (restriction enzyme amplification of digested cDNAs) (Prashar and Weissman, *Methods Enzymol.*, **1999**, 303, 258-72), TOGA (total gene expression analysis) (Sutcliffe, et al., *Proc. Natl. Acad. Sci. U. S. A.*, **2000**, 97, 1976-81),
30 protein arrays and proteomics (Celis, et al., *FEBS Lett.*, **2000**, 480, 2-16; Jungblut, et al., *Electrophoresis*, **1999**, 20, 2100-10), expressed sequence tag (EST) sequencing (Celis, et al., *FEBS Lett.*, **2000**, 480, 2-16; Larsson, et al., J.

-18-

Biotechnol., **2000**, 80, 143-57), subtractive RNA fingerprinting (SuRF) (Fuchs, et al., *Anal. Biochem.*, **2000**, 286, 91-98; Larson, et al., *Cytometry*, **2000**, 41, 203-208), subtractive cloning, differential display (DD) (Jurecic and Belmont, *Curr. Opin. Microbiol.*, **2000**, 3, 316-21), comparative genomic hybridization (Carulli, et al., *J. Cell Biochem. Suppl.*, **1998**, 31, 286-96), FISH (fluorescent *in situ* hybridization) techniques (Going and Gusterson, *Eur. J. Cancer*, **1999**, 35, 1895-904) and mass spectrometry methods (reviewed in To, *Comb. Chem. High Throughput Screen*, **2000**, 3, 235-41).

The specificity and sensitivity of antisense is also harnessed by those of skill in the art for therapeutic uses. Antisense oligonucleotides have been employed as therapeutic moieties in the treatment of disease states in animals and man. Antisense oligonucleotide drugs, including ribozymes, have been safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus established that oligonucleotides can be useful therapeutic modalities that can be configured to be useful in treatment regimes for treatment of cells, tissues and animals, especially humans.

In the context of this invention, the term "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. This term includes oligonucleotides composed of naturally-occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally-occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid

-19-

target and increased stability in the presence of nucleases.

While antisense oligonucleotides are a preferred form of antisense compound, the present invention comprehends other oligomeric antisense compounds, including but not
5 limited to oligonucleotide mimetics such as are described below. The antisense compounds in accordance with this invention preferably comprise from about 8 to about 80 nucleobases (i.e. from about 8 to about 80 linked nucleosides). Particularly preferred antisense compounds are
10 antisense oligonucleotides from about 8 to about 50 nucleobases, even more preferably those comprising from about 12 to about 30 nucleobases. Antisense compounds include ribozymes, external guide sequence (EGS) oligonucleotides (oligozymes), and other short catalytic RNAs or catalytic
15 oligonucleotides which hybridize to the target nucleic acid and modulate its expression.

Antisense compounds 8-80 nucleobases in length comprising a stretch of at least eight (8) consecutive nucleobases selected from within the illustrative antisense
20 compounds are considered to be suitable antisense compounds as well.

Exemplary preferred antisense compounds include DNA or RNA sequences that comprise at least the 8 consecutive nucleobases from the 5'-terminus of one of the illustrative
25 preferred antisense compounds (the remaining nucleobases being a consecutive stretch of the same DNA or RNA beginning immediately upstream of the 5'-terminus of the antisense compound which is specifically hybridizable to the target nucleic acid and continuing until the DNA or RNA contains
30 about 8 to about 80 nucleobases). Similarly preferred antisense compounds are represented by DNA or RNA sequences that comprise at least the 8 consecutive nucleobases from the 3'-terminus of one of the illustrative preferred antisense

-20-

compounds (the remaining nucleobases being a consecutive stretch of the same DNA or RNA beginning immediately downstream of the 3'-terminus of the antisense compound which is specifically hybridizable to the target nucleic acid and continuing until the DNA or RNA contains about 8 to about 80 nucleobases). One having skill in the art, once armed with the empirically-derived preferred antisense compounds illustrated herein will be able, without undue experimentation, to identify further preferred antisense compounds.

Antisense and other compounds of the invention, which hybridize to the target and inhibit expression of the target, are identified through experimentation, and representative sequences of these compounds are herein identified as preferred embodiments of the invention. While specific sequences of the antisense compounds are set forth herein, one of skill in the art will recognize that these serve to illustrate and describe particular embodiments within the scope of the present invention. Additional preferred antisense compounds may be identified by one having ordinary skill.

As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to either the 2', 3' or 5' hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn, the respective ends of this

-21-

linear polymeric structure can be further joined to form a circular structure, however, open linear structures are generally preferred. In addition, linear structures may also have internal nucleobase complementarity and may therefore
5 fold in a manner as to produce a double stranded structure. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal linkage or backbone of RNA and DNA is a 3' to 5' phosphodiester linkage.

10 Specific examples of preferred antisense compounds useful in this invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus
15 atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to
20 be oligonucleosides.

Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-
25 alkylene phosphonates, 5'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, selenophosphates and borano-
30 phosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein one or more internucleotide linkages is a 3' to 3', 5' to 5' or 2' to 2' linkage. Preferred oligonucleotides having inverted

-22-

polarity comprise a single 3' to 3' linkage at the 3'-most internucleotide linkage i.e. a single inverted nucleoside residue which may be abasic (the nucleobase is missing or has a hydroxyl group in place thereof). Various salts, mixed
5 salts and free acid forms are also included.

Representative United States patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S.: 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423;
10 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; 5,194,599; 5,565,555; 5,527,899; 5,721,218; 5,672,697 and 5,625,050, certain of which are
15 commonly owned with this application, and each of which is herein incorporated by reference.

Preferred modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside
20 linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones;
25 sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; riboacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide
30 backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts.

Representative United States patents that teach the preparation of the above oligonucleosides include, but are

-23-

not limited to, U.S.: 5,034,506; 5,166,315; 5,185,444;
5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564;
5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677;
5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289;
5 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070;
5,663,312; 5,633,360; 5,677,437; 5,792,608; 5,646,269 and
5,677,439, certain of which are commonly owned with this
application, and each of which is herein incorporated by
reference.

10 In other preferred oligonucleotide mimetics, both the
sugar and the internucleoside linkage, i.e., the backbone, of
the nucleotide units are replaced with novel groups. The
base units are maintained for hybridization with an
appropriate nucleic acid target compound. One such
15 oligomeric compound, an oligonucleotide mimetic that has been
shown to have excellent hybridization properties, is referred
to as a peptide nucleic acid (PNA). In PNA compounds, the
sugar-backbone of an oligonucleotide is replaced with an
amide containing backbone, in particular an aminoethylglycine
20 backbone. The nucleobases are retained and are bound
directly or indirectly to aza nitrogen atoms of the amide
portion of the backbone. Representative United States
patents that teach the preparation of PNA compounds include,
but are not limited to, U.S.: 5,539,082; 5,714,331; and
25 5,719,262, each of which is herein incorporated by reference.
Further teaching of PNA compounds can be found in Nielsen et
al., *Science*, **1991**, 254, 1497-1500.

Most preferred embodiments of the invention are
oligonucleotides with phosphorothioate backbones and
30 oligonucleosides with heteroatom backbones, and in particular
-CH₂-NH-O-CH₂-, -CH₂-N(CH₃)-O-CH₂- [known as a methylene
(methylimino) or MMI backbone], -CH₂-O-N(CH₃)-CH₂-, -CH₂-
N(CH₃)-N(CH₃)-CH₂- and -O-N(CH₃)-CH₂-CH₂- [wherein the native

-24-

phosphodiester backbone is represented as -O-P-O-CH₂-] of the above referenced U.S. patent 5,489,677, and the amide backbones of the above referenced U.S. patent 5,602,240.

Also preferred are oligonucleotides having morpholino

5 backbone structures of the above-referenced U.S. patent 5,034,506.

Modified oligonucleotides may also contain one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2' position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C₁ to C₁₀ alkyl or C₂ to C₁₀ alkenyl and alkynyl. Particularly preferred are O[(CH₂)_nO]_mCH₃, O(CH₂)_nOCH₃, O(CH₂)_nNH₂, O(CH₂)_nCH₃, O(CH₂)_nONH₂,
10 and O(CH₂)_nON[(CH₂)_nCH₃]₂, where n and m are from 1 to about 10. Other preferred oligonucleotides comprise one of the following at the 2' position: C₁ to C₁₀ lower alkyl, substituted lower alkyl, alkenyl, alkynyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH₃, OCN, Cl, Br, CN, CF₃, OCF₃,
20 SOCH₃, SO₂CH₃, ONO₂, NO₂, N₃, NH₂, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving
25 the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred modification includes 2'-methoxyethoxy (2'-O-CH₂CH₂OCH₃, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., *Helv. Chim. Acta*, **1995**, 78, 486-504) i.e., an alkoxyalkoxy
30 group. A further preferred modification includes 2'-dimethylaminoethoxy, i.e., a O(CH₂)₂ON(CH₃)₂ group, also known as 2'-DMAOE, as described in examples hereinbelow, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O-

-25-

dimethyl-amino-ethoxy-ethyl or 2'-DMAEOE), i.e., 2'-O-CH₂-O-CH₂-N(CH₃)₂, also described in examples hereinbelow.

Other preferred modifications include 2'-methoxy (2'-O-CH₃), 2'-aminopropoxy (2'-OCH₂CH₂CH₂NH₂), 2'-allyl (2'-CH₂-CH=CH₂), 2'-O-allyl (2'-O-CH₂-CH=CH₂) and 2'-fluoro (2'-F). The 2'-modification may be in the arabino (up) position or ribo (down) position. A preferred 2'-arabino modification is 2'-F. Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S.: 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; 5,792,747; and 5,700,920, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

A further preferred modification includes Locked Nucleic Acids (LNAs) in which the 2'-hydroxyl group is linked to the 3' or 4' carbon atom of the sugar ring thereby forming a bicyclic sugar moiety. The linkage is preferably a methylene (-CH₂-)_n group bridging the 2' oxygen atom and the 4' carbon atom wherein n is 1 or 2. LNAs and preparation thereof are described in WO 98/39352 and WO 99/14226.

Oligonucleotides may also include nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine

-26-

(G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl ($-C\equiv C-CH_3$) uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further modified nucleobases include tricyclic pyrimidines such as phenoxazine cytidine (1H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), phenothiazine cytidine (1H-pyrimido[5,4-b][1,4]benzothiazin-2(3H)-one), G-clamps such as a substituted phenoxazine cytidine (e.g. 9-(2-aminoethoxy)-H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), carbazole cytidine (2H-pyrimido[4,5-b]indol-2-one), pyridoindole cytidine (H-pyrido[3',2':4,5]pyrrolo[2,3-d]pyrimidin-2-one). Modified nucleobases may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone. Further nucleobases include those disclosed in United States Patent No. 3,687,808, those disclosed in *The Concise Encyclopedia Of Polymer Science And Engineering*, pages 858-859, Kroschwitz, J.I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., *Angewandte Chemie*,

-27-

International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y.S., Chapter 15, *Antisense Research and Applications*, pages 289-302, Crooke, S.T. and Lebleu, B. , ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y.S., Crooke, S.T. and Lebleu, B., eds., *Antisense Research and Applications*, CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.

Representative United States patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. 3,687,808, as well as U.S.: 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; 5,645,985; 5,830,653; 5,763,588; 6,005,096; and 5,681,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference, and United States patent 5,750,692, which is commonly owned with the instant application and also herein incorporated by reference.

Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. The compounds of the invention can include

-28-

conjugate groups covalently bound to functional groups such as primary or secondary hydroxyl groups. Conjugate groups of the invention include intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, polyethers, groups that enhance the pharmacodynamic properties of oligomers, and groups that enhance the pharmacokinetic properties of oligomers. Typical conjugate groups include cholesterols, lipids, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes. Groups that enhance the pharmacodynamic properties, in the context of this invention, include groups that improve oligomer uptake, enhance oligomer resistance to degradation, and/or strengthen sequence-specific hybridization with RNA. Groups that enhance the pharmacokinetic properties, in the context of this invention, include groups that improve oligomer uptake, distribution, metabolism or excretion. Representative conjugate groups are disclosed in International Patent Application PCT/US92/09196, filed October 23, 1992 the entire disclosure of which is incorporated herein by reference. Conjugate moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., *Proc. Natl. Acad. Sci. USA*, **1989**, 86, 6553-6556), cholic acid (Manoharan et al., *Bioorg. Med. Chem. Lett.*, **1994**, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., *Ann. N.Y. Acad. Sci.*, **1992**, 660, 306-309; Manoharan et al., *Bioorg. Med. Chem. Lett.*, **1993**, 3, 2765-2770), a thiocholesterol (Oberhauser et al., *Nucl. Acids Res.*, **1992**, 20, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., *EMBO J.*, **1991**, 10, 1111-1118; Kabanov et al., *FEBS Lett.*, **1990**, 259, 327-330; Svinarchuk et al., *Biochimie*, **1993**, 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethyl-

-29-

ammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., *Tetrahedron Lett.*, **1995**, 36, 3651-3654; Shea et al., *Nucl. Acids Res.*, **1990**, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., *Nucleosides & Nucleotides*, **1995**, 14, 969-973), or adamantane acetic acid (Manoharan et al., *Tetrahedron Lett.*, **1995**, 36, 3651-3654), a palmityl moiety (Mishra et al., *Biochim. Biophys. Acta*, **1995**, 1264, 229-237), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., *J. Pharmacol. Exp. Ther.*, **1996**, 277, 923-937). Oligonucleotides of the invention may also be conjugated to active drug substances, for example, aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fenbufen, ketoprofen, (S)-(+)-pranoprofen, carprofen, dansylsarcosine, 2,3,5-triiodobenzoic acid, flufenamic acid, folinic acid, a benzothiadiazide, chlorothiazide, a diazepine, indomethicin, a barbiturate, a cephalosporin, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic. Oligonucleotide-drug conjugates and their preparation are described in United States Patent Application 09/334,130 (filed June 15, 1999) which is incorporated herein by reference in its entirety.

Representative United States patents that teach the preparation of such oligonucleotide conjugates include, but are not limited to, U.S.: 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717, 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241, 5,391,723; 5,416,203, 5,451,463; 5,510,475; 5,512,667;

-30-

5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481;
5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and
5,688,941, certain of which are commonly owned with the
instant application, and each of which is herein incorporated
5 by reference.

It is not necessary for all positions in a given
compound to be uniformly modified, and in fact more than one
of the aforementioned modifications may be incorporated in a
single compound or even at a single nucleoside within an
10 oligonucleotide. The present invention also includes
antisense compounds which are chimeric compounds. "Chimeric"
antisense compounds or "chimeras," in the context of this
invention, are antisense compounds, particularly
oligonucleotides, which contain two or more chemically
15 distinct regions, each made up of at least one monomer unit,
i.e., a nucleotide in the case of an oligonucleotide
compound. These oligonucleotides typically contain at least
one region wherein the oligonucleotide is modified so as to
confer upon the oligonucleotide increased resistance to
20 nuclease degradation, increased cellular uptake, increased
stability and/or increased binding affinity for the target
nucleic acid. An additional region of the oligonucleotide
may serve as a substrate for enzymes capable of cleaving
RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a
25 cellular endonuclease which cleaves the RNA strand of an
RNA:DNA duplex. Activation of RNase H, therefore, results in
cleavage of the RNA target, thereby greatly enhancing the
efficiency of oligonucleotide inhibition of gene expression.
The cleavage of RNA:RNA hybrids can, in like fashion, be
30 accomplished through the actions of endoribonucleases, such
as interferon-induced RNaseL which cleaves both cellular and
viral RNA. Consequently, comparable results can often be
obtained with shorter oligonucleotides when chimeric

-31-

oligonucleotides are used, compared to phosphorothioate deoxyoligonucleotides hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

Chimeric antisense compounds of the invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures include, but are not limited to, U.S.: 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

The antisense compounds used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, CA). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkylated derivatives.

The compounds of the invention may also be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor-targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. Representative United States patents that teach the preparation of such

-32-

uptake, distribution and/or absorption-assisting formulations include, but are not limited to, U.S.: 5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291; 5,543,158; 5,547,932; 5,583,020; 5,591,721; 4,426,330; 4,534,899; 5,013,556; 5,108,921; 5,213,804; 5,227,170; 5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978; 5,462,854; 5,469,854; 5,512,295; 5,527,528; 5,534,259; 5,543,152; 5,556,948; 5,580,575; and 5,595,756, each of which is herein incorporated by reference.

10 The antisense compounds of the invention encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to an animal, including a human, is capable of providing (directly or indirectly) the biologically active metabolite
15 or residue thereof. Accordingly, for example, the disclosure is also drawn to prodrugs and pharmaceutically acceptable salts of the compounds of the invention, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents.

 The term "prodrug" indicates a therapeutic agent that is
20 prepared in an inactive form that is converted to an active form (i.e., drug) within the body or cells thereof by the action of endogenous enzymes or other chemicals and/or conditions. In particular, prodrug versions of the oligonucleotides of the invention are prepared as SATE
25 [(S-acetyl-2-thioethyl) phosphate] derivatives according to the methods disclosed in WO 93/24510 to Gosselin et al., published December 9, 1993 or in WO 94/26764 and U.S. 5,770,713 to Imbach et al.

 The term "pharmaceutically acceptable salts" refers to
30 physiologically and pharmaceutically acceptable salts of the compounds of the invention: i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto.

-33-

Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are N,N'-dibenzylethylenediamine, chlorprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge et al., "Pharmaceutical Salts," *J. of Pharma Sci.*, **1977**, 66, 1-19). The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner. The free acid form may be regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner. The free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention. As used herein, a "pharmaceutical addition salt" includes a pharmaceutically acceptable salt of an acid form of one of the components of the compositions of the invention. These include organic or inorganic acid salts of the amines. Preferred acid salts are the hydrochlorides, acetates, salicylates, nitrates and phosphates. Other suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of a variety of inorganic and organic acids, such as, for example, with inorganic acids, such as for example hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid; with organic carboxylic, sulfonic, sulfo or phospho acids or N-substituted sulfamic acids, for example acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylemaleic acid, fumaric

-34-

acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2-phenoxybenzoic acid,

5 2-acetoxybenzoic acid, embonic acid, nicotinic acid or isonicotinic acid; and with amino acids, such as the 20 alpha-amino acids involved in the synthesis of proteins in nature, for example glutamic acid or aspartic acid, and also with phenylacetic acid, methanesulfonic acid, ethanesulfonic

10 acid, 2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 2- or 3-phosphoglycerate, glucose-6-phosphate, N-cyclohexylsulfamic acid (with the formation of cyclamates),

15 or with other acid organic compounds, such as ascorbic acid. Pharmaceutically acceptable salts of compounds may also be prepared with a pharmaceutically acceptable cation. Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth,

20 ammonium and quaternary ammonium cations. Carbonates or hydrogen carbonates are also possible.

For oligonucleotides, preferred examples of pharmaceutically acceptable salts include but are not limited to (a) salts formed with cations such as sodium, potassium,

25 ammonium, magnesium, calcium, polyamines such as spermine and spermidine, etc.; (b) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; (c) salts formed with organic acids such as, for

30 example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid,

-35-

naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; and (d) salts formed from elemental anions such as chlorine, bromine, and iodine.

5 The antisense compounds of the present invention can be utilized for diagnostics, therapeutics, prophylaxis and as research reagents and kits. For therapeutics, an animal, preferably a human, suspected of having a disease or disorder which can be treated by modulating the expression of IL-1
10 receptor-associated kinase-1 is treated by administering antisense compounds in accordance with this invention. The compounds of the invention can be utilized in pharmaceutical compositions by adding an effective amount of an antisense compound to a suitable pharmaceutically acceptable diluent or
15 carrier. Use of the antisense compounds and methods of the invention may also be useful prophylactically, e.g., to prevent or delay infection, inflammation or tumor formation, for example.

 The antisense compounds of the invention are useful for
20 research and diagnostics, because these compounds hybridize to nucleic acids encoding IL-1 receptor-associated kinase-1, enabling sandwich and other assays to easily be constructed to exploit this fact. Hybridization of the antisense oligonucleotides of the invention with a nucleic acid
25 encoding IL-1 receptor-associated kinase-1 can be detected by means known in the art. Such means may include conjugation of an enzyme to the oligonucleotide, radiolabelling of the oligonucleotide or any other suitable detection means. Kits using such detection means for detecting the level of IL-1
30 receptor-associated kinase-1 in a sample may also be prepared.

 The present invention also includes pharmaceutical compositions and formulations which include the antisense

-36-

compounds of the invention. The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Oligonucleotides with at least one 2'-O-methoxyethyl modification are believed to be particularly useful for oral administration.

Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful. Preferred topical formulations include those in which the oligonucleotides of the invention are in admixture with a topical delivery agent such as lipids, liposomes, fatty acids, fatty acid esters, steroids, chelating agents and surfactants. Preferred lipids and liposomes include neutral (e.g. dioleoylphosphatidyl DOPE ethanolamine, dimyristoylphosphatidyl choline DMPC, distearoylphosphatidyl choline) negative (e.g. dimyristoylphosphatidyl glycerol DMPG) and cationic (e.g. dioleoyltetramethylaminopropyl DOTAP and dioleoylphosphatidyl ethanolamine DOTMA). Oligonucleotides of the invention may be encapsulated within liposomes or may form complexes

-37-

thereto, in particular to cationic liposomes. Alternatively, oligonucleotides may be complexed to lipids, in particular to cationic lipids. Preferred fatty acids and esters include but are not limited arachidonic acid, oleic acid, eicosanoic acid, lauric acid, caprylic acid, capric acid, myristic acid, 5 palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein, dilaurin, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, an acylcarnitine, an acylcholine, or a C₁₋₁₀ alkyl ester (e.g. isopropylmyristate IPM), monoglyceride, diglyceride or 10 pharmaceutically acceptable salt thereof. Topical formulations are described in detail in United States patent application 09/315,298 filed on May 20, 1999 which is incorporated herein by reference in its entirety.

15 Compositions and formulations for oral administration include powders or granules, microparticulates, nanoparticulates, suspensions or solutions in water or non-aqueous media, capsules, gel capsules, sachets, tablets or minitables. Thickeners, flavoring agents, diluents, 20 emulsifiers, dispersing aids or binders may be desirable. Preferred oral formulations are those in which oligonucleotides of the invention are administered in conjunction with one or more penetration enhancers surfactants and chelators. Preferred surfactants include 25 fatty acids and/or esters or salts thereof, bile acids and/or salts thereof. Preferred bile acids/salts include chenodeoxycholic acid (CDCA) and ursodeoxychenodeoxycholic acid (UDCA), cholic acid, dehydrocholic acid, deoxycholic acid, glucolic acid, glycholic acid, glycodeoxycholic acid, 30 taurocholic acid, taurodeoxycholic acid, sodium tauro-24,25-dihydro-fusidate and sodium glycodihydrofusidate. Preferred fatty acids include arachidonic acid, undecanoic acid, oleic acid, lauric acid, caprylic acid, capric acid, myristic acid,

-38-

palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein, dilaurin, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, an acylcarnitine, an acylcholine, or a monoglyceride, a diglyceride or a pharmaceutically acceptable salt thereof (e.g. sodium). Also preferred are combinations of penetration enhancers, for example, fatty acids/salts in combination with bile acids/salts. A particularly preferred combination is the sodium salt of lauric acid, capric acid and UDCA. Further penetration enhancers include polyoxyethylene-9-lauryl ether, polyoxyethylene-20-cetyl ether. Oligonucleotides of the invention may be delivered orally, in granular form including sprayed dried particles, or complexed to form micro or nanoparticles. Oligonucleotide complexing agents include poly-amino acids; polyimines; polyacrylates; polyalkylacrylates, polyoxethanes, polyalkylcyanoacrylates; cationized gelatins, albumins, starches, acrylates, polyethyleneglycols (PEG) and starches; polyalkylcyanoacrylates; DEAE-derivatized polyimines, pollulans, celluloses and starches. Particularly preferred complexing agents include chitosan, N-trimethylchitosan, poly-L-lysine, polyhistidine, polyornithine, polyspermines, protamine, polyvinylpyridine, polythiodiethylamino-methylethylene P(TDAE), polyaminostyrene (e.g. p-amino), poly(methylcyanoacrylate), poly(ethylcyanoacrylate), poly(butylcyanoacrylate), poly(isobutylcyanoacrylate), poly(isohexylcyanoacrylate), DEAE-methacrylate, DEAE-hexylacrylate, DEAE-acrylamide, DEAE-albumin and DEAE-dextran, polymethylacrylate, polyhexylacrylate, poly(D,L-lactic acid), poly(DL-lactic-co-glycolic acid (PLGA), alginate, and polyethyleneglycol (PEG). Oral formulations for oligonucleotides and their preparation are described in detail in United States applications 08/886,829 (filed July

-39-

1, 1997), 09/108,673 (filed July 1, 1998), 09/256,515 (filed February 23, 1999), 09/082,624 (filed May 21, 1998) and 09/315,298 (filed May 20, 1999), each of which is incorporated herein by reference in their entirety.

5 Compositions and formulations for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and
10 other pharmaceutically acceptable carriers or excipients.

Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions may be generated from a variety of components that include, but are
15 not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids.

The pharmaceutical formulations of the present invention, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques
20 well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into association the active
25 ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

The compositions of the present invention may be formulated into any of many possible dosage forms such as,
30 but not limited to, tablets, capsules, gel capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present invention may also be formulated as suspensions in aqueous, non-aqueous or mixed media.

-40-

Aqueous suspensions may further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

5 In one embodiment of the present invention the pharmaceutical compositions may be formulated and used as foams. Pharmaceutical foams include formulations such as, but not limited to, emulsions, microemulsions, creams, jellies and liposomes. While basically similar in nature
10 these formulations vary in the components and the consistency of the final product. The preparation of such compositions and formulations is generally known to those skilled in the pharmaceutical and formulation arts and may be applied to the formulation of the compositions of the present invention.

15

Emulsions

The compositions of the present invention may be prepared and formulated as emulsions. Emulsions are typically heterogenous systems of one liquid dispersed in
20 another in the form of droplets usually exceeding 0.1 μm in diameter (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199; Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988,
25 Marcel Dekker, Inc., New York, N.Y., Volume 1, p. 245; Block in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 2, p. 335; Higuchi et al., in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, 1985, p. 301).
30 Emulsions are often biphasic systems comprising two immiscible liquid phases intimately mixed and dispersed with each other. In general, emulsions may be of either the water-in-oil (w/o) or the oil-in-water (o/w) variety. When

-41-

an aqueous phase is finely divided into and dispersed as minute droplets into a bulk oily phase, the resulting composition is called a water-in-oil (w/o) emulsion.

Alternatively, when an oily phase is finely divided into and

5 dispersed as minute droplets into a bulk aqueous phase, the resulting composition is called an oil-in-water (o/w)

emulsion. Emulsions may contain additional components in addition to the dispersed phases, and the active drug which may be present as a solution in either the aqueous phase,

10 oily phase or itself as a separate phase. Pharmaceutical excipients such as emulsifiers, stabilizers, dyes, and anti-oxidants may also be present in emulsions as needed.

Pharmaceutical emulsions may also be multiple emulsions that are comprised of more than two phases such as, for example,

15 in the case of oil-in-water-in-oil (o/w/o) and water-in-oil-in-water (w/o/w) emulsions. Such complex formulations often provide certain advantages that simple binary emulsions do

not. Multiple emulsions in which individual oil droplets of an o/w emulsion enclose small water droplets constitute a

20 w/o/w emulsion. Likewise a system of oil droplets enclosed in globules of water stabilized in an oily continuous phase provides an o/w/o emulsion.

Emulsions are characterized by little or no thermodynamic stability. Often, the dispersed or

25 discontinuous phase of the emulsion is well dispersed into the external or continuous phase and maintained in this form through the means of emulsifiers or the viscosity of the formulation. Either of the phases of the emulsion may be a semisolid or a solid, as is the case of emulsion-style

30 ointment bases and creams. Other means of stabilizing emulsions entail the use of emulsifiers that may be incorporated into either phase of the emulsion. Emulsifiers may broadly be classified into four categories: synthetic

-42-

surfactants, naturally occurring emulsifiers, absorption bases, and finely dispersed solids (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

5 Synthetic surfactants, also known as surface active agents, have found wide applicability in the formulation of emulsions and have been reviewed in the literature (Rieger, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), Marcel Dekker, Inc., New York, N.Y., 1988, volume 1, p. 199). Surfactants are typically amphiphilic and comprise a hydrophilic and a hydrophobic portion. The ratio of the hydrophilic to the hydrophobic
15 nature of the surfactant has been termed the hydrophile/lipophile balance (HLB) and is a valuable tool in categorizing and selecting surfactants in the preparation of formulations. Surfactants may be classified into different classes based on the nature of the hydrophilic group:
20 nonionic, anionic, cationic and amphoteric (Rieger, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285).

Naturally occurring emulsifiers used in emulsion
25 formulations include lanolin, beeswax, phosphatides, lecithin and acacia. Absorption bases possess hydrophilic properties such that they can soak up water to form w/o emulsions yet retain their semisolid consistencies, such as anhydrous lanolin and hydrophilic petrolatum. Finely divided solids
30 have also been used as good emulsifiers especially in combination with surfactants and in viscous preparations. These include polar inorganic solids, such as heavy metal hydroxides, nonswelling clays such as bentonite, attapulgite,

-43-

hectorite, kaolin, montmorillonite, colloidal aluminum silicate and colloidal magnesium aluminum silicate, pigments and nonpolar solids such as carbon or glyceryl tristearate.

A large variety of non-emulsifying materials are also included in emulsion formulations and contribute to the properties of emulsions. These include fats, oils, waxes, fatty acids, fatty alcohols, fatty esters, humectants, hydrophilic colloids, preservatives and antioxidants (Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Hydrophilic colloids or hydrocolloids include naturally occurring gums and synthetic polymers such as polysaccharides (for example, acacia, agar, alginic acid, carrageenan, guar gum, karaya gum, and tragacanth), cellulose derivatives (for example, carboxymethylcellulose and carboxypropylcellulose), and synthetic polymers (for example, carbomers, cellulose ethers, and carboxyvinyl polymers). These disperse or swell in water to form colloidal solutions that stabilize emulsions by forming strong interfacial films around the dispersed-phase droplets and by increasing the viscosity of the external phase.

Since emulsions often contain a number of ingredients such as carbohydrates, proteins, sterols and phosphatides that may readily support the growth of microbes, these formulations often incorporate preservatives. Commonly used preservatives included in emulsion formulations include methyl paraben, propyl paraben, quaternary ammonium salts, benzalkonium chloride, esters of p-hydroxybenzoic acid, and boric acid. Antioxidants are also commonly added to emulsion formulations to prevent deterioration of the formulation.

-44-

Antioxidants used may be free radical scavengers such as tocopherols, alkyl gallates, butylated hydroxyanisole, butylated hydroxytoluene, or reducing agents such as ascorbic acid and sodium metabisulfite, and antioxidant synergists
5 such as citric acid, tartaric acid, and lecithin.

The application of emulsion formulations via dermatological, oral and parenteral routes and methods for their manufacture have been reviewed in the literature (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and
10 Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Emulsion formulations for oral delivery have been very widely used because of ease of formulation, as well as efficacy from an absorption and bioavailability standpoint (Rosoff, in *Pharmaceutical Dosage Forms*,
15 Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Mineral-oil base laxatives, oil-soluble vitamins
20 and high fat nutritive preparations are among the materials that have commonly been administered orally as o/w emulsions.

In one embodiment of the present invention, the compositions of oligonucleotides and nucleic acids are formulated as microemulsions. A microemulsion may be defined
25 as a system of water, oil and amphiphile which is a single optically isotropic and thermodynamically stable liquid solution (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Typically microemulsions are
30 systems that are prepared by first dispersing an oil in an aqueous surfactant solution and then adding a sufficient amount of a fourth component, generally an intermediate chain-length alcohol to form a transparent system.

-45-

Therefore, microemulsions have also been described as thermodynamically stable, isotropically clear dispersions of two immiscible liquids that are stabilized by interfacial films of surface-active molecules (Leung and Shah, in: 5 *Controlled Release of Drugs: Polymers and Aggregate Systems*, Rosoff, M., Ed., 1989, VCH Publishers, New York, pages 185-215). Microemulsions commonly are prepared via a combination of three to five components that include oil, water, surfactant, cosurfactant and electrolyte. Whether the 10 microemulsion is of the water-in-oil (w/o) or an oil-in-water (o/w) type is dependent on the properties of the oil and surfactant used and on the structure and geometric packing of the polar heads and hydrocarbon tails of the surfactant molecules (Schott, in *Remington's Pharmaceutical Sciences*, 15 Mack Publishing Co., Easton, PA, 1985, p. 271).

The phenomenological approach utilizing phase diagrams has been extensively studied and has yielded a comprehensive knowledge, to one skilled in the art, of how to formulate microemulsions (Rosoff, in *Pharmaceutical Dosage Forms*, 20 Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335). Compared to conventional emulsions, microemulsions 25 offer the advantage of solubilizing water-insoluble drugs in a formulation of thermodynamically stable droplets that are formed spontaneously.

Surfactants used in the preparation of microemulsions include, but are not limited to, ionic surfactants, non-ionic 30 surfactants, Brij 96, polyoxyethylene oleyl ethers, polyglycerol fatty acid esters, tetraglycerol monolaurate (ML310), tetraglycerol monooleate (MO310), hexaglycerol monooleate (PO310), hexaglycerol pentaoleate (PO500),

-46-

decaglycerol monocaprate (MCA750), decaglycerol monooleate (MO750), decaglycerol sequioleate (SO750), decaglycerol decaoleate (DAO750), alone or in combination with cosurfactants. The cosurfactant, usually a short-chain alcohol such as ethanol, 1-propanol, and 1-butanol, serves to increase the interfacial fluidity by penetrating into the surfactant film and consequently creating a disordered film because of the void space generated among surfactant molecules. Microemulsions may, however, be prepared without the use of cosurfactants and alcohol-free self-emulsifying microemulsion systems are known in the art. The aqueous phase may typically be, but is not limited to, water, an aqueous solution of the drug, glycerol, PEG300, PEG400, polyglycerols, propylene glycols, and derivatives of ethylene glycol. The oil phase may include, but is not limited to, materials such as Captex 300, Captex 355, Capmul MCM, fatty acid esters, medium chain (C8-C12) mono, di, and tri-glycerides, polyoxyethylated glyceryl fatty acid esters, fatty alcohols, polyglycolized glycerides, saturated polyglycolized C8-C10 glycerides, vegetable oils and silicone oil.

Microemulsions are particularly of interest from the standpoint of drug solubilization and the enhanced absorption of drugs. Lipid based microemulsions (both o/w and w/o) have been proposed to enhance the oral bioavailability of drugs, including peptides (Constantinides *et al.*, *Pharmaceutical Research*, **1994**, *11*, 1385-1390; Ritschel, *Meth. Find. Exp. Clin. Pharmacol.*, **1993**, *13*, 205). Microemulsions afford advantages of improved drug solubilization, protection of drug from enzymatic hydrolysis, possible enhancement of drug absorption due to surfactant-induced alterations in membrane fluidity and permeability, ease of preparation, ease of oral administration over solid dosage forms, improved clinical

-47-

potency, and decreased toxicity (Constantinides et al.,
Pharmaceutical Research, 1994, 11, 1385; Ho et al., *J. Pharm.*
Sci., 1996, 85, 138-143). Often microemulsions may form
spontaneously when their components are brought together at
5 ambient temperature. This may be particularly advantageous
when formulating thermolabile drugs, peptides or
oligonucleotides. Microemulsions have also been effective in
the transdermal delivery of active components in both
cosmetic and pharmaceutical applications. It is expected
10 that the microemulsion compositions and formulations of the
present invention will facilitate the increased systemic
absorption of oligonucleotides and nucleic acids from the
gastrointestinal tract, as well as improve the local cellular
uptake of oligonucleotides and nucleic acids within the
15 gastrointestinal tract, vagina, buccal cavity and other areas
of administration.

Microemulsions of the present invention may also contain
additional components and additives such as sorbitan
monostearate (Grill 3), Labrasol, and penetration enhancers
20 to improve the properties of the formulation and to enhance
the absorption of the oligonucleotides and nucleic acids of
the present invention. Penetration enhancers used in the
microemulsions of the present invention may be classified as
belonging to one of five broad categories - surfactants,
25 fatty acids, bile salts, chelating agents, and non-chelating
non-surfactants (Lee et al., *Critical Reviews in Therapeutic*
Drug Carrier Systems, 1991, p. 92). Each of these classes
has been discussed above.

30 Liposomes

There are many organized surfactant structures besides
microemulsions that have been studied and used for the
formulation of drugs. These include monolayers, micelles,

-48-

bilayers and vesicles. Vesicles, such as liposomes, have attracted great interest because of their specificity and the duration of action they offer from the standpoint of drug delivery. As used in the present invention, the term

5 "liposome" means a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers.

Liposomes are unilamellar or multilamellar vesicles which have a membrane formed from a lipophilic material and an aqueous interior. The aqueous portion contains the

10 composition to be delivered. Cationic liposomes possess the advantage of being able to fuse to the cell wall. Non-cationic liposomes, although not able to fuse as efficiently with the cell wall, are taken up by macrophages *in vivo*.

In order to cross intact mammalian skin, lipid vesicles

15 must pass through a series of fine pores, each with a diameter less than 50 nm, under the influence of a suitable transdermal gradient. Therefore, it is desirable to use a liposome which is highly deformable and able to pass through such fine pores.

20 Further advantages of liposomes include; liposomes obtained from natural phospholipids are biocompatible and biodegradable; liposomes can incorporate a wide range of water and lipid soluble drugs; liposomes can protect encapsulated drugs in their internal compartments from

25 metabolism and degradation (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Important considerations in the preparation of liposome formulations are the lipid surface charge, vesicle size and the aqueous

30 volume of the liposomes.

Liposomes are useful for the transfer and delivery of active ingredients to the site of action. Because the liposomal membrane is structurally similar to biological

-49-

membranes, when liposomes are applied to a tissue, the liposomes start to merge with the cellular membranes and as the merging of the liposome and cell progresses, the liposomal contents are emptied into the cell where the active agent may act.

Liposomal formulations have been the focus of extensive investigation as the mode of delivery for many drugs. There is growing evidence that for topical administration, liposomes present several advantages over other formulations. Such advantages include reduced side-effects related to high systemic absorption of the administered drug, increased accumulation of the administered drug at the desired target, and the ability to administer a wide variety of drugs, both hydrophilic and hydrophobic, into the skin.

Several reports have detailed the ability of liposomes to deliver agents including high-molecular weight DNA into the skin. Compounds including analgesics, antibodies, hormones and high-molecular weight DNAs have been administered to the skin. The majority of applications resulted in the targeting of the upper epidermis.

Liposomes fall into two broad classes. Cationic liposomes are positively charged liposomes which interact with the negatively charged DNA molecules to form a stable complex. The positively charged DNA/liposome complex binds to the negatively charged cell surface and is internalized in an endosome. Due to the acidic pH within the endosome, the liposomes are ruptured, releasing their contents into the cell cytoplasm (Wang et al., *Biochem. Biophys. Res. Commun.*, 1987, 147, 980-985).

Liposomes which are pH-sensitive or negatively-charged, entrap DNA rather than complex with it. Since both the DNA and the lipid are similarly charged, repulsion rather than complex formation occurs. Nevertheless, some DNA is entrapped

-50-

within the aqueous interior of these liposomes. pH-sensitive liposomes have been used to deliver DNA encoding the thymidine kinase gene to cell monolayers in culture. Expression of the exogenous gene was detected in the target
5 cells (Zhou et al., *Journal of Controlled Release*, **1992**, *19*, 269-274).

One major type of liposomal composition includes phospholipids other than naturally-derived phosphatidylcholine. Neutral liposome compositions, for
10 example, can be formed from dimyristoyl phosphatidylcholine (DMPC) or dipalmitoyl phosphatidylcholine (DPPC). Anionic liposome compositions generally are formed from dimyristoyl phosphatidylglycerol, while anionic fusogenic liposomes are formed primarily from dioleoyl phosphatidylethanolamine
15 (DOPE). Another type of liposomal composition is formed from phosphatidylcholine (PC) such as, for example, soybean PC, and egg PC. Another type is formed from mixtures of phospholipid and/or phosphatidylcholine and/or cholesterol.

Several studies have assessed the topical delivery of
20 liposomal drug formulations to the skin. Application of liposomes containing interferon to guinea pig skin resulted in a reduction of skin herpes sores while delivery of interferon via other means (e.g. as a solution or as an emulsion) were ineffective (Weiner et al., *Journal of Drug*
25 *Targeting*, **1992**, *2*, 405-410). Further, an additional study tested the efficacy of interferon administered as part of a liposomal formulation to the administration of interferon using an aqueous system, and concluded that the liposomal formulation was superior to aqueous administration (du
30 Plessis et al., *Antiviral Research*, **1992**, *18*, 259-265).

Non-ionic liposomal systems have also been examined to determine their utility in the delivery of drugs to the skin, in particular systems comprising non-ionic surfactant and

-51-

cholesterol. Non-ionic liposomal formulations comprising Novasome™ I (glyceryl dilaurate/cholesterol/polyoxyethylene-10-stearyl ether) and Novasome™ II (glyceryl distearate/cholesterol/polyoxyethylene-10-stearyl ether) were used to deliver cyclosporin-A into the dermis of mouse skin. Results indicated that such non-ionic liposomal systems were effective in facilitating the deposition of cyclosporin-A into different layers of the skin (Hu et al. *S.T.P. Pharma. Sci.*, 1994, 4, 6, 466).

Liposomes also include "sterically stabilized" liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome (A) comprises one or more glycolipids, such as monosialoganglioside G_{M1}, or (B) is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. While not wishing to be bound by any particular theory, it is thought in the art that, at least for sterically stabilized liposomes containing gangliosides, sphingomyelin, or PEG-derivatized lipids, the enhanced circulation half-life of these sterically stabilized liposomes derives from a reduced uptake into cells of the reticuloendothelial system (RES) (Allen et al., *FEBS Letters*, 1987, 223, 42; Wu et al., *Cancer Research*, 1993, 53, 3765).

Various liposomes comprising one or more glycolipids are known in the art. Papahadjopoulos et al. (*Ann. N.Y. Acad. Sci.*, 1987, 507, 64) reported the ability of monosialoganglioside G_{M1}, galactocerebroside sulfate and phosphatidylinositol to improve blood half-lives of liposomes. These findings were expounded upon by Gabizon et

-52-

al. (*Proc. Natl. Acad. Sci. U.S.A.*, **1988**, 85, 6949). U.S. Patent No. 4,837,028 and WO 88/04924, both to Allen et al., disclose liposomes comprising (1) sphingomyelin and (2) the ganglioside G_{M1} or a galactocerebroside sulfate ester. U.S. Patent No. 5,543,152 (Webb et al.) discloses liposomes comprising sphingomyelin. Liposomes comprising 1,2-sn-dimyristoylphosphatidylcholine are disclosed in WO 97/13499 (Lim et al.).

Many liposomes comprising lipids derivatized with one or more hydrophilic polymers, and methods of preparation thereof, are known in the art. Sunamoto et al. (*Bull. Chem. Soc. Jpn.*, **1980**, 53, 2778) described liposomes comprising a nonionic detergent, 2C₁₂15G, that contains a PEG moiety. Illum et al. (*FEBS Lett.*, **1984**, 167, 79) noted that hydrophilic coating of polystyrene particles with polymeric glycols results in significantly enhanced blood half-lives. Synthetic phospholipids modified by the attachment of carboxylic groups of polyalkylene glycols (e.g., PEG) are described by Sears (U.S. Patent Nos. 4,426,330 and 4,534,899). Klibanov et al. (*FEBS Lett.*, **1990**, 268, 235) described experiments demonstrating that liposomes comprising phosphatidylethanolamine (PE) derivatized with PEG or PEG stearate have significant increases in blood circulation half-lives. Blume et al. (*Biochimica et Biophysica Acta*, **1990**, 1029, 91) extended such observations to other PEG-derivatized phospholipids, e.g., DSPE-PEG, formed from the combination of distearoylphosphatidylethanolamine (DSPE) and PEG. Liposomes having covalently bound PEG moieties on their external surface are described in European Patent No. EP 0 445 131 B1 and WO 90/04384 to Fisher. Liposome compositions containing 1-20 mole percent of PE derivatized with PEG, and methods of use thereof, are described by Woodle et al. (U.S. Patent Nos. 5,013,556 and 5,356,633) and Martin et al. (U.S.

-53-

Patent No. 5,213,804 and European Patent No. EP 0 496 813 B1). Liposomes comprising a number of other lipid-polymer conjugates are disclosed in WO 91/05545 and U.S. Patent No. 5,225,212 (both to Martin *et al.*) and in WO 94/20073

5 (Zalipsky *et al.*) Liposomes comprising PEG-modified ceramide lipids are described in WO 96/10391 (Choi *et al.*). U.S. Patent Nos. 5,540,935 (Miyazaki *et al.*) and 5,556,948 (Tagawa *et al.*) describe PEG-containing liposomes that can be further derivatized with functional moieties on their surfaces.

10 A limited number of liposomes comprising nucleic acids are known in the art. WO 96/40062 to Thierry *et al.* discloses methods for encapsulating high molecular weight nucleic acids in liposomes. U.S. Patent No. 5,264,221 to Tagawa *et al.* discloses protein-bonded liposomes and asserts
15 that the contents of such liposomes may include an antisense RNA. U.S. Patent No. 5,665,710 to Rahman *et al.* describes certain methods of encapsulating oligodeoxynucleotides in liposomes. WO 97/04787 to Love *et al.* discloses liposomes comprising antisense oligonucleotides targeted to the raf
20 gene.

Transfersomes are yet another type of liposomes, and are highly deformable lipid aggregates which are attractive candidates for drug delivery vehicles. Transfersomes may be described as lipid droplets which are so highly deformable
25 that they are easily able to penetrate through pores which are smaller than the droplet. Transfersomes are adaptable to the environment in which they are used, e.g. they are self-optimizing (adaptive to the shape of pores in the skin), self-repairing, frequently reach their targets without
30 fragmenting, and often self-loading. To make transfersomes it is possible to add surface edge-activators, usually surfactants, to a standard liposomal composition. Transfersomes have been used to deliver serum albumin to the

-54-

skin. The transfersome-mediated delivery of serum albumin has been shown to be as effective as subcutaneous injection of a solution containing serum albumin.

Surfactants find wide application in formulations such as emulsions (including microemulsions) and liposomes. The most common way of classifying and ranking the properties of the many different types of surfactants, both natural and synthetic, is by the use of the hydrophile/lipophile balance (HLB). The nature of the hydrophilic group (also known as the "head") provides the most useful means for categorizing the different surfactants used in formulations (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, NY, 1988, p. 285).

If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants find wide application in pharmaceutical and cosmetic products and are usable over a wide range of pH values. In general their HLB values range from 2 to about 18 depending on their structure. Nonionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters. Nonionic alkanolamides and ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated block polymers are also included in this class. The polyoxyethylene surfactants are the most popular members of the nonionic surfactant class.

If the surfactant molecule carries a negative charge when it is dissolved or dispersed in water, the surfactant is classified as anionic. Anionic surfactants include carboxylates such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and

-55-

sulfosuccinates, and phosphates. The most important members of the anionic surfactant class are the alkyl sulfates and the soaps.

If the surfactant molecule carries a positive charge when it is dissolved or dispersed in water, the surfactant is classified as cationic. Cationic surfactants include quaternary ammonium salts and ethoxylated amines. The quaternary ammonium salts are the most used members of this class.

If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as amphoteric. Amphoteric surfactants include acrylic acid derivatives, substituted alkylamides, N-alkylbetaines and phosphatides.

The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, NY, 1988, p. 285).

Penetration Enhancers

In one embodiment, the present invention employs various penetration enhancers to effect the efficient delivery of nucleic acids, particularly oligonucleotides, to the skin of animals. Most drugs are present in solution in both ionized and nonionized forms. However, usually only lipid soluble or lipophilic drugs readily cross cell membranes. It has been discovered that even non-lipophilic drugs may cross cell membranes if the membrane to be crossed is treated with a penetration enhancer. In addition to aiding the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also enhance the permeability of lipophilic drugs.

Penetration enhancers may be classified as belonging to one of five broad categories, i.e., surfactants, fatty acids,

-56-

bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92). Each of the above mentioned classes of penetration enhancers are described below in greater detail.

Surfactants: In connection with the present invention, surfactants (or "surface-active agents") are chemical entities which, when dissolved in an aqueous solution, reduce the surface tension of the solution or the interfacial tension between the aqueous solution and another liquid, with the result that absorption of oligonucleotides through the mucosa is enhanced. In addition to bile salts and fatty acids, these penetration enhancers include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92); and perfluorochemical emulsions, such as FC-43. Takahashi et al., *J. Pharm. Pharmacol.*, 1988, 40, 252).

Fatty acids: Various fatty acids and their derivatives which act as penetration enhancers include, for example, oleic acid, lauric acid, capric acid (n-decanoic acid), myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein (1-monooleoyl-rac-glycerol), dilaurin, caprylic acid, arachidonic acid, glycerol 1-monocaprate, 1-dodecylazacycloheptan-2-one, acylcarnitines, acylcholines, C₁₋₁₀ alkyl esters thereof (e.g., methyl, isopropyl and t-butyl), and mono- and di-glycerides thereof (i.e., oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, etc.) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92; Muranishi, *Critical Reviews in*

-57-

Therapeutic Drug Carrier Systems, 1990, 7, 1-33; El Hariri et al., *J. Pharm. Pharmacol.*, 1992, 44, 651-654).

Bile salts: The physiological role of bile includes the facilitation of dispersion and absorption of lipids and fat-soluble vitamins (Brunton, Chapter 38 in: Goodman & Gilman's *The Pharmacological Basis of Therapeutics*, 9th Ed., Hardman et al. Eds., McGraw-Hill, New York, 1996, pp. 934-935). Various natural bile salts, and their synthetic derivatives, act as penetration enhancers. Thus the term "bile salts" includes any of the naturally occurring components of bile as well as any of their synthetic derivatives. The bile salts of the invention include, for example, cholic acid (or its pharmaceutically acceptable sodium salt, sodium cholate), dehydrocholic acid (sodium dehydrocholate), deoxycholic acid (sodium deoxycholate), glucolic acid (sodium glucolate), glycholic acid (sodium glycocholate), glycodeoxycholic acid (sodium glycodeoxycholate), taurocholic acid (sodium taurocholate), taurodeoxycholic acid (sodium taurodeoxycholate), chenodeoxycholic acid (sodium chenodeoxycholate), ursodeoxycholic acid (UDCA), sodium tauro-24,25-dihydro-fusidate (STDHF), sodium glycodihydrofusidate and polyoxyethylene-9-lauryl ether (POE) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92; Swinyard, Chapter 39 In: *Remington's Pharmaceutical Sciences*, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, PA, 1990, pages 782-783; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; Yamamoto et al., *J. Pharm. Exp. Ther.*, 1992, 263, 25; Yamashita et al., *J. Pharm. Sci.*, 1990, 79, 579-583).

Chelating Agents: Chelating agents, as used in connection with the present invention, can be defined as

-58-

compounds that remove metallic ions from solution by forming complexes therewith, with the result that absorption of oligonucleotides through the mucosa is enhanced. With regards to their use as penetration enhancers in the present invention, chelating agents have the added advantage of also serving as DNase inhibitors, as most characterized DNA nucleases require a divalent metal ion for catalysis and are thus inhibited by chelating agents (Jarrett, *J. Chromatogr.*, **1993**, *618*, 315-339). Chelating agents of the invention include but are not limited to disodium ethylenediaminetetraacetate (EDTA), citric acid, salicylates (e.g., sodium salicylate, 5-methoxysalicylate and homovanilate), *N*-acyl derivatives of collagen, laureth-9 and *N*-amino acyl derivatives of beta-diketones (enamines) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, **1991**, page 92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, **1990**, *7*, 1-33; Buur et al., *J. Control Rel.*, **1990**, *14*, 43-51).

Non-chelating non-surfactants: As used herein, non-chelating non-surfactant penetration enhancing compounds can be defined as compounds that demonstrate insignificant activity as chelating agents or as surfactants but that nonetheless enhance absorption of oligonucleotides through the alimentary mucosa (Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, **1990**, *7*, 1-33). This class of penetration enhancers include, for example, unsaturated cyclic ureas, 1-alkyl- and 1-alkenylazacyclo-alkanone derivatives (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, **1991**, page 92); and non-steroidal anti-inflammatory agents such as diclofenac sodium, indomethacin and phenylbutazone (Yamashita et al., *J. Pharm. Pharmacol.*, **1987**, *39*, 621-626).

-59-

Agents that enhance uptake of oligonucleotides at the cellular level may also be added to the pharmaceutical and other compositions of the present invention. For example, cationic lipids, such as lipofectin (Junichi et al, U.S.

5 Patent No. 5,705,188), cationic glycerol derivatives, and polycationic molecules, such as polylysine (Lollo et al., PCT Application WO 97/30731), are also known to enhance the cellular uptake of oligonucleotides.

10 Other agents may be utilized to enhance the penetration of the administered nucleic acids, including glycols such as ethylene glycol and propylene glycol, pyrrols such as 2-pyrrol, azones, and terpenes such as limonene and menthone.

Carriers

15 Certain compositions of the present invention also incorporate carrier compounds in the formulation. As used herein, "carrier compound" or "carrier" can refer to a nucleic acid, or analog thereof, which is inert (i.e., does not possess biological activity *per se*) but is recognized as
20 a nucleic acid by *in vivo* processes that reduce the bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic acid or promoting its removal from circulation. The coadministration of a nucleic acid and a carrier compound,
25 typically with an excess of the latter substance, can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition between the carrier compound and the nucleic acid for a common receptor. For
30 example, the recovery of a partially phosphorothioate oligonucleotide in hepatic tissue can be reduced when it is coadministered with polyinosinic acid, dextran sulfate, polycytidic acid or 4-acetamido-4'-isothiocyano-stilbene-2,2'-

-60-

disulfonic acid (Miyao et al., *Antisense Res. Dev.*, 1995, 5, 115-121; Takakura et al., *Antisense & Nucl. Acid Drug Dev.*, 1996, 6, 177-183).

5 Excipients

In contrast to a carrier compound, a "pharmaceutical carrier" or "excipient" is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an
10 animal. The excipient may be liquid or solid and is selected, with the planned manner of administration in mind, so as to provide for the desired bulk, consistency, etc., when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutical
15 carriers include, but are not limited to, binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc.); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or
20 calcium hydrogen phosphate, etc.); lubricants (e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrants (e.g., starch, sodium
25 starch glycolate, etc.); and wetting agents (e.g., sodium lauryl sulphate, etc.).

Pharmaceutically acceptable organic or inorganic excipient suitable for non-parenteral administration which do not deleteriously react with nucleic acids can also be used
30 to formulate the compositions of the present invention. Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatin, lactose, amylose, magnesium

-61-

stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

Formulations for topical administration of nucleic acids may include sterile and non-sterile aqueous solutions, non-
5 aqueous solutions in common solvents such as alcohols, or solutions of the nucleic acids in liquid or solid oil bases. The solutions may also contain buffers, diluents and other suitable additives. Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral
10 administration which do not deleteriously react with nucleic acids can be used.

Suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylose, magnesium
15 stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

Other Components

20 The compositions of the present invention may additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions may contain additional, compatible,
25 pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the compositions of the present invention, such as dyes,
30 flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the

-62-

present invention. The formulations can be sterilized and, if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously interact with the nucleic acid(s) of the formulation.

Aqueous suspensions may contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

Certain embodiments of the invention provide pharmaceutical compositions containing (a) one or more antisense compounds and (b) one or more other chemotherapeutic agents which function by a non-antisense mechanism. Examples of such chemotherapeutic agents include but are not limited to daunorubicin, daunomycin, dactinomycin, doxorubicin, epirubicin, idarubicin, esorubicin, bleomycin, mafosfamide, ifosfamide, cytosine arabinoside, bis-chloroethylnitrosurea, busulfan, mitomycin C, actinomycin D, mithramycin, prednisone, hydroxyprogesterone, testosterone, tamoxifen, dacarbazine, procarbazine, hexamethylmelamine, pentamethylmelamine, mitoxantrone, amsacrine, chlorambucil, methylcyclohexylnitrosurea, nitrogen mustards, melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-azacytidine, hydroxyurea, deoxycoformycin, 4-hydroxyperoxycyclophosphoramide, 5-fluorouracil (5-FU), 5-fluorodeoxyuridine (5-FUdR), methotrexate (MTX), colchicine, taxol, vincristine, vinblastine, etoposide (VP-16), trimetrexate, irinotecan, topotecan, gemcitabine, teniposide, cisplatin and diethylstilbestrol (DES). See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed. 1987, pp.

-63-

1206-1228, Berkow et al., eds., Rahway, N.J. When used with the compounds of the invention, such chemotherapeutic agents may be used individually (e.g., 5-FU and oligonucleotide), sequentially (e.g., 5-FU and oligonucleotide for a period of
5 time followed by MTX and oligonucleotide), or in combination with one or more other such chemotherapeutic agents (e.g., 5-FU, MTX and oligonucleotide, or 5-FU, radiotherapy and oligonucleotide). Anti-inflammatory drugs, including but not limited to nonsteroidal anti-inflammatory drugs and
10 corticosteroids, and antiviral drugs, including but not limited to ribivirin, vidarabine, acyclovir and ganciclovir, may also be combined in compositions of the invention. See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed., Berkow et al., eds., 1987, Rahway, N.J., pages 2499-2506
15 and 46-49, respectively). Other non-antisense chemotherapeutic agents are also within the scope of this invention. Two or more combined compounds may be used together or sequentially.

In another related embodiment, compositions of the
20 invention may contain one or more antisense compounds, particularly oligonucleotides, targeted to a first nucleic acid and one or more additional antisense compounds targeted to a second nucleic acid target. Numerous examples of antisense compounds are known in the art. Two or more
25 combined compounds may be used together or sequentially.

The formulation of therapeutic compositions and their subsequent administration is believed to be within the skill of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the
30 course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body

-64-

of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on EC_{50} s found to be effective in *in vitro* and *in vivo* animal models. In general, dosage is from 0.01 ug to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01 ug to 100 g per kg of body weight, once or more daily, to once every 20 years.

While the present invention has been described with specificity in accordance with certain of its preferred embodiments, the following examples serve only to illustrate the invention and are not intended to limit the same.

EXAMPLES**Example 1****5 Nucleoside Phosphoramidites for Oligonucleotide Synthesis
Deoxy and 2'-alkoxy amidites**

2'-Deoxy and 2'-methoxy beta-cyanoethyl-diisopropyl phosphoramidites were purchased from commercial sources (e.g. Chemgenes, Needham MA or Glen Research, Inc. Sterling VA).
10 Other 2'-O-alkoxy substituted nucleoside amidites are prepared as described in U.S. Patent 5,506,351, herein incorporated by reference. For oligonucleotides synthesized using 2'-alkoxy amidites, optimized synthesis cycles were developed that incorporate multiple steps coupling longer
15 wait times relative to standard synthesis cycles.

The following abbreviations are used in the text: thin layer chromatography (TLC), melting point (MP), high pressure liquid chromatography (HPLC), Nuclear Magnetic Resonance (NMR), argon (Ar), methanol (MeOH), dichloromethane (CH₂Cl₂),
20 triethylamine (TEA), dimethyl formamide (DMF), ethyl acetate (EtOAc), dimethyl sulfoxide (DMSO), tetrahydrofuran (THF).

Oligonucleotides containing 5-methyl-2'-deoxycytidine (5-Me-dC) nucleotides were synthesized according to published methods (Sanghvi, et. al., *Nucleic Acids Research*, **1993**, 21,
25 3197-3203) using commercially available phosphoramidites (Glen Research, Sterling VA or ChemGenes, Needham MA) or prepared as follows:

**30 Preparation of 5'-O-Dimethoxytrityl-thymidine intermediate
for 5-methyl dC amidite**

To a 50 L glass reactor equipped with air stirrer and Ar gas line was added thymidine (1.00 kg, 4.13 mol) in anhydrous pyridine (6 L) at ambient temperature. Dimethoxytrityl (DMT)

-66-

chloride (1.47 kg, 4.34 mol, 1.05 eq) was added as a solid in four portions over 1 h. After 30 min, TLC indicated approx. 95% product, 2% thymidine, 5% DMT reagent and by-products and 2 % 3',5'-bis DMT product (R_f in EtOAc 0.45, 0.05, 0.98, 0.95 respectively). Saturated sodium bicarbonate (4 L) and CH_2Cl_2 were added with stirring (pH of the aqueous layer 7.5). An additional 18 L of water was added, the mixture was stirred, the phases were separated, and the organic layer was transferred to a second 50 L vessel. The aqueous layer was extracted with additional CH_2Cl_2 (2 x 2 L). The combined organic layer was washed with water (10 L) and then concentrated in a rotary evaporator to approx. 3.6 kg total weight. This was redissolved in CH_2Cl_2 (3.5 L), added to the reactor followed by water (6 L) and hexanes (13 L). The mixture was vigorously stirred and seeded to give a fine white suspended solid starting at the interface. After stirring for 1 h, the suspension was removed by suction through a 1/2" diameter teflon tube into a 20 L suction flask, poured onto a 25 cm Coors Buchner funnel, washed with water (2 x 3 L) and a mixture of hexanes- CH_2Cl_2 (4:1, 2x3 L) and allowed to air dry overnight in pans (1" deep). This was further dried in a vacuum oven (75°C, 0.1 mm Hg, 48 h) to a constant weight of 2072 g (93%) of a white solid, (mp 122-124°C). TLC indicated a trace contamination of the bis DMT product. NMR spectroscopy also indicated that 1-2 mole percent pyridine and about 5 mole percent of hexanes was still present.

Preparation of 5'-O-Dimethoxytrityl-2'-deoxy-5-methylcytidine intermediate for 5-methyl-dC amidite

To a 50 L Schott glass-lined steel reactor equipped with an electric stirrer, reagent addition pump (connected to an addition funnel), heating/cooling system, internal

-67-

thermometer and an Ar gas line was added 5'-O-dimethoxytrityl-thymidine (3.00 kg, 5.51 mol), anhydrous acetonitrile (25 L) and TEA (12.3 L, 88.4 mol, 16 eq). The mixture was chilled with stirring to -10°C internal temperature (external -20°C). Trimethylsilylchloride (2.1 L, 16.5 mol, 3.0 eq) was added over 30 minutes while maintaining the internal temperature below -5°C, followed by a wash of anhydrous acetonitrile (1 L). Note: the reaction is mildly exothermic and copious hydrochloric acid fumes form over the course of the addition. The reaction was allowed to warm to 0°C and the reaction progress was confirmed by TLC (EtOAc-hexanes 4:1; R_f 0.43 to 0.84 of starting material and silyl product, respectively). Upon completion, triazole (3.05 kg, 44 mol, 8.0 eq) was added the reaction was cooled to -20°C internal temperature (external -30°C). Phosphorous oxychloride (1035 mL, 11.1 mol, 2.01 eq) was added over 60 min so as to maintain the temperature between -20°C and -10°C during the strongly exothermic process, followed by a wash of anhydrous acetonitrile (1 L). The reaction was warmed to 0°C and stirred for 1 h. TLC indicated a complete conversion to the triazole product (R_f 0.83 to 0.34 with the product spot glowing in long wavelength UV light). The reaction mixture was a peach-colored thick suspension, which turned darker red upon warming without apparent decomposition. The reaction was cooled to -15°C internal temperature and water (5 L) was slowly added at a rate to maintain the temperature below +10°C in order to quench the reaction and to form a homogenous solution. (Caution: this reaction is initially very strongly exothermic). Approximately one-half of the reaction volume (22 L) was transferred by air pump to another vessel, diluted with EtOAc (12 L) and extracted with water (2 x 8 L). The combined water layers were back-extracted with EtOAc (6 L). The water layer was discarded and the organic

-68-

layers were concentrated in a 20 L rotary evaporator to an oily foam. The foam was coevaporated with anhydrous acetonitrile (4 L) to remove EtOAc. (note: dioxane may be used instead of anhydrous acetonitrile if dried to a hard foam). The second half of the reaction was treated in the same way. Each residue was dissolved in dioxane (3 L) and concentrated ammonium hydroxide (750 mL) was added. A homogenous solution formed in a few minutes and the reaction was allowed to stand overnight (although the reaction is complete within 1 h).

TLC indicated a complete reaction (product R_f 0.35 in EtOAc-MeOH 4:1). The reaction solution was concentrated on a rotary evaporator to a dense foam. Each foam was slowly redissolved in warm EtOAc (4 L; 50°C), combined in a 50 L glass reactor vessel, and extracted with water (2 x 4L) to remove the triazole by-product. The water was back-extracted with EtOAc (2 L). The organic layers were combined and concentrated to about 8 kg total weight, cooled to 0°C and seeded with crystalline product. After 24 hours, the first crop was collected on a 25 cm Coors Buchner funnel and washed repeatedly with EtOAc (3 x 3L) until a white powder was left and then washed with ethyl ether (2 x 3L). The solid was put in pans (1" deep) and allowed to air dry overnight. The filtrate was concentrated to an oil, then redissolved in EtOAc (2 L), cooled and seeded as before. The second crop was collected and washed as before (with proportional solvents) and the filtrate was first extracted with water (2 x 1L) and then concentrated to an oil. The residue was dissolved in EtOAc (1 L) and yielded a third crop which was treated as above except that more washing was required to remove a yellow oily layer.

After air-drying, the three crops were dried in a vacuum oven (50°C, 0.1 mm Hg, 24 h) to a constant weight (1750, 600

-69-

and 200 g, respectively) and combined to afford 2550 g (85%) of a white crystalline product (MP 215-217°C) when TLC and NMR spectroscopy indicated purity. The mother liquor still contained mostly product (as determined by TLC) and a small amount of triazole (as determined by NMR spectroscopy), bis DMT product and unidentified minor impurities. If desired, the mother liquor can be purified by silica gel chromatography using a gradient of MeOH (0-25%) in EtOAc to further increase the yield.

Preparation of 5'-O-Dimethoxytrityl-2'-deoxy-N⁴-benzoyl-5-methylcytidine penultimate intermediate for 5-methyl dC amidite

Crystalline 5'-O-dimethoxytrityl-5-methyl-2'-deoxycytidine (2000 g, 3.68 mol) was dissolved in anhydrous DMF (6.0 kg) at ambient temperature in a 50 L glass reactor vessel equipped with an air stirrer and argon line. Benzoic anhydride (Chem Impex not Aldrich, 874 g, 3.86 mol, 1.05 eq) was added and the reaction was stirred at ambient temperature for 8 h. TLC (CH₂Cl₂-EtOAc; CH₂Cl₂-EtOAc 4:1; R_f 0.25) indicated approx. 92% complete reaction. An additional amount of benzoic anhydride (44 g, 0.19 mol) was added. After a total of 18 h, TLC indicated approx. 96% reaction completion. The solution was diluted with EtOAc (20 L), TEA (1020 mL, 7.36 mol, ca 2.0 eq) was added with stirring, and the mixture was extracted with water (15 L, then 2 x 10 L). The aqueous layer was removed (no back-extraction was needed) and the organic layer was concentrated in 2 x 20 L rotary evaporator flasks until a foam began to form. The residues were coevaporated with acetonitrile (1.5 L each) and dried (0.1 mm Hg, 25°C, 24 h) to 2520 g of a dense foam. High pressure liquid chromatography (HPLC) revealed a

-70-

contamination of 6.3% of N4, 3'-O-dibenzoyl product, but very little other impurities.

The product was purified by Biotage column chromatography (5 kg Biotage) prepared with 65:35:1 hexanes-EtOAc-TEA (4L). The crude product (800 g), dissolved in CH₂Cl₂ (2 L), was applied to the column. The column was washed with the 65:35:1 solvent mixture (20 kg), then 20:80:1 solvent mixture (10 kg), then 99:1 EtOAc:TEA (17kg). The fractions containing the product were collected, and any fractions containing the product and impurities were retained to be resubjected to column chromatography. The column was re-equilibrated with the original 65:35:1 solvent mixture (17 kg). A second batch of crude product (840 g) was applied to the column as before. The column was washed with the following solvent gradients: 65:35:1 (9 kg), 55:45:1 (20 kg), 20:80:1 (10 kg), and 99:1 EtOAc:TEA (15 kg). The column was reequilibrated as above, and a third batch of the crude product (850 g) plus impure fractions recycled from the two previous columns (28 g) was purified following the procedure for the second batch. The fractions containing pure product combined and concentrated on a 20L rotary evaporator, co-evaporated with acetontirile (3 L) and dried (0.1 mm Hg, 48 h, 25°C) to a constant weight of 2023 g (85%) of white foam and 20 g of slightly contaminated product from the third run. HPLC indicated a purity of 99.8% with the balance as the diBenzoyl product.

[5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-deoxy-N⁴-benzoyl-5-methylcytidin-3'-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (5-methyl dC amidite)

5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-deoxy-N⁴-benzoyl-5-methylcytidine (998 g, 1.5 mol) was dissolved in anhydrous DMF (2 L). The solution was co-evaporated with toluene (300

-71-

ml) at 50°C under reduced pressure, then cooled to room temperature and 2-cyanoethyl tetraisopropylphosphorodiamidite (680 g, 2.26 mol) and tetrazole (52.5 g, 0.75 mol) were added. The mixture was shaken until all tetrazole was dissolved, N-methylimidazole (15 ml) was added and the mixture was left at room temperature for 5 hours. TEA (300 ml) was added, the mixture was diluted with DMF (2.5 L) and water (600 ml), and extracted with hexane (3 x 3 L). The mixture was diluted with water (1.2 L) and extracted with a mixture of toluene (7.5 L) and hexane (6 L). The two layers were separated, the upper layer was washed with DMF-water (7:3 v/v, 3 x 2 L) and water (3 x 2 L), and the phases were separated. The organic layer was dried (Na₂SO₄), filtered and rotary evaporated. The residue was co-evaporated with acetonitrile (2 x 2 L) under reduced pressure and dried to a constant weight (25 °C, 0.1mm Hg, 40 h) to afford 1250 g an off-white foam solid (96%).

2'-Fluoro amidites

2'-Fluorodeoxyadenosine amidites

2'-fluoro oligonucleotides were synthesized as described previously [Kawasaki, et. al., *J. Med. Chem.*, **1993**, 36, 831-841] and United States patent 5,670,633, herein incorporated by reference. The preparation of 2'-fluoropyrimidines containing a 5-methyl substitution are described in US Patent 5,861,493. Briefly, the protected nucleoside N6-benzoyl-2'-deoxy-2'-fluoroadenosine was synthesized utilizing commercially available 9-beta-D-arabinofuranosyladenine as starting material and whereby the 2'-alpha-fluoro atom is introduced by a S_N2-displacement of a 2'-beta-triflate group. Thus N6-benzoyl-9-beta-D-arabinofuranosyladenine was selectively protected in moderate yield as the 3',5'-ditetrahydropyranyl (THP) intermediate. Deprotection of the

-72-

THP and N6-benzoyl groups was accomplished using standard methodologies to obtain the 5'-dimethoxytrityl-(DMT) and 5'-DMT-3'-phosphoramidite intermediates.

5 **2'-Fluorodeoxyguanosine**

The synthesis of 2'-deoxy-2'-fluoroguanosine was accomplished using tetraisopropylidisiloxanyl (TPDS) protected 9-beta-D-arabinofuranosylguanine as starting material, and conversion to the intermediate isobutyryl-arabinofuranosylguanosine. Alternatively, isobutyryl-arabinofuranosylguanosine was prepared as described by Ross et al., (Nucleosides & Nucleosides, 16, 1645, 1997). Deprotection of the TPDS group was followed by protection of the hydroxyl group with THP to give isobutyryl di-THP protected arabinofuranosylguanine. Selective O-deacylation and triflation was followed by treatment of the crude product with fluoride, then deprotection of the THP groups. Standard methodologies were used to obtain the 5'-DMT- and 5'-DMT-3'-phosphoramidites.

20

2'-Fluorouridine

Synthesis of 2'-deoxy-2'-fluorouridine was accomplished by the modification of a literature procedure in which 2,2'-anhydro-1-beta-D-arabinofuranosyluracil was treated with 70% hydrogen fluoride-pyridine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

2'-Fluorodeoxycytidine

2'-deoxy-2'-fluorocytidine was synthesized via amination of 2'-deoxy-2'-fluorouridine, followed by selective protection to give N4-benzoyl-2'-deoxy-2'-fluorocytidine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

-73-

2'-O-(2-Methoxyethyl) modified amidites

2'-O-Methoxyethyl-substituted nucleoside amidites (otherwise known as MOE amidites) are prepared as follows, or alternatively, as per the methods of Martin, P., (Helvetica Chimica Acta, 1995, 78, 486-504).

Preparation of 2'-O-(2-methoxyethyl)-5-methyluridine intermediate

10 2,2'-Anhydro-5-methyl-uridine (2000 g, 8.32 mol),
tris(2-methoxyethyl)borate (2504 g, 10.60 mol), sodium
bicarbonate (60 g, 0.70 mol) and anhydrous 2-methoxyethanol
(5 L) were combined in a 12 L three necked flask and heated
to 130 °C (internal temp) at atmospheric pressure, under an
15 argon atmosphere with stirring for 21 h. TLC indicated a
complete reaction. The solvent was removed under reduced
pressure until a sticky gum formed (50-85°C bath temp and
100-11 mm Hg) and the residue was redissolved in water (3 L)
and heated to boiling for 30 min in order the hydrolyze the
20 borate esters. The water was removed under reduced pressure
until a foam began to form and then the process was repeated.
HPLC indicated about 77% product, 15% dimer (5' of product
attached to 2' of starting material) and unknown derivatives,
and the balance was a single unresolved early eluting peak.
25 The gum was redissolved in brine (3 L), and the flask
was rinsed with additional brine (3 L). The combined aqueous
solutions were extracted with chloroform (20 L) in a heavier-
than continuous extractor for 70 h. The chloroform layer was
concentrated by rotary evaporation in a 20 L flask to a
30 sticky foam (2400 g). This was coevaporated with MeOH (400
mL) and EtOAc (8 L) at 75°C and 0.65 atm until the foam
dissolved at which point the vacuum was lowered to about 0.5
atm. After 2.5 L of distillate was collected a precipitate

-74-

began to form and the flask was removed from the rotary evaporator and stirred until the suspension reached ambient temperature. EtOAc (2 L) was added and the slurry was filtered on a 25 cm table top Buchner funnel and the product
5 was washed with EtOAc (3 x 2 L). The bright white solid was air dried in pans for 24 h then further dried in a vacuum oven (50°C, 0.1 mm Hg, 24 h) to afford 1649 g of a white crystalline solid (mp 115.5-116.5°C).

The brine layer in the 20 L continuous extractor was
10 further extracted for 72 h with recycled chloroform. The chloroform was concentrated to 120 g of oil and this was combined with the mother liquor from the above filtration (225 g), dissolved in brine (250 mL) and extracted once with chloroform (250 mL). The brine solution was continuously
15 extracted and the product was crystallized as described above to afford an additional 178 g of crystalline product containing about 2% of thymine. The combined yield was 1827 g (69.4%). HPLC indicated about 99.5% purity with the balance being the dimer.

20

Preparation of 5'-O-DMT-2'-O-(2-methoxyethyl)-5-methyluridine penultimate intermediate

In a 50 L glass-lined steel reactor, 2'-O-(2-methoxyethyl)-5-methyl-uridine (MOE-T, 1500 g, 4.738 mol),
25 lutidine (1015 g, 9.476 mol) were dissolved in anhydrous acetonitrile (15 L). The solution was stirred rapidly and chilled to -10°C (internal temperature). Dimethoxytriphenylmethyl chloride (1765.7 g, 5.21 mol) was added as a solid in one portion. The reaction was allowed to
30 warm to -2°C over 1 h. (Note: The reaction was monitored closely by TLC (EtOAc) to determine when to stop the reaction so as to not generate the undesired bis-DMT substituted side product). The reaction was allowed to warm from -2 to 3°C

-75-

over 25 min. then quenched by adding MeOH (300 mL) followed after 10 min by toluene (16 L) and water (16 L). The solution was transferred to a clear 50 L vessel with a bottom outlet, vigorously stirred for 1 minute, and the layers
5 separated. The aqueous layer was removed and the organic layer was washed successively with 10% aqueous citric acid (8 L) and water (12 L). The product was then extracted into the aqueous phase by washing the toluene solution with aqueous sodium hydroxide (0.5N, 16 L and 8 L). The combined aqueous
10 layer was overlaid with toluene (12 L) and solid citric acid (8 moles, 1270 g) was added with vigorous stirring to lower the pH of the aqueous layer to 5.5 and extract the product into the toluene. The organic layer was washed with water (10 L) and TLC of the organic layer indicated a trace of DMT-
15 O-Me, bis DMT and dimer DMT.

The toluene solution was applied to a silica gel column (6 L sintered glass funnel containing approx. 2 kg of silica gel slurried with toluene (2 L) and TEA(25 mL)) and the fractions were eluted with toluene (12 L) and EtOAc (3 x 4 L)
20 using vacuum applied to a filter flask placed below the column. The first EtOAc fraction containing both the desired product and impurities were resubjected to column chromatography as above. The clean fractions were combined, rotary evaporated to a foam, coevaporated with acetonitrile
25 (6 L) and dried in a vacuum oven (0.1 mm Hg, 40 h, 40°C) to afford 2850 g of a white crisp foam. NMR spectroscopy indicated a 0.25 mole % remainder of acetonitrile (calculates to be approx. 47 g) to give a true dry weight of 2803 g (96%). HPLC indicated that the product was 99.41% pure, with
30 the remainder being 0.06 DMT-O-Me, 0.10 unknown, 0.44 bis DMT, and no detectable dimer DMT or 3'-O-DMT.

-76-

Preparation of [5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-5-methyluridin-3'-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (MOE T amidite)

5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-5-methyluridine (1237 g, 2.0 mol) was dissolved in anhydrous DMF (2.5 L). The solution was co-evaporated with toluene (200 ml) at 50°C under reduced pressure, then cooled to room temperature and 2-cyanoethyl tetraisopropylphosphorodiamidite (900 g, 3.0 mol) and tetrazole (70 g, 1.0 mol) were added. The mixture was shaken until all tetrazole was dissolved, N-methylimidazole (20 ml) was added and the solution was left at room temperature for 5 hours. TEA (300 ml) was added, the mixture was diluted with DMF (3.5 L) and water (600 ml) and extracted with hexane (3 x 3L). The mixture was diluted with water (1.6 L) and extracted with the mixture of toluene (12 L) and hexanes (9 L). The upper layer was washed with DMF-water (7:3 v/v, 3x3 L) and water (3x3 L). The organic layer was dried (Na₂SO₄), filtered and evaporated. The residue was co-evaporated with acetonitrile (2 x 2 L) under reduced pressure and dried in a vacuum oven (25°C, 0.1mm Hg, 40 h) to afford 1526 g of an off-white foamy solid (95%).

Preparation of 5'-O-Dimethoxytrityl-2'-O-(2-methoxyethyl)-5-methylcytidine intermediate

To a 50 L Schott glass-lined steel reactor equipped with an electric stirrer, reagent addition pump (connected to an addition funnel), heating/cooling system, internal thermometer and argon gas line was added 5'-O-dimethoxytrityl-2'-O-(2-methoxyethyl)-5-methyl-uridine (2.616 kg, 4.23 mol, purified by base extraction only and no scrub column), anhydrous acetonitrile (20 L), and TEA (9.5 L, 67.7 mol, 16 eq). The mixture was chilled with stirring to -10°C

-77-

internal temperature (external -20°C).

Trimethylsilylchloride (1.60 L, 12.7 mol, 3.0 eq) was added over 30 min. while maintaining the internal temperature below -5°C, followed by a wash of anhydrous acetonitrile (1 L).

5 (Note: the reaction is mildly exothermic and copious hydrochloric acid fumes form over the course of the addition). The reaction was allowed to warm to 0°C and the reaction progress was confirmed by TLC (EtOAc, R_f 0.68 and 0.87 for starting material and silyl product, respectively).

10 Upon completion, triazole (2.34 kg, 33.8 mol, 8.0 eq) was added the reaction was cooled to -20°C internal temperature (external -30°C). Phosphorous oxychloride (793 mL, 8.51 mol, 2.01 eq) was added slowly over 60 min so as to maintain the temperature between -20°C and -10°C (note: strongly

15 exothermic), followed by a wash of anhydrous acetonitrile (1 L). The reaction was warmed to 0°C and stirred for 1 h, at which point it was an off-white thick suspension. TLC indicated a complete conversion to the triazole product (EtOAc, R_f 0.87 to 0.75 with the product spot glowing in long

20 wavelength UV light). The reaction was cooled to -15°C and water (5 L) was slowly added at a rate to maintain the temperature below +10°C in order to quench the reaction and to form a homogenous solution. (Caution: this reaction is initially very strongly exothermic). Approximately one-half

25 of the reaction volume (22 L) was transferred by air pump to another vessel, diluted with EtOAc (12 L) and extracted with water (2 x 8 L). The second half of the reaction was treated in the same way. The combined aqueous layers were back-

30 extracted with EtOAc (8 L) The organic layers were combined and concentrated in a 20 L rotary evaporator to an oily foam. The foam was coevaporated with anhydrous acetonitrile (4 L) to remove EtOAc. (note: dioxane may be used instead of anhydrous acetonitrile if dried to a hard foam). The residue

-78-

was dissolved in dioxane (2 L) and concentrated ammonium hydroxide (750 mL) was added. A homogenous solution formed in a few minutes and the reaction was allowed to stand overnight

5 TLC indicated a complete reaction (CH_2Cl_2 -acetone-MeOH, 20:5:3, R_f 0.51). The reaction solution was concentrated on a rotary evaporator to a dense foam and slowly redissolved in warm CH_2Cl_2 (4 L, 40°C) and transferred to a 20 L glass extraction vessel equipped with a air-powered stirrer. The
10 organic layer was extracted with water (2 x 6 L) to remove the triazole by-product. (Note: In the first extraction an emulsion formed which took about 2 h to resolve). The water layer was back-extracted with CH_2Cl_2 (2 x 2 L), which in turn was washed with water (3 L). The combined organic layer was
15 concentrated in 2 x 20 L flasks to a gum and then recrystallized from EtOAc seeded with crystalline product. After sitting overnight, the first crop was collected on a 25 cm Coors Buchner funnel and washed repeatedly with EtOAc until a white free-flowing powder was left (about 3 x 3 L).
20 The filtrate was concentrated to an oil recrystallized from EtOAc, and collected as above. The solid was air-dried in pans for 48 h, then further dried in a vacuum oven (50°C , 0.1mm Hg, 17 h) to afford 2248 g of a bright white, dense solid (86%). An HPLC analysis indicated both crops to be
25 99.4% pure and NMR spectroscopy indicated only a faint trace of EtOAc remained.

Preparation of 5'-O-dimethoxytrityl-2'-O-(2-methoxyethyl)-N4-benzoyl-5-methyl-cytidine penultimate intermediate:

30 Crystalline 5'-O-dimethoxytrityl-2'-O-(2-methoxyethyl)-5-methyl-cytidine (1000 g, 1.62 mol) was suspended in anhydrous DMF (3 kg) at ambient temperature and stirred under an Ar atmosphere. Benzoic anhydride (439.3 g, 1.94 mol) was

-79-

added in one portion. The solution clarified after 5 hours and was stirred for 16 h. HPLC indicated 0.45% starting material remained (as well as 0.32% N⁴, 3'-O-bis Benzoyl). An additional amount of benzoic anhydride (6.0 g, 0.0265 mol) was added and after 17 h, HPLC indicated no starting material was present. TEA (450 mL, 3.24 mol) and toluene (6 L) were added with stirring for 1 minute. The solution was washed with water (4 x 4 L), and brine (2 x 4 L). The organic layer was partially evaporated on a 20 L rotary evaporator to remove 4 L of toluene and traces of water. HPLC indicated that the bis benzoyl side product was present as a 6% impurity. The residue was diluted with toluene (7 L) and anhydrous DMSO (200 mL, 2.82 mol) and sodium hydride (60% in oil, 70 g, 1.75 mol) was added in one portion with stirring at ambient temperature over 1 h. The reaction was quenched by slowly adding then washing with aqueous citric acid (10%, 100 mL over 10 min, then 2 x 4 L), followed by aqueous sodium bicarbonate (2%, 2 L), water (2 x 4 L) and brine (4 L). The organic layer was concentrated on a 20 L rotary evaporator to about 2 L total volume. The residue was purified by silica gel column chromatography (6 L Buchner funnel containing 1.5 kg of silica gel wetted with a solution of EtOAc-hexanes-TEA(70:29:1)). The product was eluted with the same solvent (30 L) followed by straight EtOAc (6 L). The fractions containing the product were combined, concentrated on a rotary evaporator to a foam and then dried in a vacuum oven (50°C, 0.2 mm Hg, 8 h) to afford 1155 g of a crisp, white foam (98%). HPLC indicated a purity of >99.7%.

30 **Preparation of [5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-N⁴-benzoyl-5-methylcytidin-3'-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (MOE 5-Me-C amidite)**

-80-

5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-N⁴-benzoyl-5-methylcytidine (1082 g, 1.5 mol) was dissolved in anhydrous DMF (2 L) and co-evaporated with toluene (300 ml) at 50 °C under reduced pressure. The mixture was cooled to room temperature and 2-cyanoethyl tetraisopropylphosphorodiamidite (680 g, 2.26 mol) and tetrazole (52.5 g, 0.75 mol) were added. The mixture was shaken until all tetrazole was dissolved, N-methylimidazole (30 ml) was added, and the mixture was left at room temperature for 5 hours. TEA (300 ml) was added, the mixture was diluted with DMF (1 L) and water (400 ml) and extracted with hexane (3 x 3 L). The mixture was diluted with water (1.2 L) and extracted with a mixture of toluene (9 L) and hexanes (6 L). The two layers were separated and the upper layer was washed with DMF-water (60:40 v/v, 3 x 3 L) and water (3 x 2 L). The organic layer was dried (Na₂SO₄), filtered and evaporated. The residue was co-evaporated with acetonitrile (2 x 2 L) under reduced pressure and dried in a vacuum oven (25 °C, 0.1mm Hg, 40 h) to afford 1336 g of an off-white foam (97%).

Preparation of [5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-N⁶-benzoyl-adenosine-3'-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (MOE A amidite)

5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-N⁶-benzoyl-adenosine (purchased from Reliable Biopharmaceutical, St. Lois, MO), 1098 g, 1.5 mol) was dissolved in anhydrous DMF (3 L) and co-evaporated with toluene (300 ml) at 50 °C. The mixture was cooled to room temperature and 2-cyanoethyl tetraisopropylphosphorodiamidite (680 g, 2.26 mol) and tetrazole (78.8 g, 1.24 mol) were added. The mixture was shaken until all tetrazole was dissolved, N-methylimidazole (30 ml) was added, and mixture was left at room temperature for 5 hours. TEA (300 ml) was

-81-

added, the mixture was diluted with DMF (1 L) and water (400 ml) and extracted with hexanes (3 x 3 L). The mixture was diluted with water (1.4 L) and extracted with the mixture of toluene (9 L) and hexanes (6 L). The two layers were
5 separated and the upper layer was washed with DMF-water (60:40, v/v, 3 x 3 L) and water (3 x 2 L). The organic layer was dried (Na₂SO₄), filtered and evaporated to a sticky foam. The residue was co-evaporated with acetonitrile (2.5 L) under reduced pressure and dried in a vacuum oven (25 °C, 0.1mm Hg,
10 40 h) to afford 1350 g of an off-white foam solid (96%).

Preparation of [5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-N⁴-isobutyrylguanosin-3'-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (MOE G amidite)

15 5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-N⁴-isobutyrylguanosine (purchased from Reliable Biopharmaceutical, St. Louis, MO, 1426 g, 2.0 mol) was dissolved in anhydrous DMF (2 L). The solution was co-evaporated with toluene (200 ml) at 50 °C, cooled to room
20 temperature and 2-cyanoethyl tetraisopropylphosphorodiamidite (900 g, 3.0 mol) and tetrazole (68 g, 0.97 mol) were added. The mixture was shaken until all tetrazole was dissolved, N-methylimidazole (30 ml) was added, and the mixture was left at room temperature for 5 hours. TEA (300 ml) was added, the
25 mixture was diluted with DMF (2 L) and water (600 ml) and extracted with hexanes (3 x 3 L). The mixture was diluted with water (2 L) and extracted with a mixture of toluene (10 L) and hexanes (5 L). The two layers were separated and the upper layer was washed with DMF-water (60:40, v/v, 3x3 L).
30 EtOAc (4 L) was added and the solution was washed with water (3 x 4 L). The organic layer was dried (Na₂SO₄), filtered and evaporated to approx. 4 kg. Hexane (4 L) was added, the mixture was shaken for 10 min, and the supernatant liquid was

-82-

decanted. The residue was co-evaporated with acetonitrile (2 x 2 L) under reduced pressure and dried in a vacuum oven (25 °C, 0.1mm Hg, 40 h) to afford 1660 g of an off-white foamy solid (91%).

5

2'-O-(Aminooxyethyl) nucleoside amidites and 2'-O-(dimethylaminooxyethyl) nucleoside amidites

2'-(Dimethylaminooxyethoxy) nucleoside amidites

2'-(Dimethylaminooxyethoxy) nucleoside amidites (also known in the art as 2'-O-(dimethylaminooxyethyl) nucleoside amidites) are prepared as described in the following paragraphs. Adenosine, cytidine and guanosine nucleoside amidites are prepared similarly to the thymidine (5-methyluridine) except the exocyclic amines are protected with a benzoyl moiety in the case of adenosine and cytidine and with isobutyryl in the case of guanosine.

5'-O-tert-Butyldiphenylsilyl-O²-2'-anhydro-5-methyluridine

O²-2'-anhydro-5-methyluridine (Pro. Bio. Sint., Varese, Italy, 100.0g, 0.416 mmol), dimethylaminopyridine (0.66g, 0.013eq, 0.0054mmol) were dissolved in dry pyridine (500 ml) at ambient temperature under an argon atmosphere and with mechanical stirring. tert-Butyldiphenylchlorosilane (125.8g, 119.0mL, 1.1eq, 0.458mmol) was added in one portion. The reaction was stirred for 16 h at ambient temperature. TLC (R_f 0.22, EtOAc) indicated a complete reaction. The solution was concentrated under reduced pressure to a thick oil. This was partitioned between CH₂Cl₂ (1 L) and saturated sodium bicarbonate (2 x 1 L) and brine (1 L). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure to a thick oil. The oil was dissolved in a 1:1 mixture of EtOAc and ethyl ether (600mL) and cooling the

-83-

solution to -10°C afforded a white crystalline solid which was collected by filtration, washed with ethyl ether (3 x 200 mL) and dried (40°C, 1mm Hg, 24 h) to afford 149g of white solid (74.8%). TLC and NMR spectroscopy were consistent with pure product.

5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine

In the fume hood, ethylene glycol (350 mL, excess) was added cautiously with manual stirring to a 2 L stainless steel pressure reactor containing borane in tetrahydrofuran (1.0 M, 2.0 eq, 622 mL). (Caution : evolves hydrogen gas). 5'-O-tert-Butyldiphenylsilyl-2'-anhydro-5-methyluridine (149 g, 0.311 mol) and sodium bicarbonate (0.074 g, 0.003 eq) were added with manual stirring. The reactor was sealed and heated in an oil bath until an internal temperature of 160 °C was reached and then maintained for 16 h (pressure < 100 psig). The reaction vessel was cooled to ambient temperature and opened. TLC (EtOAc, R_f 0.67 for desired product and R_f 0.82 for ara-T side product) indicated about 70% conversion to the product. The solution was concentrated under reduced pressure (10 to 1mm Hg) in a warm water bath (40-100°C) with the more extreme conditions used to remove the ethylene glycol. (Alternatively, once the THF has evaporated the solution can be diluted with water and the product extracted into EtOAc). The residue was purified by column chromatography (2kg silica gel, EtOAc-hexanes gradient 1:1 to 4:1). The appropriate fractions were combined, evaporated and dried to afford 84 g of a white crisp foam (50%), contaminated starting material (17.4g, 12% recovery) and pure reusable starting material (20g, 13% recovery). TLC and NMR spectroscopy were consistent with 99% pure product.

-84-

2'-O-([2-phthalimidoxy)ethyl]-5'-t-butylidiphenylsilyl-5-methyluridine

5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine (20g, 36.98mmol) was mixed with
5 triphenylphosphine (11.63g, 44.36mmol) and N-hydroxyphthalimide (7.24g, 44.36mmol) and dried over P₂O₅ under high vacuum for two days at 40°C. The reaction mixture was flushed with argon and dissolved in dry THF (369.8mL, Aldrich, sure seal bottle). Diethyl-azodicarboxylate
10 (6.98mL, 44.36mmol) was added dropwise to the reaction mixture with the rate of addition maintained such that the resulting deep red coloration is just discharged before adding the next drop. The reaction mixture was stirred for 4 hrs., after which time TLC (EtOAc:hexane, 60:40) indicated
15 that the reaction was complete. The solvent was evaporated in vacuo and the residue purified by flash column chromatography (eluted with 60:40 EtOAc:hexane), to yield 2'-O-([2-phthalimidoxy)ethyl]-5'-t-butylidiphenylsilyl-5-methyluridine as white foam (21.819 g, 86%) upon rotary
20 evaporation.

5'-O-tert-butylidiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine

2'-O-([2-phthalimidoxy)ethyl]-5'-t-butylidiphenylsilyl-5-methyluridine (3.1g, 4.5mmol) was dissolved in dry CH₂Cl₂
25 (4.5mL) and methylhydrazine (300mL, 4.64mmol) was added dropwise at -10°C to 0°C. After 1 h the mixture was filtered, the filtrate washed with ice cold CH₂Cl₂, and the combined organic phase was washed with water and brine and dried
30 (anhydrous Na₂SO₄). The solution was filtered and evaporated to afford 2'-O-(aminooxyethyl) thymidine, which was then dissolved in MeOH (67.5mL). Formaldehyde (20% aqueous solution, w/w, 1.1 eq.) was added and the resulting mixture

-85-

was stirred for 1 h. The solvent was removed under vacuum and the residue was purified by column chromatography to yield 5'-O-*tert*-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine as white foam (1.95 g, 78%) upon rotary evaporation.

5'-O-*tert*-Butyldiphenylsilyl-2'-O-[N,N-dimethylaminooxyethyl]-5-methyluridine

5'-O-*tert*-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine (1.77g, 3.12mmol) was dissolved in a solution of 1M pyridinium *p*-toluenesulfonate (PPTS) in dry MeOH (30.6mL) and cooled to 10°C under inert atmosphere. Sodium cyanoborohydride (0.39g, 6.13mmol) was added and the reaction mixture was stirred. After 10 minutes the reaction was warmed to room temperature and stirred for 2 h. while the progress of the reaction was monitored by TLC (5% MeOH in CH₂Cl₂). Aqueous NaHCO₃ solution (5%, 10mL) was added and the product was extracted with EtOAc (2 x 20 mL). The organic phase was dried over anhydrous Na₂SO₄, filtered, and evaporated to dryness. This entire procedure was repeated with the resulting residue, with the exception that formaldehyde (20% w/w, 30 mL, 3.37 mol) was added upon dissolution of the residue in the PPTS/MeOH solution. After the extraction and evaporation, the residue was purified by flash column chromatography and (eluted with 5% MeOH in CH₂Cl₂) to afford 5'-O-*tert*-butyldiphenylsilyl-2'-O-[N,N-dimethylaminooxyethyl]-5-methyluridine as a white foam (14.6g, 80%) upon rotary evaporation.

2'-O-(dimethylaminooxyethyl)-5-methyluridine

Triethylamine trihydrofluoride (3.91mL, 24.0mmol) was dissolved in dry THF and TEA (1.67mL, 12mmol, dry, stored over KOH) and added to 5'-O-*tert*-butyldiphenylsilyl-2'-O-

-86-

[N,N-dimethylaminoxyethyl]-5-methyluridine (1.40g, 2.4mmol). The reaction was stirred at room temperature for 24 hrs and monitored by TLC (5% MeOH in CH₂Cl₂). The solvent was removed under vacuum and the residue purified by flash column chromatography (eluted with 10% MeOH in CH₂Cl₂) to afford 2'-O-(dimethylaminoxyethyl)-5-methyluridine (766mg, 92.5%) upon rotary evaporation of the solvent.

5'-O-DMT-2'-O-(dimethylaminoxyethyl)-5-methyluridine

2'-O-(dimethylaminoxyethyl)-5-methyluridine (750 mg, 2.17 mmol) was dried over P₂O₅ under high vacuum overnight at 40°C, co-evaporated with anhydrous pyridine (20 mL), and dissolved in pyridine (11 mL) under argon atmosphere. 4-dimethylaminopyridine (26.5 mg, 2.60 mmol) and 4,4'-dimethoxytrityl chloride (880 mg, 2.60 mmol) were added to the pyridine solution and the reaction mixture was stirred at room temperature until all of the starting material had reacted. Pyridine was removed under vacuum and the residue was purified by column chromatography (eluted with 10% MeOH in CH₂Cl₂ containing a few drops of pyridine) to yield 5'-O-DMT-2'-O-(dimethylamino-oxyethyl)-5-methyluridine (1.13g, 80%) upon rotary evaporation.

5'-O-DMT-2'-O-(2-N,N-dimethylaminoxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]

5'-O-DMT-2'-O-(dimethylaminoxyethyl)-5-methyluridine (1.08 g, 1.67 mmol) was co-evaporated with toluene (20 mL), N,N-diisopropylamine tetrazonide (0.29 g, 1.67 mmol) was added and the mixture was dried over P₂O₅ under high vacuum overnight at 40°C. This was dissolved in anhydrous acetonitrile (8.4 mL) and 2-cyanoethyl-N,N,N¹,N¹-tetraisopropylphosphoramidite (2.12 mL, 6.08 mmol) was added.

-87-

The reaction mixture was stirred at ambient temperature for 4 h under inert atmosphere. The progress of the reaction was monitored by TLC (hexane:EtOAc 1:1). The solvent was evaporated, then the residue was dissolved in EtOAc (70mL) and washed with 5% aqueous NaHCO₃ (40mL). The EtOAc layer was dried over anhydrous Na₂SO₄, filtered, and concentrated. The residue obtained was purified by column chromatography (EtOAc as eluent) to afford 5'-O-DMT-2'-O-(2-N,N-dimethylaminoxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite] as a foam (1.04g, 74.9%) upon rotary evaporation.

2'-(Aminooxyethoxy) nucleoside amidites

2'-(Aminooxyethoxy) nucleoside amidites (also known in the art as 2'-O-(aminooxyethyl) nucleoside amidites) are prepared as described in the following paragraphs. Adenosine, cytidine and thymidine nucleoside amidites are prepared similarly.

N2-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]

The 2'-O-aminooxyethyl guanosine analog may be obtained by selective 2'-O-alkylation of diaminopurine riboside. Multigram quantities of diaminopurine riboside may be purchased from Schering AG (Berlin) to provide 2'-O-(2-ethylacetyl) diaminopurine riboside along with a minor amount of the 3'-O-isomer. 2'-O-(2-ethylacetyl) diaminopurine riboside may be resolved and converted to 2'-O-(2-ethylacetyl)guanosine by treatment with adenosine deaminase. (McGee, D. P. C., Cook, P. D., Guinosso, C. J., WO 94/02501 A1 940203.) Standard protection procedures should afford 2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine and

-88-

2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine which may be reduced to provide 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-hydroxyethyl)-5'-O-(4,4'-dimethoxytrityl)guanosine. As before
5 the hydroxyl group may be displaced by N-hydroxyphthalimide via a Mitsunobu reaction, and the protected nucleoside may be phosphitylated as usual to yield 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-([2-phthalamidoxy]ethyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-
10 diisopropylphosphoramidite].

2'-dimethylaminoethoxyethoxy (2'-DMAEOE) nucleoside amidites

2'-dimethylaminoethoxyethoxy nucleoside amidites (also known in the art as 2'-O-dimethylaminoethoxyethyl, i.e., 2'-O-CH₂-O-CH₂-N(CH₂)₂, or 2'-DMAEOE nucleoside amidites) are
15 prepared as follows. Other nucleoside amidites are prepared similarly.

2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine

20 2[2-(Dimethylamino)ethoxy]ethanol (Aldrich, 6.66 g, 50 mmol) was slowly added to a solution of borane in tetrahydrofuran (1 M, 10 mL, 10 mmol) with stirring in a 100 mL bomb. (Caution: Hydrogen gas evolves as the solid dissolves). O²-,2'-anhydro-5-methyluridine (1.2 g, 5 mmol),
25 and sodium bicarbonate (2.5 mg) were added and the bomb was sealed, placed in an oil bath and heated to 155°C for 26 h. then cooled to room temperature. The crude solution was concentrated, the residue was diluted with water (200 mL) and extracted with hexanes (200 mL). The product was extracted
30 from the aqueous layer with EtOAc (3 x 200 mL) and the combined organic layers were washed once with water, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography

-89-

(eluted with 5:100:2 MeOH/CH₂Cl₂/TEA) as the eluent. The appropriate fractions were combined and evaporated to afford the product as a white solid.

5 **5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl)]-5-methyl uridine**

To 0.5 g (1.3 mmol) of 2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl)]-5-methyl uridine in anhydrous pyridine (8 mL), was added TEA (0.36 mL) and dimethoxytrityl chloride (DMT-Cl, 10 0.87 g, 2 eq.) and the reaction was stirred for 1 h. The reaction mixture was poured into water (200 mL) and extracted with CH₂Cl₂ (2 x 200 mL). The combined CH₂Cl₂ layers were washed with saturated NaHCO₃ solution, followed by saturated NaCl solution, dried over anhydrous sodium sulfate, filtered 15 and evaporated. The residue was purified by silica gel column chromatography (eluted with 5:100:1 MeOH/CH₂Cl₂/TEA) to afford the product.

20 **5'-O-Dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl)]-5-methyl uridine-3'-O-(cyanoethyl-N,N-diisopropyl)phosphoramidite**

Diisopropylaminotetrazolide (0.6 g) and 2-cyanoethoxy-N,N-diisopropyl phosphoramidite (1.1 mL, 2 eq.) were added to a solution of 5'-O-dimethoxytrityl-2'-O-[2(2-N,N- 25 dimethylaminoethoxy)ethyl)]-5-methyluridine (2.17 g, 3 mmol) dissolved in CH₂Cl₂ (20 mL) under an atmosphere of argon. The reaction mixture was stirred overnight and the solvent evaporated. The resulting residue was purified by silica gel column chromatography with EtOAc as the eluent to afford the 30 title compound.

Example 2

Oligonucleotide synthesis

-90-

Unsubstituted and substituted phosphodiester (P=O) oligonucleotides are synthesized on an automated DNA synthesizer (Applied Biosystems model 394) using standard phosphoramidite chemistry with oxidation by iodine.

5 Phosphorothioates (P=S) are synthesized similar to phosphodiester oligonucleotides with the following exceptions: thiation was effected by utilizing a 10% w/v solution of 3H-1,2-benzodithiole-3-one 1,1-dioxide in acetonitrile for the oxidation of the phosphite linkages.

10 The thiation reaction step time was increased to 180 sec and preceded by the normal capping step. After cleavage from the CPG column and deblocking in concentrated ammonium hydroxide at 55°C (12-16 hr), the oligonucleotides were recovered by precipitating with >3 volumes of ethanol from a 1 M NH₄OAc

15 solution. Phosphinate oligonucleotides are prepared as described in U.S. Patent 5,508,270, herein incorporated by reference.

Alkyl phosphonate oligonucleotides are prepared as described in U.S. Patent 4,469,863, herein incorporated by

20 reference.

3'-Deoxy-3'-methylene phosphonate oligonucleotides are prepared as described in U.S. Patents 5,610,289 or 5,625,050, herein incorporated by reference.

Phosphoramidite oligonucleotides are prepared as

25 described in U.S. Patent, 5,256,775 or U.S. Patent 5,366,878, herein incorporated by reference.

Alkylphosphonothioate oligonucleotides are prepared as described in published PCT applications PCT/US94/00902 and PCT/US93/06976 (published as WO 94/17093 and WO 94/02499,

30 respectively), herein incorporated by reference.

3'-Deoxy-3'-amino phosphoramidate oligonucleotides are prepared as described in U.S. Patent 5,476,925, herein incorporated by reference.

-91-

Phosphotriester oligonucleotides are prepared as described in U.S. Patent 5,023,243, herein incorporated by reference.

5 Borano phosphate oligonucleotides are prepared as described in U.S. Patents 5,130,302 and 5,177,198, both herein incorporated by reference.

Example 3

Oligonucleoside Synthesis

10 Methylenemethylimino linked oligonucleosides, also identified as MMI linked oligonucleosides, methylenedimethylhydrazo linked oligonucleosides, also identified as MDH linked oligonucleosides, and methylenecarbonylamino linked oligonucleosides, also identified as amide-3 linked
15 oligonucleosides, and methyleneaminocarbonyl linked oligonucleosides, also identified as amide-4 linked oligonucleosides, as well as mixed backbone compounds having, for instance, alternating MMI and P=O or P=S linkages are prepared as described in U.S. Patents 5,378,825, 5,386,023,
20 5,489,677, 5,602,240 and 5,610,289, all of which are herein incorporated by reference.

Formacetal and thioformacetal linked oligonucleosides are prepared as described in U.S. Patents 5,264,562 and 5,264,564, herein incorporated by reference.

25 Ethylene oxide linked oligonucleosides are prepared as described in U.S. Patent 5,223,618, herein incorporated by reference.

Example 4

30 PNA Synthesis

Peptide nucleic acids (PNAs) are prepared in accordance with any of the various procedures referred to in Peptide Nucleic Acids (PNA): Synthesis, Properties and Potential

-92-

Applications, *Bioorganic & Medicinal Chemistry*, 1996, 4, 5-23. They may also be prepared in accordance with U.S. Patents 5,539,082, 5,700,922, and 5,719,262, herein incorporated by reference.

5

Example 5**Synthesis of Chimeric Oligonucleotides**

Chimeric oligonucleotides, oligonucleosides or mixed oligonucleotides/oligonucleosides of the invention can be of several different types. These include a first type wherein the "gap" segment of linked nucleosides is positioned between 5' and 3' "wing" segments of linked nucleosides and a second "open end" type wherein the "gap" segment is located at either the 3' or the 5' terminus of the oligomeric compound. Oligonucleotides of the first type are also known in the art as "gapmers" or gapped oligonucleotides. Oligonucleotides of the second type are also known in the art as "hemimers" or "wingmers".

20

**[2'-O-Me]--[2'-deoxy]--[2'-O-Me] Chimeric
Phosphorothioate Oligonucleotides**

25

Chimeric oligonucleotides having 2'-O-alkyl phosphorothioate and 2'-deoxy phosphorothioate oligonucleotide segments are synthesized using an Applied Biosystems automated DNA synthesizer Model 394, as above. Oligonucleotides are synthesized using the automated synthesizer and 2'-deoxy-5'-dimethoxytrityl-3'-O-phosphoramidite for the DNA portion and 5'-dimethoxytrityl-2'-O-methyl-3'-O-phosphoramidite for 5' and 3' wings. The standard synthesis cycle is modified by incorporating coupling steps with increased reaction times for the 5'-dimethoxytrityl-2'-O-methyl-3'-O-phosphoramidite. The fully protected oligonucleotide is cleaved from the support and deprotected in concentrated ammonia (NH₄OH) for 12-16 hr at

-93-

55°C. The deprotected oligo is then recovered by an appropriate method (precipitation, column chromatography, volume reduced *in vacuo* and analyzed spectrophotometrically for yield and for purity by capillary electrophoresis and by mass spectrometry.

[2'-O-(2-Methoxyethyl)]--[2'-deoxy]--[2'-O-(Methoxyethyl)] Chimeric Phosphorothioate Oligonucleotides

[2'-O-(2-methoxyethyl)]--[2'-deoxy]--[2'-O-(methoxyethyl)] chimeric phosphorothioate oligonucleotides were prepared as per the procedure above for the 2'-O-methyl chimeric oligonucleotide, with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites.

[2'-O-(2-Methoxyethyl) Phosphodiester]--[2'-deoxy Phosphorothioate]--[2'-O-(2-Methoxyethyl) Phosphodiester] Chimeric Oligonucleotides

[2'-O-(2-methoxyethyl phosphodiester)]--[2'-deoxy phosphorothioate]--[2'-O-(methoxyethyl) phosphodiester] chimeric oligonucleotides are prepared as per the above procedure for the 2'-O-methyl chimeric oligonucleotide with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites, oxidation with iodine to generate the phosphodiester internucleotide linkages within the wing portions of the chimeric structures and sulfurization utilizing 3,4-dithiolane-2-one 1,1-dioxide (Beaucage Reagent) to generate the phosphorothioate internucleotide linkages for the center gap.

Other chimeric oligonucleotides, chimeric oligonucleosides and mixed chimeric oligonucleotides/oligonucleosides are synthesized according to United States patent 5,623,065, herein incorporated by

-94-

reference.

Example 6

Oligonucleotide Isolation

5 After cleavage from the controlled pore glass solid support and deblocking in concentrated ammonium hydroxide at 55°C for 12-16 hours, the oligonucleotides or oligonucleosides are recovered by precipitation out of 1 M NH₄OAc with >3 volumes of ethanol. Synthesized oligonucleotides were
10 analyzed by electrospray mass spectroscopy (molecular weight determination) and by capillary gel electrophoresis and judged to be at least 70% full length material. The relative amounts of phosphorothioate and phosphodiester linkages obtained in the synthesis was determined by the ratio of
15 correct molecular weight relative to the -16 amu product (+/- 32 +/-48). For some studies oligonucleotides were purified by HPLC, as described by Chiang et al., *J. Biol. Chem.* **1991**, 266, 18162-18171. Results obtained with HPLC-purified material were similar to those obtained with non-HPLC
20 purified material.

Example 7

Oligonucleotide Synthesis - 96 Well Plate Format

25 Oligonucleotides were synthesized via solid phase P(III) phosphoramidite chemistry on an automated synthesizer capable of assembling 96 sequences simultaneously in a 96-well format. Phosphodiester internucleotide linkages were afforded by oxidation with aqueous iodine. Phosphorothioate internucleotide linkages were generated by sulfurization
30 utilizing 3,4-dihydro-2H-benzothiole-3-one 1,1-dioxide (Beaucage Reagent) in anhydrous acetonitrile. Standard base-protected beta-cyanoethyl-diisopropyl phosphoramidites were purchased from commercial vendors (e.g. PE-Applied Biosystems, Foster

-95-

City, CA, or Pharmacia, Piscataway, NJ). Non-standard nucleosides are synthesized as per standard or patented methods. They are utilized as base protected beta-cyanoethyl-diisopropyl phosphoramidites.

5 Oligonucleotides were cleaved from support and deprotected with concentrated NH_4OH at elevated temperature (55-60°C) for 12-16 hours and the released product then dried *in vacuo*. The dried product was then re-suspended in sterile water to afford a master plate from which all analytical and
10 test plate samples are then diluted utilizing robotic pipettors.

Example 8

15 Oligonucleotide Analysis - 96-Well Plate Format

The concentration of oligonucleotide in each well was assessed by dilution of samples and UV absorption spectroscopy. The full-length integrity of the individual products was evaluated by capillary electrophoresis (CE) in
20 either the 96-well format (Beckman P/ACE™ MDQ) or, for individually prepared samples, on a commercial CE apparatus (e.g., Beckman P/ACE™ 5000, ABI 270). Base and backbone composition was confirmed by mass analysis of the compounds utilizing electrospray-mass spectroscopy. All assay test
25 plates were diluted from the master plate using single and multi-channel robotic pipettors. Plates were judged to be acceptable if at least 85% of the compounds on the plate were at least 85% full length.

30 Example 9

Cell culture and oligonucleotide treatment

The effect of antisense compounds on target nucleic acid expression can be tested in any of a variety of cell types

-96-

provided that the target nucleic acid is present at measurable levels. This can be routinely determined using, for example, PCR or Northern blot analysis. The following cell types are provided for illustrative purposes, but other cell types can be routinely used, provided that the target is expressed in the cell type chosen. This can be readily determined by methods routine in the art, for example Northern blot analysis, ribonuclease protection assays, or RT-PCR.

10

T-24 cells:

The human transitional cell bladder carcinoma cell line T-24 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). T-24 cells were routinely cultured in complete McCoy's 5A basal media (Invitrogen Corporation, Carlsbad, CA) supplemented with 10% fetal calf serum (Invitrogen Corporation, Carlsbad, CA), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Invitrogen Corporation, Carlsbad, CA). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

20

For Northern blotting or other analysis, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

25

A549 cells:

The human lung carcinoma cell line A549 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). A549 cells were routinely cultured in DMEM basal media (Invitrogen Corporation, Carlsbad, CA) supplemented with 10% fetal calf serum (Invitrogen Corporation, Carlsbad, CA),

30

-97-

penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Invitrogen Corporation, Carlsbad, CA). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence.

5

NHDF cells:

Human neonatal dermal fibroblast (NHDF) were obtained from the Clonetics Corporation (Walkersville, MD). NHDFs were routinely maintained in Fibroblast Growth Medium (Clonetics Corporation, Walkersville, MD) supplemented as recommended by the supplier. Cells were maintained for up to 10 passages as recommended by the supplier.

HEK cells:

Human embryonic keratinocytes (HEK) were obtained from the Clonetics Corporation (Walkersville, MD). HEKs were routinely maintained in Keratinocyte Growth Medium (Clonetics Corporation, Walkersville, MD) formulated as recommended by the supplier. Cells were routinely maintained for up to 10 passages as recommended by the supplier.

Treatment with antisense compounds:

When cells reached 70% confluency, they were treated with oligonucleotide. For cells grown in 96-well plates, wells were washed once with 100 μ L OPTI-MEMTM-1 reduced-serum medium (Invitrogen Corporation, Carlsbad, CA) and then treated with 130 μ L of OPTI-MEMTM-1 containing 3.75 μ g/mL LIPOFECTINTM (Invitrogen Corporation, Carlsbad, CA) and the desired concentration of oligonucleotide. After 4-7 hours of treatment, the medium was replaced with fresh medium. Cells were harvested 16-24 hours after oligonucleotide treatment.

The concentration of oligonucleotide used varies from cell line to cell line. To determine the optimal

-98-

oligonucleotide concentration for a particular cell line, the cells are treated with a positive control oligonucleotide at a range of concentrations. For human cells the positive control oligonucleotide is selected from either ISIS 13920 (TCCGTCATCGCT**CCTCAGGG**, SEQ ID NO: 1) which is targeted to human H-ras, or ISIS 18078, (GTGCGCGAGCCCGAAATC, SEQ ID NO: 2) which is targeted to human Jun-N-terminal kinase-2 (JNK2). Both controls are 2'-O-methoxyethyl gapmers (2'-O-methoxyethyls shown in bold) with a phosphorothioate backbone. For mouse or rat cells the positive control oligonucleotide is ISIS 15770, **ATGCATTCTGCCCCAAGGA**, SEQ ID NO: 3, a 2'-O-methoxyethyl gapmer (2'-O-methoxyethyls shown in bold) with a phosphorothioate backbone which is targeted to both mouse and rat c-raf. The concentration of positive control oligonucleotide that results in 80% inhibition of c-Ha-ras (for ISIS 13920) or c-raf (for ISIS 15770) mRNA is then utilized as the screening concentration for new oligonucleotides in subsequent experiments for that cell line. If 80% inhibition is not achieved, the lowest concentration of positive control oligonucleotide that results in 60% inhibition of H-ras or c-raf mRNA is then utilized as the oligonucleotide screening concentration in subsequent experiments for that cell line. If 60% inhibition is not achieved, that particular cell line is deemed as unsuitable for oligonucleotide transfection experiments. The concentrations of antisense oligonucleotides used herein are from 50 nM to 300 nM.

Example 10

30 Analysis of oligonucleotide inhibition of IL-1 receptor-associated kinase-1 expression

Antisense modulation of IL-1 receptor-associated kinase-1 expression can be assayed in a variety of ways known in the

-99-

art. For example, IL-1 receptor-associated kinase-1 mRNA levels can be quantitated by, e.g., Northern blot analysis, competitive polymerase chain reaction (PCR), or real-time PCR (RT-PCR). Real-time quantitative PCR is presently preferred.

5 RNA analysis can be performed on total cellular RNA or poly(A)+ mRNA. The preferred method of RNA analysis of the present invention is the use of total cellular RNA as described in other examples herein. Methods of RNA isolation are taught in, for example, Ausubel, F.M. et al., *Current*
10 *Protocols in Molecular Biology*, Volume 1, pp. 4.1.1-4.2.9 and 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Northern blot analysis is routine in the art and is taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.2.1-4.2.9, John Wiley & Sons, Inc., 1996.
15 Real-time quantitative (PCR) can be conveniently accomplished using the commercially available ABI PRISM™ 7700 Sequence Detection System, available from PE-Applied Biosystems, Foster City, CA and used according to manufacturer's instructions.

20 Protein levels of IL-1 receptor-associated kinase-1 can be quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis (immunoblotting), ELISA or fluorescence-activated cell sorting (FACS). Antibodies directed to IL-1 receptor-
25 associated kinase-1 can be identified and obtained from a variety of sources, such as the MSRS catalog of antibodies (Aerie Corporation, Birmingham, MI), or can be prepared via conventional antibody generation methods. Methods for preparation of polyclonal antisera are taught in, for
30 example, Ausubel, F.M. et al., (*Current Protocols in Molecular Biology*, Volume 2, pp. 11.12.1-11.12.9, John Wiley & Sons, Inc., 1997). Preparation of monoclonal antibodies is taught in, for example, Ausubel, F.M. et al., (*Current*

-100-

Protocols in Molecular Biology, Volume 2, pp. 11.4.1-11.11.5, John Wiley & Sons, Inc., 1997).

Immunoprecipitation methods are standard in the art and can be found at, for example, Ausubel, F.M. et al., (*Current Protocols in Molecular Biology*, Volume 2, pp. 10.16.1-10.16.11, John Wiley & Sons, Inc., 1998). Western blot (immunoblot) analysis is standard in the art and can be found at, for example, Ausubel, F.M. et al., (*Current Protocols in Molecular Biology*, Volume 2, pp. 10.8.1-10.8.21, John Wiley & Sons, Inc., 1997). Enzyme-linked immunosorbent assays (ELISA) are standard in the art and can be found at, for example, Ausubel, F.M. et al., (*Current Protocols in Molecular Biology*, Volume 2, pp. 11.2.1-11.2.22, John Wiley & Sons, Inc., 1991).

Example 11

Poly(A)+ mRNA isolation

Poly(A)+ mRNA was isolated according to Miura et al., (*Clin. Chem.*, 1996, 42, 1758-1764). Other methods for poly(A)+ mRNA isolation are taught in, for example, Ausubel, F.M. et al., (*Current Protocols in Molecular Biology*, Volume 1, pp. 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993). Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 μ L cold PBS. 60 μ L lysis buffer (10 mM Tris-HCl, pH 7.6, 1 mM EDTA, 0.5 M NaCl, 0.5% NP-40, 20 mM vanadyl-ribonucleoside complex) was added to each well, the plate was gently agitated and then incubated at room temperature for five minutes. 55 μ L of lysate was transferred to Oligo d(T) coated 96-well plates (AGCT Inc., Irvine CA). Plates were incubated for 60 minutes at room temperature, washed 3 times with 200 μ L of wash buffer (10 mM Tris-HCl pH 7.6, 1 mM EDTA, 0.3 M NaCl). After the final wash, the plate was blotted on paper towels to

-101-

remove excess wash buffer and then air-dried for 5 minutes.
60 μ L of elution buffer (5 mM Tris-HCl pH 7.6), preheated to
70°C, was added to each well, the plate was incubated on a
90°C hot plate for 5 minutes, and the eluate was then
5 transferred to a fresh 96-well plate.

Cells grown on 100 mm or other standard plates may be
treated similarly, using appropriate volumes of all
solutions.

10 Example 12

Total RNA Isolation

Total RNA was isolated using an RNEASY 96™ kit and
buffers purchased from Qiagen Inc. (Valencia, CA) following
the manufacturer's recommended procedures. Briefly, for
15 cells grown on 96-well plates, growth medium was removed from
the cells and each well was washed with 200 μ L cold PBS. 150
 μ L Buffer RLT was added to each well and the plate vigorously
agitated for 20 seconds. 150 μ L of 70% ethanol was then
added to each well and the contents mixed by pipetting three
20 times up and down. The samples were then transferred to the
RNEASY 96™ well plate attached to a QIAVAC™ manifold fitted
with a waste collection tray and attached to a vacuum source.
Vacuum was applied for 1 minute. 500 μ L of Buffer RW1 was
added to each well of the RNEASY 96™ plate and incubated for
25 15 minutes and the vacuum was again applied for 1 minute. An
additional 500 μ L of Buffer RW1 was added to each well of the
RNEASY 96™ plate and the vacuum was applied for 2 minutes. 1
mL of Buffer RPE was then added to each well of the RNEASY
96™ plate and the vacuum applied for a period of 90 seconds.
30 The Buffer RPE wash was then repeated and the vacuum was
applied for an additional 3 minutes. The plate was then
removed from the QIAVAC™ manifold and blotted dry on paper

-102-

towels. The plate was then re-attached to the QIAVAC™ manifold fitted with a collection tube rack containing 1.2 mL collection tubes. RNA was then eluted by pipetting 170 µL water into each well, incubating 1 minute, and then applying
5 the vacuum for 3 minutes.

The repetitive pipetting and elution steps may be automated using a QIAGEN Bio-Robot 9604 (Qiagen, Inc., Valencia CA). Essentially, after lysing of the cells on the culture plate, the plate is transferred to the robot deck
10 where the pipetting, DNase treatment and elution steps are carried out.

Example 13

15 Real-time Quantitative PCR Analysis of IL-1 receptor-associated kinase-1 mRNA Levels

Quantitation of IL-1 receptor-associated kinase-1 mRNA levels was determined by real-time quantitative PCR using the ABI PRISM™ 7700 Sequence Detection System (PE-Applied
20 Biosystems, Foster City, CA) according to manufacturer's instructions. This is a closed-tube, non-gel-based, fluorescence detection system which allows high-throughput quantitation of polymerase chain reaction (PCR) products in real-time. As opposed to standard PCR in which amplification
25 products are quantitated after the PCR is completed, products in real-time quantitative PCR are quantitated as they accumulate. This is accomplished by including in the PCR reaction an oligonucleotide probe that anneals specifically between the forward and reverse PCR primers, and contains two
30 fluorescent dyes. A reporter dye (e.g., FAM or JOE, obtained from either PE-Applied Biosystems, Foster City, CA, Operon Technologies Inc., Alameda, CA or Integrated DNA Technologies Inc., Coralville, IA) is attached to the 5' end of the probe

-103-

and a quencher dye (e.g., TAMRA, obtained from either PE-Applied Biosystems, Foster City, CA, Operon Technologies Inc., Alameda, CA or Integrated DNA Technologies Inc., Coralville, IA) is attached to the 3' end of the probe. When
5 the probe and dyes are intact, reporter dye emission is quenched by the proximity of the 3' quencher dye. During amplification, annealing of the probe to the target sequence creates a substrate that can be cleaved by the 5'-exonuclease activity of Taq polymerase. During the extension phase of
10 the PCR amplification cycle, cleavage of the probe by Taq polymerase releases the reporter dye from the remainder of the probe (and hence from the quencher moiety) and a sequence-specific fluorescent signal is generated. With each cycle, additional reporter dye molecules are cleaved from
15 their respective probes, and the fluorescence intensity is monitored at regular intervals by laser optics built into the ABI PRISM™ 7700 Sequence Detection System. In each assay, a series of parallel reactions containing serial dilutions of mRNA from untreated control samples generates a standard
20 curve that is used to quantitate the percent inhibition after antisense oligonucleotide treatment of test samples.

Prior to quantitative PCR analysis, primer-probe sets specific to the target gene being measured are evaluated for their ability to be "multiplexed" with a GAPDH amplification
25 reaction. In multiplexing, both the target gene and the internal standard gene GAPDH are amplified concurrently in a single sample. In this analysis, mRNA isolated from untreated cells is serially diluted. Each dilution is amplified in the presence of primer-probe sets specific for
30 GAPDH only, target gene only ("single-plexing"), or both (multiplexing). Following PCR amplification, standard curves of GAPDH and target mRNA signal as a function of dilution are generated from both the single-plexed and multiplexed

-104-

samples. If both the slope and correlation coefficient of the GAPDH and target signals generated from the multiplexed samples fall within 10% of their corresponding values generated from the single-plexed samples, the primer-probe set specific for that target is deemed multiplexable. Other methods of PCR are also known in the art.

PCR reagents were obtained from Invitrogen Corporation, (Carlsbad, CA). RT-PCR reactions were carried out by adding 20 μ L PCR cocktail (2.5x PCR buffer (-MgCl₂), 6.6 mM MgCl₂, 375 μ M each of dATP, dCTP, dGTP and dGTP, 375 nM each of forward primer and reverse primer, 125 nM of probe, 4 Units RNase inhibitor, 1.25 Units PLATINUM® Taq, 5 Units MuLV reverse transcriptase, and 2.5x ROX dye) to 96-well plates containing 30 μ L total RNA solution. The RT reaction was carried out by incubation for 30 minutes at 48°C. Following a 10 minute incubation at 95°C to activate the PLATINUM® Taq, 40 cycles of a two-step PCR protocol were carried out: 95°C for 15 seconds (denaturation) followed by 60°C for 1.5 minutes (annealing/extension).

Gene target quantities obtained by real time RT-PCR are normalized using either the expression level of GAPDH, a gene whose expression is constant, or by quantifying total RNA using RiboGreen™ (Molecular Probes, Inc. Eugene, OR). GAPDH expression is quantified by real time RT-PCR, by being run simultaneously with the target, multiplexing, or separately. Total RNA is quantified using RiboGreen™ RNA quantification reagent from Molecular Probes. Methods of RNA quantification by RiboGreen™ are taught in Jones, L.J., et al, (Analytical Biochemistry, 1998, 265, 368-374).

In this assay, 170 μ L of RiboGreen™ working reagent (RiboGreen™ reagent diluted 1:350 in 10mM Tris-HCl, 1 mM EDTA, pH 7.5) is pipetted into a 96-well plate containing 30

-105-

μL purified, cellular RNA. The plate is read in a CytoFluor 4000 (PE Applied Biosystems) with excitation at 480nm and emission at 520nm.

Probes and primers to human IL-1 receptor-associated kinase-1 were designed to hybridize to a human IL-1 receptor-associated kinase-1 sequence, using published sequence information (GenBank accession number L76191.1, incorporated herein as SEQ ID NO:4). For human IL-1 receptor-associated kinase-1 the PCR primers were:

forward primer: ACTTCTCGGAGGAGCTCAAGATC (SEQ ID NO: 5)
reverse primer: GCATACACCGTGTTCTCATCA (SEQ ID NO: 6) and the PCR probe was: FAM-CGCCCCGGTACACGCACCCAA-TAMRA (SEQ ID NO: 7) where FAM is the fluorescent dye and TAMRA is the quencher dye. For human GAPDH the PCR primers were:
forward primer: GAAGGTGAAGGTCGGAGTC (SEQ ID NO:8)
reverse primer: GAAGATGGTGATGGGATTTTC (SEQ ID NO:9) and the PCR probe was: 5' JOE-CAAGCTTCCCGTTCTCAGCC- TAMRA 3' (SEQ ID NO: 10) where JOE is the fluorescent reporter dye and TAMRA is the quencher dye.

20

Example 14

Northern blot analysis of IL-1 receptor-associated kinase-1 mRNA levels

Eighteen hours after antisense treatment, cell monolayers were washed twice with cold PBS and lysed in 1 mL RNAZOL™ (TEL-TEST "B" Inc., Friendswood, TX). Total RNA was prepared following manufacturer's recommended protocols. Twenty micrograms of total RNA was fractionated by electrophoresis through 1.2% agarose gels containing 1.1% formaldehyde using a MOPS buffer system (AMRESCO, Inc. Solon, OH). RNA was transferred from the gel to HYBOND™-N+ nylon membranes (Amersham Pharmacia Biotech, Piscataway, NJ) by

-106-

overnight capillary transfer using a Northern/Southern Transfer buffer system (TEL-TEST "B" Inc., Friendswood, TX). RNA transfer was confirmed by UV visualization. Membranes were fixed by UV cross-linking using a STRATALINKER™ UV
5 Crosslinker 2400 (Stratagene, Inc, La Jolla, CA) and then probed using QUICKHYB™ hybridization solution (Stratagene, La Jolla, CA) using manufacturer's recommendations for stringent conditions.

To detect human IL-1 receptor-associated kinase-1, a
10 human IL-1 receptor-associated kinase-1 specific probe was prepared by PCR using the forward primer ACTTCTCGGAGGAGCTCAAGATC (SEQ ID NO: 5) and the reverse primer GCATACACCGTGTTCCTCATCA (SEQ ID NO: 6). To normalize for variations in loading and transfer efficiency membranes were
15 stripped and probed for human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, CA).

Hybridized membranes were visualized and quantitated using a PHOSPHORIMAGER™ and IMAGEQUANT™ Software V3.3 (Molecular Dynamics, Sunnyvale, CA). Data was normalized to
20 GAPDH levels in untreated controls.

Example 15

**Antisense inhibition of human IL-1 receptor-associated
25 kinase-1 expression by chimeric phosphorothioate
oligonucleotides having 2'-MOE wings and a deoxy gap**

In accordance with the present invention, a series of oligonucleotides were designed to target different regions of the human IL-1 receptor-associated kinase-1 RNA, using
30 published sequences (GenBank accession number L76191.1, incorporated herein as SEQ ID NO: 4, nucleotides 1 to 13000 of GenBank accession number AF031075.1, the complement of which is incorporated herein as SEQ ID NO: 11, GenBank

-107-

accession number BG479917.1, incorporated herein as SEQ ID NO: 12, and GenBank accession number AL581159.1, the complement of which is incorporated herein as SEQ ID NO: 13). The oligonucleotides are shown in Table 1. "Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 1 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE) nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on human IL-1 receptor-associated kinase-1 mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments in which T-24 cells were treated with the antisense oligonucleotides of the present invention. The positive control for each datapoint is identified in the table by sequence ID number. If present, "N.D." indicates "no data".

Table 1

Inhibition of human IL-1 receptor-associated kinase-1 mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO	CONTROL SEQ ID NO
151391	3'UTR	4	3139	cctggccttgccaggccaccac	91	14	2
151392	3'UTR	4	2424	gatgccagccttccttgccc	94	15	2
151393	Coding	4	965	cagtggagacggtcctccag	90	16	2
151394	3'UTR	4	3196	cttgtggcctccgaagcctg	96	17	2
151395	Coding	4	2127	ggacgacagcagctgcaggc	84	18	2
151396	Coding	4	1448	tctgcagccagacctgcttg	60	19	2

-108-

151397	Coding	4	1443	agccagacctgcttgcaagt	92	20	2
151398	3'UTR	4	3450	gtgaagcctgtgtacagcc	93	21	2
151399	Coding	4	191	tggcaccagtcggcgggctc	92	22	2
151400	Coding	4	2070	gaccatcttctgtcgggcag	81	23	2
151401	Coding	4	1264	ccagccttcccgtcttgatg	92	24	2
151402	3'UTR	4	2465	agccagcagcctcccaacat	94	25	2
151403	Stop Codon	4	2199	tcagctctgaaattcatcac	94	26	2
151404	Coding	4	1995	cagtccttcacggctgtgg	90	27	2
151405	Coding	4	1315	ccaaggctctctagcactacc	95	28	2
151406	3'UTR	4	3269	ctaggctcttgggcctagcta	85	29	2
151407	Coding	4	766	acaccgtgttcctcatcacc	99	30	2
151408	Coding	4	2195	ctctgaaattcatcactttc	32	31	2
151409	Coding	4	1598	tgggtcataggagcctcct	64	32	2
151410	3'UTR	4	3171	gctcggagctcgtctgtggc	11	33	2
151411	Coding	4	1348	tggcacctgtcgtcttcaca	91	34	2
151412	Coding	4	146	cggcacatgaccaggggcgg	94	35	2
151413	Coding	4	1322	tgaccagccaaggctcttag	0	36	2
151414	Coding	4	1383	ctcctcttccaccaggcttt	89	37	2
151415	3'UTR	4	2252	tgaccatgagaactttgact	97	38	2
151416	Coding	4	2001	aagggccagtccttccacgg	1	39	2
151417	Coding	4	1709	ctggacacgtaggagttctc	96	40	2
151418	Coding	4	1711	tgctggacacgtaggagttc	90	41	2
151419	Coding	4	2069	accatcttctgtcgggcagg	92	42	2
151420	Coding	4	1432	cttgcaagtgtgctctgggtg	78	43	2
151421	Coding	4	854	ctggacagctgctccacctc	93	44	2
151422	3'UTR	4	3436	acagccctgggctacttttg	89	45	2
151423	3'UTR	4	2390	ggaggcagggttccactctg	90	46	2
151424	Coding	4	1446	tgcagccagacctgcttgca	71	47	2
151425	3'UTR	4	3246	cttgggtagtggcccctctg	94	48	2
151426	Coding	4	1998	ggccagtccttccacggctg	92	49	2
151427	Coding	4	901	tctgagcacagtagccagca	97	50	2
194303	Coding	4	341	cggagcagctgcaggtgcgt	79	51	2
194304	Coding	4	556	aagcagggttggaaccagg	84	52	2
194305	Coding	4	715	cgatcttgagctcctccgag	81	53	2
194306	Coding	4	840	cacctcggtcaggaagctct	87	54	2
194307	Coding	4	933	caggaagccgtacaccaggc	88	55	2
194308	Coding	4	1211	actgtctgtgtccgggccac	76	56	2
194309	Coding	4	1548	cagctggcccaggcccaggc	50	57	2
194310	Coding	4	1574	gcccggcggtgcaggcagca	87	58	2
194311	Coding	4	1621	gcttctctagcctctcgtac	81	59	2
194312	Coding	4	1748	ggctgccatggagcagcccc	23	60	2
194313	Coding	4	1795	gcagctgctctgctgcctgg	64	61	2
194314	Coding	4	1848	agagaggccgcctaggctct	76	62	2
194315	Coding	4	1890	cagagggcagcttgaggtca	43	63	2
194316	Coding	4	2084	agggccagcttctggaccat	87	64	2
194317	Stop Codon	4	2209	ggtgaacacatcagctctga	0	65	2
194318	3'UTR	4	2577	agctgctgccagaggcctgg	81	66	2
194319	3'UTR	4	2994	ttacagccatacttcacttt	75	67	2
194320	3'UTR	4	3029	aattctcgcttcttgctagg	89	68	2
194321	3'UTR	4	3115	ggccagctcgcaggtcccca	91	69	2
194322	3'UTR	4	3332	ccttccctgtctgccatgct	90	70	2
194323	3'UTR	4	3413	acgcaagaggacactcggtt	92	71	2
194324	3'UTR	4	3469	ggctgaacacaaaatcactg	88	72	2
194325	3'UTR	4	3477	tgactcacggctgaacacaa	85	73	2
194326	3'UTR	4	3544	atacgtttttattactcaag	89	74	2

-109-

194327	3'UTR	4	3551	aggggaacatacgttttttatt	30	75	2
194328	intron	11	2441	cctggaaaagcttcataaag	32	76	2
194329	exon	11	3229	ctggcctcacctggacagct	42	77	2
194330	intron	11	4066	agaccctccagctacgctgc	36	78	2
194331	intron	11	5276	ggagagcccacttgaagaca	61	79	2
194332	exon	11	7478	agctggctacctgggtcata	37	80	2
194333	intron	11	7534	tacagagcaaggcctggaat	62	81	2
194334	intron	11	7694	tccttctctctatgtgaagg	62	82	2
194335	intron	11	9602	aggccaagcctacagaagg	34	83	2
194336	genomic	12	184	aggccagctggcccaggcgc	19	84	2
194337	3' UTR	13	136	accaggctggagatggcgg	61	85	2

As shown in Table 1, SEQ ID NOS 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 32, 34, 35, 37, 38, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 74, 79, 81, 82 and 85 demonstrated at least 60% inhibition of human IL-1 receptor-associated kinase-1 expression in this assay and are therefore preferred. The target sites to which these preferred sequences are complementary are herein referred to as "preferred target regions" and are therefore preferred sites for targeting by compounds of the present invention. These preferred target regions are shown in Table 2. The sequences represent the reverse complement of the preferred antisense compounds shown in Table 1. "Target site" indicates the first (5'-most) nucleotide number of the corresponding target nucleic acid. Also shown in Table 2 is the species in which each of the preferred target regions was found.

Table 2
Sequence and position of preferred target regions identified in IL-1 receptor-associated kinase-1.

SITE ID	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	REV COMP OF SEQ ID	ACTIVE IN	SEQ ID NO
66912	4	3139	gtggtggcctgcaagccagg	14	<i>H. sapiens</i>	86

-110-

66913	4	2424	gggcaaggaaggctggcatc	15	<i>H. sapiens</i>	87
66914	4	965	ctggaggaccgtctccactg	16	<i>H. sapiens</i>	88
66915	4	3196	caggcttcggaggccacaag	17	<i>H. sapiens</i>	89
66916	4	2127	gcctgcagctgctgtcgtcc	18	<i>H. sapiens</i>	90
66917	4	1448	caagcaggtctggctgcaga	19	<i>H. sapiens</i>	91
66918	4	1443	cactgcaagcaggtctggct	20	<i>H. sapiens</i>	92
66919	4	3450	ggctgtagcacaggcttcac	21	<i>H. sapiens</i>	93
66920	4	191	gagcccgccgactggcgcca	22	<i>H. sapiens</i>	94
66921	4	2070	ctgcccgcacagaagatggc	23	<i>H. sapiens</i>	95
66922	4	1264	catcaagacgggaaggctgg	24	<i>H. sapiens</i>	96
66923	4	2465	atgttgggaggctgctggct	25	<i>H. sapiens</i>	97
66924	4	2199	gtgatgaatttcagagctga	26	<i>H. sapiens</i>	98
66925	4	1995	ccacagccgtggaaggactg	27	<i>H. sapiens</i>	99
66926	4	1315	ggtagtgctagagaccttg	28	<i>H. sapiens</i>	100
66927	4	3269	tagctaggcccaagacctag	29	<i>H. sapiens</i>	101
66928	4	766	ggtgatgaggaacacgggt	30	<i>H. sapiens</i>	102
66930	4	1598	aggaggcctcctatgaccca	32	<i>H. sapiens</i>	103
66932	4	1348	tgtgaagacgcacgggtgcca	34	<i>H. sapiens</i>	104
66933	4	146	ccgccctgggtcatgtgccg	35	<i>H. sapiens</i>	105
66935	4	1383	aagacctggtggaaggagg	37	<i>H. sapiens</i>	106
66936	4	2252	agtcaaagtctctcatgggtca	38	<i>H. sapiens</i>	107
66938	4	1709	gagaactcctacgtgtccag	40	<i>H. sapiens</i>	108
66939	4	1711	gaactcctacgtgtccagca	41	<i>H. sapiens</i>	109
66940	4	2069	cctgcccgcacagaagatggt	42	<i>H. sapiens</i>	110
66941	4	1432	caccagagcacactgcaag	43	<i>H. sapiens</i>	111
66942	4	854	gaggtggagcagctgtccag	44	<i>H. sapiens</i>	112
66943	4	3436	caaaagtagcccagggtgt	45	<i>H. sapiens</i>	113
66944	4	2390	cagagtggaaacctgcctcc	46	<i>H. sapiens</i>	114
66945	4	1446	tgcaagcaggtctggctgca	47	<i>H. sapiens</i>	115
66946	4	3246	cagagggggccactacccaag	48	<i>H. sapiens</i>	116
66947	4	1998	cagccgtggaaggactggcc	49	<i>H. sapiens</i>	117
66948	4	901	tgctggctactgtgctcaga	50	<i>H. sapiens</i>	118
112415	4	341	acgcacctgcagctgtccg	51	<i>H. sapiens</i>	119
112416	4	556	cctgggtccaagccctgctt	52	<i>H. sapiens</i>	120
112417	4	715	ctcgaggagctcaagatcg	53	<i>H. sapiens</i>	121
112418	4	840	agagcttcctgaccgagggtg	54	<i>H. sapiens</i>	122
112419	4	933	gcctgggtgtacggcttcctg	55	<i>H. sapiens</i>	123
112420	4	1211	gtggcccgacacagacagt	56	<i>H. sapiens</i>	124
112422	4	1574	tgctgcctgcaccgcccggc	58	<i>H. sapiens</i>	125
112423	4	1621	gtacgagaggctagagaagc	59	<i>H. sapiens</i>	126
112425	4	1795	ccaggcagcagagcagctgc	61	<i>H. sapiens</i>	127
112426	4	1848	agagcctaggcgccctctct	62	<i>H. sapiens</i>	128
112428	4	2084	atgggtccagaagctggccct	64	<i>H. sapiens</i>	129
112430	4	2577	ccaggcctctggcagcagct	66	<i>H. sapiens</i>	130
112431	4	2994	aaagtgaagtatggctgtaa	67	<i>H. sapiens</i>	131
112432	4	3029	cctagcaagaagcagagaatt	68	<i>H. sapiens</i>	132
112433	4	3115	tggggacctgcgagctggcc	69	<i>H. sapiens</i>	133
112434	4	3332	agcatggcagacagggaagg	70	<i>H. sapiens</i>	134
112435	4	3413	aaccgagtgtcctcttgcgt	71	<i>H. sapiens</i>	135
112436	4	3469	cagtgattttgtgttcagcc	72	<i>H. sapiens</i>	136
112437	4	3477	ttgtgttcagccgtgagtc	73	<i>H. sapiens</i>	137
112438	4	3544	cttgagtaataaaaacgtat	74	<i>H. sapiens</i>	138
112443	11	5276	tgtcttcaagtgggtctcc	79	<i>H. sapiens</i>	139
112445	11	7534	attccaggccttgctctgta	81	<i>H. sapiens</i>	140
112446	11	7694	ccttcacatagagagaagga	82	<i>H. sapiens</i>	141
112449	13	136	ccgccatctccagcctgggt	85	<i>H. sapiens</i>	142

-111-

As these "preferred target regions" have been found by experimentation to be open to, and accessible for, hybridization with the antisense compounds of the present invention, one of skill in the art will recognize or be able to ascertain, using no more than routine experimentation, further embodiments of the invention that encompass other compounds that specifically hybridize to these sites and consequently inhibit the expression of IL-1 receptor-associated kinase-1.

Example 16**15 Western blot analysis of IL-1 receptor-associated kinase-1 protein levels**

Western blot analysis (immunoblot analysis) is carried out using standard methods. Cells are harvested 16-20 h after oligonucleotide treatment, washed once with PBS, suspended in Laemmli buffer (100 ul/well), boiled for 5 minutes and loaded on a 16% SDS-PAGE gel. Gels are run for 1.5 hours at 150 V, and transferred to membrane for western blotting. Appropriate primary antibody directed to IL-1 receptor-associated kinase-1 is used, with a radiolabeled or fluorescently labeled secondary antibody directed against the primary antibody species. Bands are visualized using a PHOSPHORIMAGER™ (Molecular Dynamics, Sunnyvale CA).

-112-

What is claimed is:

1. A compound 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding IL-1 receptor-associated kinase-1, wherein said compound specifically hybridizes with said nucleic acid molecule encoding IL-1 receptor-associated kinase-1 and inhibits the expression of IL-1 receptor-associated kinase-1.
2. The compound of claim 1 which is an antisense oligonucleotide.
3. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
4. The compound of claim 3 wherein the modified internucleoside linkage is a phosphorothioate linkage.
5. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
6. The compound of claim 5 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
7. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
8. The compound of claim 7 wherein the modified nucleobase is a 5-methylcytosine.
9. The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.
10. A compound 8 to 80 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of a preferred target region on a nucleic acid molecule encoding IL-1 receptor-associated kinase-1.
11. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

-113-

12. The composition of claim 11 further comprising a colloidal dispersion system.

13. The composition of claim 11 wherein the compound is an antisense oligonucleotide.

14. A method of inhibiting the expression of IL-1 receptor-associated kinase-1 in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of IL-1 receptor-associated kinase-1 is inhibited.

15. A method of treating an animal having a disease or condition associated with IL-1 receptor-associated kinase-1 comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of IL-1 receptor-associated kinase-1 is inhibited.

16. The method of claim 15 wherein the disease or condition is a hyperproliferative disorder.

17. The method of claim 16 wherein the hyperproliferative disorder is cancer.

18. The method of claim 15 wherein the disease or condition is an autoimmune disorder.

19. The method of claim 15 wherein the disease or condition is inflammation.

20. The method of claim 15 wherein the disease or condition involves bone metabolism.

SEQUENCE LISTING

<110> Isis Pharmaceuticals, Inc
 <120> Antisense Modulation Of IL-1 Receptor-Associated Kinase-1 Expression
 <130> ISPT1000
 <150> 10/167,034
 <151> 2002-06-10
 <160> 143
 <170> PatentIn version 3.2
 <210> 1
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Antisense Oligonucleotide
 <400> 1 20
 tccgtcatcg ctcctcaggg
 <210> 2
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Antisense Oligonucleotide
 <400> 2 20
 gtgcgcgcgga gcccgaaatc
 <210> 3
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Antisense Oligonucleotide
 <400> 3 20
 atgcattctg cccccaagga
 <210> 4
 <211> 3590
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> CDS
 <222> (80)..(2218)
 <400> 4 60
 cgcggaacccg gccggcccag gcccgcgccc gcccgggccc tgagaggccc cggcaggtcc
 cggcccggcg gcggcagcc atg gcc ggg ggg ccg ggc ccg ggg gag ccc gca 112
 Met Ala Gly Gly Pro Gly Pro Gly Glu Pro Ala
 1 5 10
 gcc ccc ggc gcc cag cac ttc ttg tac gag gtg ccg ccc tgg gtc atg 160
 Ala Pro Gly Ala Gln His Phe L u Tyr Glu Val Pro Pro Trp Val Met

15	20	25	
tgc cgc ttc tac aaa gtg atg gac gcc ctg gag ccc gcc gac tgg tgc Cys Arg Phe Tyr Lys Val Met Asp Ala Leu Glu Pro Ala Asp Trp Cys 30 35 40			208
cag ttc gcc gcc ctg atc gtg cgc gac cag acc gag ctg cgg ctg tgc Gln Phe Ala Ala Leu Ile Val Arg Asp Gln Thr Glu Leu Arg Leu Cys 45 50 55			256
gag cgc tcc ggg cag cgc acg gcc agc gtc ctg tgg ccc tgg atc aac Glu Arg Ser Gly Gln Arg Thr Ala Ser Val Leu Trp Pro Trp Ile Asn 60 65 70 75			304
cgc aac gcc cgt gtg gcc gac ctc gtg cac atc ctc acg cac ctg cag Arg Asn Ala Arg Val Ala Asp Leu Val His Ile Leu Thr His Leu Gln 80 85 90			352
ctg ctc cgt gcg cgg gac atc atc aca gcc tgg cac cct ccc gcc ccg Leu Leu Arg Ala Arg Asp Ile Ile Thr Ala Trp His Pro Pro Ala Pro 95 100 105			400
ctt ccg tcc cca ggc acc act gcc ccg agg ccc agc agc atc cct gca Leu Pro Ser Pro Gly Thr Thr Ala Pro Arg Pro Ser Ser Ile Pro Ala 110 115 120			448
ccc gcc gag gcc gag gcc tgg agc ccc cgg aag ttg cca tcc tca gcc Pro Ala Glu Ala Glu Ala Trp Ser Pro Arg Lys Leu Pro Ser Ser Ala 125 130 135			496
tcc acc ttc ctc tcc cca gct ttt cca ggc tcc cag acc cat tca ggg Ser Thr Phe Leu Ser Pro Ala Phe Pro Gly Ser Gln Thr His Ser Gly 140 145 150 155			544
cct gag ctc ggc ctg gtt cca agc cct gct tcc ctg tgg cct cca ccg Pro Glu Leu Gly Leu Val Pro Ser Pro Ala Ser Leu Trp Pro Pro Pro 160 165 170			592
cca tct cca gcc cct tct tct acc aag cca ggc cca gag agc tca gtg Pro Ser Pro Ala Pro Ser Ser Thr Lys Pro Gly Pro Glu Ser Ser Val 175 180 185			640
tcc ctc ctg cag gga gcc cgc ccc tct ccg ttt tgc tgg ccc ctc tgt Ser Leu Leu Gln Gly Ala Arg Pro Ser Pro Phe Cys Trp Pro Leu Cys 190 195 200			688
gag att tcc cgg ggc acc cac aac ttc tcg gag gag ctc aag atc ggg Glu Ile Ser Arg Gly Thr His Asn Phe Ser Glu Glu Leu Lys Ile Gly 205 210 215			736
gag ggt ggc ttt ggg tgc gtg tac ccg gcg gtg atg agg aac acg gtg Glu Gly Gly Phe Gly Cys Val Tyr Arg Ala Val Met Arg Asn Thr Val 220 225 230 235			784
tat gct gtg aag agg ctg aag gag aac gct gac ctg gag tgg act gca Tyr Ala Val Lys Arg Leu Lys Glu Asn Ala Asp Leu Glu Trp Thr Ala 240 245 250			832
gtg aag cag agc ttc ctg acc gag gtg gag cag ctg tcc agg ttt cgt Val Lys Gln Ser Phe Leu Thr Glu Val Glu Gln Leu Ser Arg Phe Arg 255 260 265			880
cac cca aac att gtg gac ttt gct ggc tac tgt gct cag aac ggc ttc His Pro Asn Ile Val Asp Phe Ala Gly Tyr Cys Ala Gln Asn Gly Phe 270 275 280			928
tac tgc ctg gtg tac ggc ttc ctg ccc aac ggc tcc ctg gag gac cgt Tyr Cys Leu Val Tyr Gly Phe Leu Pro Asn Gly Ser Leu Glu Asp Arg 285 290 295			976
ctc cac tgc cag acc cag gcc tgc cca cct ctc tcc tgg cct cag cga			1024

Leu 300	His	Cys	Gln	Thr	Gln 305	Ala	Cys	Pro	Pro	Leu 310	Ser	Trp	Pro	Gln	Arg 315	
ctg	gac	atc	ctt	ctg	ggg	aca	gcc	cgg	gca	att	cag	ttt	cta	cat	cag	1072
Leu	Asp	Ile	Leu	Leu	Gly	Thr	Ala	Arg	Ala	Ile	Gln	Phe	Leu	His	Gln	
				320					325					330		
gac	agc	ccc	agc	ctc	atc	cat	gga	gac	atc	aag	agt	tcc	aac	gtc	ctt	1120
Asp	Ser	Pro	Ser	Leu	Ile	His	Gly	Asp	Ile	Lys	Ser	Ser	Asn	Val	Leu	
			335					340					345			
ctg	gat	gag	agg	ctg	aca	ccc	aag	ctg	gga	gac	ttt	ggc	ctg	gcc	cgg	1168
Leu	Asp	Glu	Arg	Leu	Thr	Pro	Lys	Leu	Gly	Asp	Phe	Gly	Leu	Ala	Arg	
		350					355					360				
ttc	agc	cgc	ttt	gcc	ggg	tcc	agc	ccc	agc	cag	agc	agc	atg	gtg	gcc	1216
Phe	Ser	Arg	Phe	Ala	Gly	Ser	Ser	Pro	Ser	Gln	Ser	Ser	Met	Val	Ala	
	365					370					375					
cgg	aca	cag	aca	gtg	cgg	ggc	acc	ctg	gcc	tac	ctg	ccc	gag	gag	tac	1264
Arg	Thr	Gln	Thr	Val	Arg	Gly	Thr	Leu	Ala	Tyr	Leu	Pro	Glu	Glu	Tyr	
				385						390					395	
atc	aag	acg	gga	agg	ctg	gct	gtg	gac	acg	gac	acc	ttc	agc	ttt	ggg	1312
Ile	Lys	Thr	Gly	Arg	Leu	Ala	Val	Asp	Thr	Asp	Thr	Phe	Ser	Phe	Gly	
				400					405					410		
gtg	gta	gtg	cta	gag	acc	ttg	gct	ggg	cag	agg	gct	gtg	aag	acg	cac	1360
Val	Val	Val	Leu	Glu	Thr	Leu	Ala	Gly	Gln	Arg	Ala	Val	Lys	Thr	His	
			415					420					425			
ggg	gcc	agg	acc	aag	tat	ctg	aaa	gac	ctg	gtg	gaa	gag	gag	gct	gag	1408
Gly	Ala	Arg	Thr	Lys	Tyr	Leu	Lys	Asp	Leu	Val	Glu	Glu	Glu	Ala	Glu	
		430					435					440				
gag	gct	gga	gtg	gct	ttg	aga	agc	acc	cag	agc	aca	ctg	caa	gca	ggg	1456
Glu	Ala	Gly	Val	Ala	Leu	Arg	Ser	Thr	Gln	Ser	Thr	Leu	Gln	Ala	Gly	
		445				450					455					
ctg	gct	gca	gat	gcc	tgg	gct	gct	ccc	atc	gcc	atg	cag	atc	tac	aag	1504
Leu	Ala	Ala	Asp	Ala	Trp	Ala	Ala	Pro	Ile	Ala	Met	Gln	Ile	Tyr	Lys	
				465						470					475	
aag	cac	ctg	gac	ccc	agg	ccc	ggg	ccc	tgc	cca	cct	gag	ctg	ggc	ctg	1552
Lys	His	Leu	Asp	Pro	Arg	Pro	Gly	Pro	Cys	Pro	Pro	Glu	Leu	Gly	Leu	
				480					485					490		
ggc	ctg	ggc	cag	ctg	gcc	tgc	tgc	tgc	ctg	cac	cgc	cgg	gcc	aaa	agg	1600
Gly	Leu	Gly	Gln	Leu	Ala	Cys	Cys	Cys	Leu	His	Arg	Arg	Ala	Lys	Arg	
			495					500					505			
agg	cct	cct	atg	acc	cag	gtg	tac	gag	agg	cta	gag	aag	ctg	cag	gca	1648
Arg	Pro	Pro	Met	Thr	Gln	Val	Tyr	Glu	Arg	Leu	Glu	Lys	Leu	Gln	Ala	
		510					515					520				
gtg	gtg	gcg	ggg	gtg	ccc	ggg	cat	ttg	gag	gcc	gcc	agc	tgc	atc	ccc	1696
Val	Val	Ala	Gly	Val	Pro	Gly	His	Leu	Glu	Ala	Ala	Ser	Cys	Ile	Pro	
		525				530					535					
cct	tcc	ccg	cag	gag	aac	tcc	tac	gtg	tcc	agc	act	ggc	aga	gcc	cac	1744
Pro	Ser	Pro	Gln	Glu	Asn	Ser	Tyr	Val	Ser	Ser	Thr	Gly	Arg	Ala	His	
				545						550					555	
agt	ggg	gct	gct	cca	tgg	cag	ccc	ctg	gca	gcg	cca	tca	gga	gcc	agt	1792
Ser	Gly	Ala	Ala	Pro	Trp	Gln	Pro	Leu	Ala	Ala	Pro	Ser	Gly	Ala	Ser	
				560					565					570		
gcc	cag	gca	gca	gag	cag	ctg	cag	aga	ggc	ccc	aac	cag	ccc	gtg	gag	1840
Ala	Gln	Ala	Ala	Glu	Gln	Leu	Gln	Arg	Gly	Pro	Asn	Gln	Pro	Val	Glu	
			575					580					585			

agt gac gag agc cta ggc ggc ctc tct gct gcc ctg cgc tcc tgg cac Ser Asp Glu Ser Leu Gly Gly Leu Ser Ala Ala Leu Arg Ser Trp His 590 595 600	1888
ttg act cca agc tgc cct ctg gac cca gca ccc ctc agg gag gcc ggc Leu Thr Pro Ser Cys Pro Leu Asp Pro Ala Pro Leu Arg Glu Ala Gly 605 610 615	1936
tgt cct cag ggg gac acg gca gga gaa tcg agc tgg ggg agt ggc cca Cys Pro Gln Gly Asp Thr Ala Gly Glu Ser Ser Trp Gly Ser Gly Pro 620 625 630 635	1984
gga tcc cgg ccc aca gcc gtg gaa gga ctg gcc ctt ggc agc tct gca Gly Ser Arg Pro Thr Ala Val Glu Gly Leu Ala Leu Gly Ser Ser Ala 640 645 650	2032
tca tcg tcg tca gag cca ccg cag att atc atc aac cct gcc cga cag Ser Ser Ser Ser Glu Pro Pro Gln Ile Ile Ile Asn Pro Ala Arg Gln 655 660 665	2080
aag atg gtc cag aag ctg gcc ctg tac gag gat ggg gcc ctg gac agc Lys Met Val Gln Lys Leu Ala Leu Tyr Glu Asp Gly Ala Leu Asp Ser 670 675 680	2128
ctg cag ctg ctg tcg tcc agc tcc ctc cca ggc ttg ggc ctg gaa cag Leu Gln Leu Leu Ser Ser Ser Ser Leu Pro Gly Leu Gly Leu Glu Gln 685 690 695	2176
gac agg cag ggg ccc gaa gaa agt gat gaa ttt cag agc tga Asp Arg Gln Gly Pro Glu Glu Ser Asp Glu Phe Gln Ser 700 705 710	2218
tgtgttcacc tgggcagatc ccccaaatcc ggaagtcaaa gttctcatgg tcagaagttc	2278
tcatggtgca cgagtcctca gcactctgcc ggcagtgggg gtggggggccc atgcccgcgg	2338
gggagagaag gaggtggccc tgctgttcta ggctctgtgg gcataggcag gcagagtgga	2398
accctgcctc catgccagca tctgggggca aggaaggctg gcatcatcca gtgaggaggc	2458
tggcgcatgt tgggaggctg ctggctgcac agaccctgta ggggaggaga ggggctgctg	2518
tgcaggggtg tggagtaggg agctggctcc cctgagagcc atgcagggcg tctgcagccc	2578
aggcctctgg cagcagctct ttgccatct ctttgacag tggccaccct gcacaatggg	2638
gccgacgagg cctagggccc tcctacctgc ttacaatttg gaaaagtgtg gccgggtgcg	2698
gtggctcacg cctgtaatcc cagcactttg ggaggccaag gcaggaggat cgctggagcc	2758
cagtaggtca agaccagcca gggcaacatg atgagacct gtctctgcca aaaaattttt	2818
taaactatta gcctggcgtg gtagcgcacg cctgtggtcc cagctgctgg ggaggctgaa	2878
gtaggaggat ctttatgct tgggaggtcg aggctgcagt gagtcatgat tgtatgactg	2938
cactccagcc tgggtgacag agcaagacct tgtttcaaaa agaaaaacc tgggaaaagt	2998
gaagtatggc tgtaagtctc atggttcagt cctagcaaga agcgagaatt ctgagatcct	3058
ccagaaagtc gagcagcacc cacctccaac ctcgggccag tgtcttcagg ctttactggg	3118
gacctgcgag ctggccta atgtgtggcct gcaagccagg ccatccctgg gcgccacaga	3178
cgagctccga gccaggtcag gcttcggagg ccacaagctc agcctcaggc ccaggcactg	3238
attgtggcag aggggccact acccaaggct tagctaggcc caagacctag ttaccagac	3298
agtgagaagc ccctggaagg cagaaaagtt gggagcatgg cagacagga agggaaacat	3358
tttcagggaa aagacatgta tcacatgtct tcagaagcaa gtcaggtttc atgtaaccga	3418

gtgtcctctt gcgtgtccaa aagtagccca gggctgtagc acaggcttca cagtgatttt 3478
 gtgttcagcc gtgagtcaca ctacatgccc ccgtgaagct gggcattggt gacgtccagg 3538
 ttgtccttga gtaataaaaaa cgtatgttcc ctataaaaaa aaaaaggaat tc 3590

<210> 5
 <211> 712
 <212> PRT
 <213> Homo sapiens
 <400> 5

Met Ala Gly Gly Pro Gly Pro Gly Glu Pro Ala Ala Pro Gly Ala Gln
 1 5 10 15
 His Phe Leu Tyr Glu Val Pro Pro Trp Val Met Cys Arg Phe Tyr Lys
 20 25 30
 Val Met Asp Ala Leu Glu Pro Ala Asp Trp Cys Gln Phe Ala Ala Leu
 35 40 45
 Ile Val Arg Asp Gln Thr Glu Leu Arg Leu Cys Glu Arg Ser Gly Gln
 50 55 60
 Arg Thr Ala Ser Val Leu Trp Pro Trp Ile Asn Arg Asn Ala Arg Val
 65 70 75 80
 Ala Asp Leu Val His Ile Leu Thr His Leu Gln Leu Leu Arg Ala Arg
 85 90 95
 Asp Ile Ile Thr Ala Trp His Pro Pro Ala Pro Leu Pro Ser Pro Gly
 100 105 110
 Thr Thr Ala Pro Arg Pro Ser Ser Ile Pro Ala Pro Ala Glu Ala Glu
 115 120 125
 Ala Trp Ser Pro Arg Lys Leu Pro Ser Ser Ala Ser Thr Phe Leu Ser
 130 135 140
 Pro Ala Phe Pro Gly Ser Gln Thr His Ser Gly Pro Glu Leu Gly Leu
 145 150 155 160
 Val Pro Ser Pro Ala Ser Leu Trp Pro Pro Pro Pro Ser Pro Ala Pro
 165 170 175
 Ser Ser Thr Lys Pro Gly Pro Glu Ser Ser Val Ser Leu Leu Gln Gly
 180 185 190
 Ala Arg Pro Ser Pro Phe Cys Trp Pro Leu Cys Glu Ile Ser Arg Gly
 195 200 205
 Thr His Asn Phe Ser Glu Glu Leu Lys Ile Gly Glu Gly Gly Phe Gly
 210 215 220

Cys Val Tyr Arg Ala Val Met Arg Asn Thr Val Tyr Ala Val Lys Arg
 225 230 235 240

Leu Lys Glu Asn Ala Asp Leu Glu Trp Thr Ala Val Lys Gln Ser Phe
 245 250 255

Leu Thr Glu Val Glu Gln Leu Ser Arg Phe Arg His Pro Asn Ile Val
 260 265 270

Asp Phe Ala Gly Tyr Cys Ala Gln Asn Gly Phe Tyr Cys Leu Val Tyr
 275 280 285

Gly Phe Leu Pro Asn Gly Ser Leu Glu Asp Arg Leu His Cys Gln Thr
 290 295 300

Gln Ala Cys Pro Pro Leu Ser Trp Pro Gln Arg Leu Asp Ile Leu Leu
 305 310 315 320

Gly Thr Ala Arg Ala Ile Gln Phe Leu His Gln Asp Ser Pro Ser Leu
 325 330 335

Ile His Gly Asp Ile Lys Ser Ser Asn Val Leu Leu Asp Glu Arg Leu
 340 345 350

Thr Pro Lys Leu Gly Asp Phe Gly Leu Ala Arg Phe Ser Arg Phe Ala
 355 360 365

Gly Ser Ser Pro Ser Gln Ser Ser Met Val Ala Arg Thr Gln Thr Val
 370 375 380

Arg Gly Thr Leu Ala Tyr Leu Pro Glu Glu Tyr Ile Lys Thr Gly Arg
 385 390 395 400

Leu Ala Val Asp Thr Asp Thr Phe Ser Phe Gly Val Val Val Leu Glu
 405 410 415

Thr Leu Ala Gly Gln Arg Ala Val Lys Thr His Gly Ala Arg Thr Lys
 420 425 430

Tyr Leu Lys Asp Leu Val Glu Glu Glu Ala Glu Glu Ala Gly Val Ala
 435 440 445

L u Arg Ser Thr Gln Ser Thr Leu Gln Ala Gly Leu Ala Ala Asp Ala
 450 455 460

Trp Ala Ala Pro Ile Ala Met Gln Ile Tyr Lys Lys His Leu Asp Pro
 465 470 475 480

Arg Pro Gly Pro Cys Pro Pro Glu Leu Gly Leu Gly Leu Gly Gln Leu
 485 490 495

Ala Cys Cys Cys Leu His Arg Arg Ala Lys Arg Arg Pro Pro Met Thr
 500 505 510

Gln Val Tyr Glu Arg Leu Glu Lys Leu Gln Ala Val Val Ala Gly Val
515 520 525

Pro Gly His Leu Glu Ala Ala Ser Cys Ile Pro Pro Ser Pro Gln Glu
530 535 540

Asn Ser Tyr Val Ser Ser Thr Gly Arg Ala His Ser Gly Ala Ala Pro
545 550 555 560

Trp Gln Pro Leu Ala Ala Pro Ser Gly Ala Ser Ala Gln Ala Ala Glu
565 570 575

Gln Leu Gln Arg Gly Pro Asn Gln Pro Val Glu Ser Asp Glu Ser Leu
580 585 590

Gly Gly Leu Ser Ala Ala Leu Arg Ser Trp His Leu Thr Pro Ser Cys
595 600 605

Pro Leu Asp Pro Ala Pro Leu Arg Glu Ala Gly Cys Pro Gln Gly Asp
610 615 620

Thr Ala Gly Glu Ser Ser Trp Gly Ser Gly Pro Gly Ser Arg Pro Thr
625 630 635 640

Ala Val Glu Gly Leu Ala Leu Gly Ser Ser Ala Ser Ser Ser Ser Glu
645 650 655

Pro Pro Gln Ile Ile Ile Asn Pro Ala Arg Gln Lys Met Val Gln Lys
660 665 670

Leu Ala Leu Tyr Glu Asp Gly Ala Leu Asp Ser Leu Gln Leu Leu Ser
675 680 685

Ser Ser Ser Leu Pro Gly Leu Gly Leu Glu Gln Asp Arg Gln Gly Pro
690 695 700

Glu Glu Ser Asp Glu Phe Gln Ser
705 710

<210> 6
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Primer

<400> 6
acttctcgga ggagctcaag atc

23

<210> 7
<211> 22
<212> DNA
<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 7

gcatacaccg tgttcctcat ca

22

<210> 8

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Probe

<400> 8

cgcccggtag acgcacccaa

20

<210> 9

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 9

gaaggtgaag gtcggagtc

19

<210> 10

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 10

gaagatggtg atgggatttc

20

<210> 11

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Probe

<400> 11

caagcttccc gttctcagcc

20

<210> 12

<211> 13000

<212> DNA

<213> Homo sapiens

<400> 12

ctcacatgac agcatggtgc tgcgtttcct cattggatct ggctgtccct ggacacaggt

60

agctgccttc aggctgcca cgagcggcca aggaagcct cctccatag ctggcctcgc

120

tggccccctca gcttcttcca agccagtgt ctccaggcac actgctccag cgtgtgacgg

180

gaagggcctg gcatgagtca gcctgcagca caacctccct gctccagacc cgtatggtag

240

gggcaccccc taggtctgga tgtgtgtgtg tgcttttgga cccccacc cccgcaggct

300

gtggctcctc ctgtgtctca ttctggccag gacctcacg tgccctctgt tgactgctaa

360

cgtggttctc tgaccaggca agggcaggct gaggggtttg cccaaagggg gcccccttgt	420
tactggcttc cttggctctc aggagcagcc tcaccagggt ggtaaggggc tggaggagac	480
aactgctcaa aggagtccag cttcacatgc acatgctaga aggtaccctc ggaaggcctg	540
gccttcaaag gtagatccca gggttgaaaa gtcaacttgt atgcattgag catctcgtat	600
gccagccctg ttccgtgagc tgatgggcct ttgtgtgtaa gtaggaccaa gtgccccctg	660
ggaggttagc atgggtgtgc agtcatttca gatacttgag ttggtacatc tcagtaaagt	720
ctgtcccgtg agaagccatg ggtttcatgg tatggtggc atcttccttg ggagtggcca	780
cagtgggtgt ggcttcagga aagagactcc aacaggggcc agctgtgggc cttgggcact	840
tctcgtttct aggaaaagtc ctaagtctgt agggctaggg gtggggaacc ccttcgctgt	900
caggatcaag agggcaaggg gaactgtcgc tggaggagac atccagctgg agaaacaaaa	960
gagtaagtct gcgttgctgc ttgtggggtc ttcccatct cagggcgggg accgggggtg	1020
gcggtccaga caagtaatca aggacgatgc ccaggagggg acaggtagcg ggtggcagga	1080
gctctgccgg cgggctcagg aagccttcac cacagctgcc tgagctcacc cttgccaaat	1140
gagggctggg gcagcagcaa cgcatacact cacggctgtg gcgggcagcg ttctcggcat	1200
atttcaggac acctaaggag actgaatggc tcaaggctgc tgccgtgtgc agggggctag	1260
acgtggggcg ggcaggcagg gctcctggtg acagccctgc aggccgcagt ggagagcagg	1320
gttccggcag ggccgccag gagctttcgg aaggccggc cccggcccct ttccgagcag	1380
cccgggcctc cgccctgccc tctgtcccca acgcccggg cgcgcgttcg tcctccagag	1440
ccccgccgg gcgagcccgg gagggcgatc gccgctcgc gaaccgccg ggaccgggc	1500
cctccccggc gcggggcgcc cccgtgtgac ccagcgcgc gccgcggcgc gcaagatggc	1560
ggcggggccg ggcaccgcc cttccgcccc gccgggcgtc gcacgaggcc ggctcgaagg	1620
ggaagtgagt cagtgtccgc ggaccggcc gggccaggcc cgcgccgcg gcggccctga	1680
gaggccccgg caggtcccgg cccggcgcg gcagccatgg ccggggggcc gggccccggg	1740
gagcccgag cccccggcgc ccagcacttc ttgtacgagg tgccgccctg ggtcatgtgc	1800
cgcttctaca aagtgatgga cgccctggag cccgccgact ggtgccagtt cgggtgggtg	1860
cggcgggctg ccggggggcg ggaggcgcg gggctcctgg cgccgacgcc tgacgcccc	1920
cgccccgag ccgccctgat cgtgcgcgac cagaccgagc tcgggctgtg cgagcgctcc	1980
gggcagcgca cggccagcgt cctgtggccc tggatcaacc gcaacgccg tgtggccgac	2040
ctcgtgcaca tcctcacgca cctgcagctg ctccgtgcgc gggacatcat cacagcctgt	2100
gagcgcggga ctccgggcac cccacggctg ggaggccggc gggccccacg gggctcccc	2160
accggggcct caaccttctt ttcttctctt ggcgtcccag ggcacctcc cgccccgctt	2220
ccgtccccag gcaccactgc cccgaggccc agcagcatcc ctgcacccgc cgaggccgag	2280
gcctggagcc cccggaagtt gccatcctca gctccacct tccttcccc aggtgaagagg	2340
gcccggttgt taggctcggg ggacccaaag aagagccac cttgaccag gccacggctg	2400
tagaccctgc tgctggtctc tgctgcctc tcaactggtg ctttatgaag cttttccagg	2460

ctcccagacc cattcagggc ctgagctcgg cctggtccca agccctgctt ccctgtggcc	2520
tccaccgccca tctccagccc cttctttctac caaggtaggt gtcccctgcc ccccagggaa	2580
gattcgagac aaggaggaag gaattcagcc tttgatgtag cgcagagccc cagtcagcca	2640
agctgggtca gctgggaggc agctgtggtg gggagagcct ggagccttg gagaagggga	2700
agagacaggg accccacctg atccaggctc tcttcccaca gccaggccca gagagctcag	2760
tgctccctcct gcagggagcc cgcctcttct cgttttctgt gcccctctgt gagatttccc	2820
ggggcaccca caacttctcg gaggagctca agatcgggga ggggtgcttt ggggtgctgt	2880
accgggcggt gatgaggaac acgggtgtatg ctgtgaagag gctgaaggag gtgagtgtcg	2940
caccctggca gggaccctgg aaggccatca gataaccctc accacttctc cagcctttcc	3000
ccctcgcttc cccacacaac tccttcagcc ctctattctgg cgtagggtcc ctggcccctt	3060
gggtggttctg ggcctcgggt aggtggcact ggtggcccga aggccttcgc ttcgagagcc	3120
tcacgctgcc cgtcttccct gccccttccc ccaccgcacc ctgggggctg cagaacgctg	3180
acctggagtg gactgcagtg aagcagagct tcctgaccga ggtggagcag ctgtccaggt	3240
gagggcagag ggggagccac accaggtccc gtggggcttc agaccgcaca ccacaggacc	3300
tggtccctt gggcacctga ggcctggcag gcccgggcga gctgaggccc cagccagggc	3360
tgcccaccca gtctggcctg atggaaagtg ctcccctttt tcaaacaggt ttcgtcacc	3420
aaacattgtg gactttgtg gctactgtgc tcagaacggc ttctactgcc tgggtgtacgg	3480
cttctgccc aacggctccc tggaggaccg tctccactgc caggtaggct cacctggccc	3540
ggcacgcttc ccaggaccca aagcactcct gacacctggc tggagccggg cgcggggcct	3600
agggttttca gcctgtgtga gtgggtcctg ccagcaggcc aggcctgcac ttccagctcc	3660
ccagcagcac ccggctcagg atttggccca cgggtgggtc aatttttttt tttttttttt	3720
tttttttttt tttgaggtgg agtcttgctc tgtcatccag gctggagtgc agtggtgtga	3780
tctcagctca ccacaacctc caccctcccg gttcaggcga tcctcctgcc gcagcctccc	3840
gagtagctgg gactacaggc atgcaccacc acacctgcct aatttttgta ttttttagtag	3900
agatgaggtt ttgccacatt ggccaggcta gtctcgaact cctgaccca ggtggtctgc	3960
gcgcctcagc ctcccaaagt gctgggatta caggcgtgag ccaccacgcc tggcccagacc	4020
caatgttttc tatagagctc tttcccaggc ctctcccctt tgcaagcagc gtagctggag	4080
ggtctcatca gcaagccccg gaggcgaggg ggtctggggc taccagctgg accacctaca	4140
gctgagggag ggcccccttg cctcctcctg catgctgctt ttggggagag cgggaagaat	4200
gccttcaagg acttcccagc caccagggac aaagggatga gccctgggag ccgaagccca	4260
gcagattcta ttgaacgtgt ccccagccat tgcttaagaa gtgcaggctca cggagacttt	4320
gctcctcgtt ttccagaagg gggaaactga ggcctagaga gtgaagtggc tgttccaggc	4380
tgcacggtga caggtagaag gatggttggg atcaaggaac ggccatccag caacctcccc	4440
tgtccccctt tgccaccca gaccaggcc tgccacctc tctcctggcc tcagcgactg	4500
gacatccttc tgggtacagc ccgggcaatt cagtttctac atcaggacag cccagcctc	4560
atccatggag acatcaagag gtgaggaggg gcccttgaga actgccgggg cagggcctgc	4620

agcaaggggg gccccgcgtc ctatcaatgt ggggatcagg catggcctgg gacctcaaca	4680
ccccggcatc gcacagggtgt gggaacgggc caaggatggg ccctactgat gagcagaggc	4740
ccccaggcag ctggagcgtc cagggcagtg ccagcgcttt ctgtgggcaa ggcaccgggc	4800
tggcagcctc gagtccagcc ttatctaagc cgggcaggtg taggagctag gaccgggctg	4860
acgccactgt cttctctccc caagttccaa cgtccttctg gatgagaggc tgacacccaa	4920
gctgggagac tttggcctgg cccggttcag ccgctttgcc ggggccagcc ccagccagag	4980
cagcatggtg gcccggacac agacagtgcg gggcaccctg gcctacctgc ccgaggagta	5040
catcaagacg ggaaggctgg ctgtggacac ggacaccttc agctttgggg tggtagacca	5100
ctgacccctc tgctggctca gaggaggaga agccacaggc aggcagaggt gggggctgca	5160
gagtgcactg cggggccaggg gccatctgcc aagaccccag gaggctgcag ctccagggtc	5220
cccctccctc cgaggccctc ctccctaccc tgcacctaac tgtgtgtttg taatttgtct	5280
tcaagtgggc tctccgagtt gcccgagctt cagtcccata acatctggct ctgcctttgt	5340
ccacaccctt gtcaggccca atccatgtcc acaccagagg cctcttccct gccaaggcca	5400
ctgccatgct ctccctcttc cctctctcca ggtagtgcta gagaccttg ctggtcagag	5460
ggctgtgaag acgcacggtg ccaggaccaa gtatctggtg agccccttga ggcagggcca	5520
ggagggacac acagctgctg gcagccagca ggcacagccc cagtggcggg gataactggg	5580
gcgcagtgcc catggatgcc tctgctgcc cagtggcctc atttttgaaa gtaggcaggg	5640
ctccaaacaa cttcgtttac cttgccgagg acaaacctgt ctgtcctgca gacactatgg	5700
gccttgtaga gacccacct gggctggggg cagggggaag ggcggtccca gggcactgag	5760
acccaagctg cagtggaact cagaggactc tggccggaga aaggcggtgg tagagaagaa	5820
gcaggccccg aggaacctcc tgggccccag caggctgcag ctgagctctc cgcaccgtgc	5880
agggcagcct gagctgcctc acggtcttac tccactcagt ctgcctcacc gtggactgtg	5940
gtggggccag gagactagag acctggggtt tagccccagc ctgacagtgg ccttcagca	6000
aattcctgct cccctgtggg cctgttttcc catatgcaaa acagacttca cagaatgtgc	6060
tcagccagta attgcttcac tgcttctcct cttgtttggg gcggttcctg tgtgctgtgg	6120
ggtctccgtc aggattcagc cccgctgaga acccaggagc cgggcttgag cctccttcc	6180
tttcccttcc ccgtccgtcc atccatgcat cctgctgaag aagcgacca ggctccttgg	6240
gggtccttgg acttccccac ttgctcccca ccctgcagcc aaagtgtct tttcaaaggc	6300
ccctttgcct tttctctgct cttggggtga aggccagtc ccttatgtgg ttgaccccc	6360
aacgccccag gtccctggga ctcggggcgc tccctgctgc ctgcttcaca gccttagtat	6420
gtgccgttcg ctctgcgaga aaagccaccg cccaccagc tggttcctcc tggctgtct	6480
gatttcagaa ctggagatgg cctccggtcc tgtttccacc ctgggggcgc ctctctgcgg	6540
ggcgctctc tctctggggt acctcttctg ctgtggggca cctctctgtg gggcgcttcc	6600
cttctcggtc ctgccctctc aggctacttc ctgccttcag accccagctc catggggctc	6660
tccccacca ggaagtcagc tctgtcaaac cgggtccag ggttctgttt gttcctgtat	6720

ccctagggcc cagagcacca ctggcccaca gtaggtgttt aataaatctc tagaagctac	6780
tcgggaatct gaggcaggag gatcgcttga gcctgggagt tggagaccag cctgggcaac	6840
atagcaagat aggcattgtg gtacacacct gtaatccag ctgctcggga ggccgaggtg	6900
ggaggatcac gaggctggga ggttgaggct gcaactgacc atgattgcac cactgcactc	6960
cagcctgggt gacagaatga gtccctgtct cagaaaaaaa gtaagttgta gaaagaccaa	7020
gagctgtggc acagtgtctc acacctgtaa caccagcact ttgggaggct gaggcgggag	7080
gatcacttga gcctacttgg agaccagcca ggccaacaaa gcgagacccc atctcttttt	7140
tttttttttt tttttttatc aaaaccata cgattgagt acaaggacct gaggactgca	7200
gctgcagggtg tggccacctg gtagccatac tgacagtatt tatcccacag aaagacctgg	7260
tggaagagga ggctgaggag gctggagtgg ctttgagaag caccagagc aactgcaag	7320
caggtctggc tgcagatgcc tgggtgtctc ccatcgccat gcagatctac aagaagcacc	7380
tggaccccag gcccgggccc tgcccacctg agctgggctt gggcctgggc cagctggcct	7440
gctgctgcct gcaccgccg gccaaaagga ggcctcctat gaccaggta gccagctgcg	7500
cactgggacg ggggtggccag atagaaagcc cgcattccag gccttgtctt gtagtgacc	7560
catctcagca cctgctaggt ctctctggag tctccacaca tttcttctt gccctttgtt	7620
tctgtttggg gcagcgcccc tctgaactga gggggcccg gcagtcctgc tttgcggagc	7680
ccagctccga ccccttcac atagagagaa ggaaagagct gctgccgcgc cccctgctgg	7740
gcgcaactga ctactgcac tgcccttttc tgtccctcc ctagtacccc acctcttctc	7800
ctctgggtgac agttgaaaat ggagaggccc cgtttgagg cagcggggca gtgagattca	7860
ttttgtagaa aagaacgagg ccattctcag tccttgcttt tggcagccgc gcttctcagc	7920
actccctgtg atgggaacag aggggcgagg ggcagagcgt tcccagctgc agggatatgc	7980
attttagagc cctggggcag gtcacggacg gcctggagca gccctgttgt ttgcccacgg	8040
ggtgaccggc cagggtgcc atctcaccct gagagtcct cttttccact tgcagggtga	8100
cgagaggcta gagaagctgc aggcagtgtt ggcgggggtg cccgggcatt cgaggccgc	8160
cagctgcac ccccttccc cgcaggagaa ctctacgtg tccagcactg gcagagccca	8220
cagtggggct gctccatggc agcccctggc agcgccatca ggagccagt cccaggcagc	8280
agagcagctg cagagaggcc ccaaccagcc cgtggagagt gacgagagcc taggcggcct	8340
ctctgctgcc ctgcgtcct ggcacttgac tccaagctgc cctctggacc cagcaccct	8400
cagggaggcc ggctgtcctc agggggacac ggcaggagaa tcgagctggg ggagtggccc	8460
aggatcccgg cccacagccg tggaaggtag ctggggagac gggttcccag gagagggacc	8520
aaggcctctt tggggccaaag cccctgtaag tccccacccc agccttctag aagagaacca	8580
ggggccaaatg ttcagctcac tgtgacctta gcaaccctgg tttcccctcc ccaggccaca	8640
tccttcccag gtggagcttg ctctccagcc ctccccccac ccattctctg aaggctggga	8700
acaaggaggg ctctgtcttg tagcctgaga gctggggcct gcccttgac ttctctgagg	8760
aattcaggcc tgaggccagg gaggcagggt gctaggctgc gggctgggga gccacagcat	8820
gaggctaagg gagtgcac tccaccccag gactggcct tggcagctct gcatcatcgt	8880

cgtcagagcc accgcagatt atcatcaacc ctgcccgcaga gaagatgggtc cagaagctgg 8940
 ccctgtacga ggatggggcc ctggacagcc tgcagctgct gtcgtccagc tccctcccag 9000
 gtgctgccgc ccaggctggc ctctgggggtg ctcaggcgca tccgtgtcag ccccaaagag 9060
 cagagtgtct gtccccactg cgctgagggc gtggggcagc cgggcaggcc actggctctg 9120
 gcgacctcta gaagcccagc cggccccaca tgcctccctt agcaagaccc tggcccactc 9180
 cttccctcgc ctctgtacag tagcacctcc tttagcccga ggggtgcctgc cccactctgt 9240
 gctttcagga aataggaagc cccagcagga attttccatc ccaggctacta tttgaagaac 9300
 cactgcttag gaaccctcag ctggggcgagg tggctcatgc ctataatacc agcacttttg 9360
 gaggccaaga tgggaggatc acttgagccc aggaggtgga ggctacagtg agctgtgatc 9420
 aagccactgc actccagcct gggagacagt tagacctgt ctcaaaaaca aatgaacaaa 9480
 caaacaacaaa ccctcaattc ccacgaacgc cccaggagat aaggagcat ggcccaggcc 9540
 ttgagccagg gcttctggca gtaggggagc ctccccatt tgctaagcgg actttcctct 9600
 tccttctgta ggcttgggccc tggaaacagga caggcagggg cccgaagaaa gtgatgaatt 9660
 tcagagctga tgtgttcacc tgggcagatc ccccaaacc ggaagtcaaa gttctcatgg 9720
 tcagaagttc tcatgggtgca cgagtcctca gcactctgcc ggagtgggg gtggggggccc 9780
 atgcccgcg ggagagaaag gaggtggccc tgctgttcta ggctctgtgg gcataggcag 9840
 gcagagtgga accctgcctc catgccagca tctgggggca aggaaggctg gcatcatcca 9900
 gtgaggaggc tggcgcatgt tgggaggctg ctggctgcac agaccctga ggggaggaga 9960
 ggggctgctg tgcaggggtg tggagtaggg agctggctcc cctgagagcc atgcagggcg 10020
 tctgcagccc aggcctctgg cagcagctct ttgccatct ctttggacag tggccaccct 10080
 gcacaatggg gccgacgagg cctagggccc tcctacctgc ttacaatttg gaaaagtgtg 10140
 gccgggtgcg gtggctcacg cctgtaatcc cagcactttg ggaggccaag gcaggaggat 10200
 cgctggagcc cagtaggtca agaccagcca gggcaacatg atgagacct gtctctgcca 10260
 aaaaattttt taaactatta gcctggcggtg gtagcgacg cctgtgggtc cagctgctgg 10320
 ggaggctgaa gtaggaggat catttatgct tgggaggctg aggtctcagt gagtcatgat 10380
 tgtatgactg cactccagcc tgggtgacag agcaagaccc tgtttcaaaa agaaaaaccc 10440
 tgggaaaagt gaagtatggc tgtaagtctc atggttcagt cctagcaaga agcgagaatt 10500
 ctgagatcct ccagaaagtc gagcagcacc cacctccaac ctggggccag tgtcttcagg 10560
 ctttactggg gacctgcgag ctggcctaata gtgggtggcct gcaagccagg ccatccctgg 10620
 gcgccacaga cgagctccga gccaggctcag gcttcggagg ccacaagctc agcctcaggc 10680
 ccaggcactg attgtggcag aggggccact acccaaggct tagctaggcc caagacctag 10740
 ttaccacagac agtgagaagc ccctggaagg cagaaaagtt gggagcatgg cagacaggga 10800
 agggaaacat tttcaggga aagacatgta tcacatgtct tcagaagcaa gtcagggttc 10860
 atgtaaccga gtgtcctctt gcgtgtccaa aagtagccca gggctgtagc acaggcttca 10920
 cagtgatattt gtgttcagcc gtgagtcaca ctacatgccc ccgtgaagct gggcattggg 10980

gacgtccagg ttgtccttga gtaataaaaaa cgtatgttgc aatctcgggc tctacttgtg 11040
 gactttgttg caccgaaagc cttgagcttt cctgatgcct tacacttcag ggttcttgag 11100
 cgtccaggggt cttgttacta ctctgggctg gccacacca gcacttcccg tgtcagggtt 11160
 ttctgatgt agtccatgtt ttttatgcta ttctaaatgg tatctttgat tttctagttc 11220
 atcatgatat tatacagaaa tgcaattgat gctgggcacg gtggctcacg cctgtgattc 11280
 cagcgctttg ggaagctaag gcgggcagat cacttgaggc caggagtgtg agaccagcct 11340
 gggcaacatg gcgaaacccc gtctctacaa aaagtacaaa aattagccag gcatggtggg 11400
 gcatgcctgt agtttgagct actcaggagg ctgaccagg aggatagttt gagcccagga 11460
 cgttgaggct gcagttagcc atgattccac cactgcactc cagcccgggc aacagagggg 11520
 gaccttgcct caaaaaaaaaa aaaaaaaaaa aaaaaagcgg ttgagttttg catatgaacc 11580
 gtatatcttg tgacctgtt taaattcttt tttttttttc tttttttgag atggagtttt 11640
 gctcttgttg ccaggtctgc agtgcaatgg cgctatctca gctcactgca acctctgcct 11700
 cctaggttca agtgattctc ctgcctcagc ctcccagagta gctgggatta cagggtgcca 11760
 ccaccacacc cggctaattt ttttgtattt ttaatagaga cagggtttcc acatgttgac 11820
 caggctgggc tcgaactcct gacctccagt gatccgccc cctcggcctc ccaaagtgc 11880
 agattacagg tgtgagccac tgcacctgtc cctggctgtc tgtatattta cttttttttt 11940
 tgagatggag tttcgtctt gtcacccagg ctgcagtgc atggtgcgat ctcggtcat 12000
 tgtaacctct gcctcccagg ttcaggatg tctcctgcct cagtctcccg agtagctggg 12060
 attacaggcg tccgctacca cgcccactg atttttctat ttttagtaga gacgggggtt 12120
 caacatgttg gccagtctga tctcgaactc ctgacctcag gtgattcacc cacctcagcc 12180
 tcccaaagtg ctgggattac aggtatgagg cactgtgccc ggcttttttt tttttttttt 12240
 ttttcttcag acaagagtct tactctgtca ccaggctga agtgacgtgg tgcaatcttg 12300
 gctcactgca acctccgcct ccagggttca agcgattctt ctgcctcagc ctccatagta 12360
 gctgggacta cagggtgtgt ccaccacgcc cagctaattt ttatattttt atttagtaga 12420
 gacaagggtt caccatgttg gccaaagtgg tctcgaactc ctgacctcaa gtgatctgcc 12480
 cgcctcagcc tcccaaagtg ctgggattac aggtgtgagc cgtggcacc agcccagcct 12540
 tattctttta aacaatctga caatctctgc ctttagttgg tctgtttaat ccatttccat 12600
 ttaatggttg gagttaagtc tatcatcttg ttatttgttt tctattacc catctgtttt 12660
 gacttttgga ttaattacat atttctggga ttctgttttt tctctgctat tggcttggtc 12720
 gctctagtaa ttcagtgaga ctgctggttc cgctcaggcc cctttgctga accatggtgt 12780
 gaaagtgcct ccaggcagaa actcagggtg cttgtaaggc tcaccttctt tgttttctct 12840
 ctggtcacag ccctgcacag cctattgtcc gatatctaaa aatagttgcc cagtgtttta 12900
 ggtgtttaca actggcatca gttattccac tgtggccaga attgcaagtt tctcctcttt 12960
 tctgaggact tcttactca taatgtcacc cgacatgatc 13000

<210> 13
 <211> 754

<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (625)..(625)
<223> n is a, c, g, or t

<400> 13
ggagaccttg gctggtcaga gggctgtgaa gacgcacggt gccaggacca agtatctgaa 60
agacctggtg gaagaggagg ctgaggaggc tggagtggct ttgagaagca cccagagcac 120
actgcaagca ggtctggctg cagatgcctg ggctgctccc atcgccatgc agatctacaa 180
gaagcgctg ggccagctgg cctgctgctg cctgcaccgc cgggccaaaa ggaggcctcc 240
tatgaccag gtgtacgaga ggctagagaa gctgcaggca gtggtggcgg ggggtgccgg 300
gcatttggtg gccgccagct gcatcccccc ttccccgcag gagaactcct acgtgtccag 360
cactggcaga gccacagtg gggctgctcc atggcagccc ctggcagcgc catcaggagc 420
cagtgtccag gcagcagagc agctgcagag agggcccaac cagcccgtgg agagtgcga 480
gagcctaggc ggcctctctg ctgccctgcg ctccctggcag ttgactccaa gctgccctct 540
ggaccagca cccctcaggc aggcgggctg tcctcagggg gacacggcag gagaatcgag 600
ctgggggagt ggcccaggat cccngccac agccgtggaa ggactggtcc ttggcagctc 660
tgcacatcg tcgtcagagc caccgcagat tatcatcaac cctgcccgcac agaagatggt 720
ccagaagctg gccctgtacg aggatggtgc cctg 754

<210> 14
<211> 577
<212> DNA
<213> Homo sapiens

<400> 14
gaggccgagg cctggagccc ccggaagttg ccacccctcag ccgccacctt cctctcccca 60
gcttttccag gctcccagac ccattcaggg cctgagctcg gcctgggtcc aagccctgct 120
tcctgtggc ctccaccgcc atctccagcc tgggtgacag agcaagacc tgtttcaaaa 180
agaaaaacc tgggaaaagt gaagtatggc tgtaagtctc atggttcagt cctagcaaga 240
agcgagaatt ctgagatcct ccagaaagtc gagcagcacc cacctccaac ctggggccag 300
tgtcttcagg ctttactggg gacctgcgag ctggcctaata gtggtggcct gcaagccagg 360
ccatccctgg gcgccacaga cgagctccga gccagggtcag gcttcggagg ccacaagctc 420
agcctcaggc ccaggcactg attgtggcag aggggccact acccaaggtc tagctaggcc 480
caagacctag ttaccagac agtgagaagc ccctggaagg cagaaaagtt gggagcatgg 540
cagacaggga agggaaamat tttcaggga aagacat 577

<210> 15
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 15
cctggcttgc aggccaccac 20

<210> 16
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 16
gatgccagcc ttccttgccc 20

<210> 17
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 17
cagtggagac ggtcctccag 20

<210> 18
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 18
cttgtggcct ccgaagcctg 20

<210> 19
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 19
ggacgacagc agctgcaggc 20

<210> 20
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 20
tctgcagcca gacctgcttg 20

<210> 21
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 21
agccagacct gcttgacgtg 20

<210> 22
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 22
gtgaagcctg tgctacagcc 20

<210> 23
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 23
tggcaccagt cggcgggctc 20

<210> 24
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 24
gaccatcttc tgcggggcag 20

<210> 25
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 25
ccagccttcc cgtcttgatg 20

<210> 26
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 26
agccagcagc ctccaacat 20

<210> 27
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 27
tcagctctga aattcatcac 20

<210> 28
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 28
cagtccttcc acggctgtgg 20

<210> 29
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 29
ccaaggtctc tagcactacc 20

<210> 30
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 30
ctaggtcttg ggcctagcta 20

<210> 31
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 31
acaccgtggt cctcatcacc 20

<210> 32
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 32
ctctgaaatt catcactttc 20

<210> 33
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 33
tgggtcatag gaggcctcct 20

<210> 34
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 34
gctcggagct cgtctgtggc 20

<210> 35
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 35
tggcaccgtg cgtcttcaca 20

<210> 36
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 36
cggcacatga cccagggcgg 20

<210> 37
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 37
tgaccagcca aggtctctag 20

<210> 38
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 38
ctcctcttcc accaggtctt 20

<210> 39
<211> 20
<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 39

tgaccatgag aactttgact

20

<210> 40

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 40

aagggccagt ccttccacgg

20

<210> 41

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 41

ctggacacgt aggagttctc

20

<210> 42

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 42

tgctggacac gtaggagttc

20

<210> 43

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 43

accatcttct gtcgggcagg

20

<210> 44

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 44

cttgacagtgt gctctgggtg

20

<210> 45

<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 45
ctggacagct gctccacctc 20

<210> 46
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 46
acagccctgg gctacttttg 20

<210> 47
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 47
ggaggcaggg ttccactctg 20

<210> 48
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 48
tgcagccaga cctgcttgca 20

<210> 49
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 49
cttgggtagt ggcccctctg 20

<210> 50
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 50
ggccagtcct tccacggctg 20

<210> 51

<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 51
tctgagcaca gtagccagca

20

<210> 52
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 52
cggagcagct gcaggtgcgt

20

<210> 53
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 53
aagcagggct tggaaccagg

20

<210> 54
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 54
cgatcttgag ctcctccgag

20

<210> 55
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 55
cacctcggtc aggaagctct

20

<210> 56
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 56
caggaagccg tacaccaggc

20

<210> 57
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 57
actgtctgtg tccgggccac

20

<210> 58
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 58
cagctggccc aggcccaggc

20

<210> 59
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 59
gcccggcggt gcaggcagca

20

<210> 60
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 60
gcttctctag cctctcgtag

20

<210> 61
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 61
ggctgccatg gagcagcccc

20

<210> 62
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 62
gcagctgctc tgctgcctgg

20

<210> 63
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 63
agagaggccg cctaggctct

20

<210> 64
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 64
cagagggcag cttggagtca

20

<210> 65
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 65
agggccagct tctggaccat

20

<210> 66
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 66
ggtgaacaca tcagctctga

20

<210> 67
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 67
agctgctgcc agaggcctgg

20

<210> 68
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 68
ttacagccat acttcacttt

20

<210> 69
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 69
aattctcgct tcttgctagg

20

<210> 70
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 70
ggccagctcg caggtcccca

20

<210> 71
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 71
ccttccctgt ctgccatgct

20

<210> 72
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 72
acgcaagagg acactcgggt

20

<210> 73
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 73
ggctgaacac aaaatcactg

20

<210> 74
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 74

tgactcacgg ctgaacacaa

20

<210> 75

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 75

atacgttttt attactcaag

20

<210> 76

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 76

agggaacata cgtttttatt

20

<210> 77

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 77

cctggaaaag cttcataaag

20

<210> 78

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 78

ctggcctcac ctggacagct

20

<210> 79

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 79

agaccctcca gctacgctgc

20

<210> 80

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 80
ggagagccca cttgaagaca 20

<210> 81
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 81
agctggctac ctgggtcata 20

<210> 82
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 82
tacagagcaa ggcctggaat 20

<210> 83
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 83
tccttctctc tatgtgaagg 20

<210> 84
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 84
aggccaagc ctacagaagg 20

<210> 85
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 85
aggccagctg gcccaggcgc 20

<210> 86
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 86
acccaggctg gagatggcgg 20

<210> 87
<211> 20
<212> DNA
<213> Homo sapiens

<400> 87
gtggtggcct gcaagccagg 20

<210> 88
<211> 20
<212> DNA
<213> Homo sapiens

<400> 88
gggcaaggaa ggctggcatc 20

<210> 89
<211> 20
<212> DNA
<213> Homo sapiens

<400> 89
ctggaggacc gtctccactg 20

<210> 90
<211> 20
<212> DNA
<213> Homo sapiens

<400> 90
caggcttcgg aggccacaag 20

<210> 91
<211> 20
<212> DNA
<213> Homo sapiens

<400> 91
gcctgcagct gctgtcgtcc 20

<210> 92
<211> 20
<212> DNA
<213> Homo sapiens

<400> 92
caagcaggtc tggctgcaga 20

<210> 93
<211> 20
<212> DNA
<213> Homo sapiens

<400> 93
cactgcaagc aggtctggct 20

<210> 94
<211> 20
<212> DNA

<213> Homo sapiens

<400> 94

ggctgtagca caggcttcac

20

<210> 95

<211> 20

<212> DNA

<213> Homo sapiens

<400> 95

gagcccgccg actggtgcca

20

<210> 96

<211> 20

<212> DNA

<213> Homo sapiens

<400> 96

ctgcccgaca gaagatggtc

20

<210> 97

<211> 20

<212> DNA

<213> Homo sapiens

<400> 97

catcaagacg ggaaggctgg

20

<210> 98

<211> 20

<212> DNA

<213> Homo sapiens

<400> 98

atgttgggag gctgctggct

20

<210> 99

<211> 20

<212> DNA

<213> Homo sapiens

<400> 99

gtgatgaatt tcagagctga

20

<210> 100

<211> 20

<212> DNA

<213> Homo sapiens

<400> 100

ccacagccgt ggaaggactg

20

<210> 101

<211> 20

<212> DNA

<213> Homo sapiens

<400> 101

ggtagtgcta gagaccttgg

20

<210> 102

<211> 20

<212> DNA
<213> Homo sapiens

<400> 102
tagctaggcc caagacctag

20

<210> 103
<211> 20
<212> DNA
<213> Homo sapiens

<400> 103
ggtgatgagg aacacggtgt

20

<210> 104
<211> 20
<212> DNA
<213> Homo sapiens

<400> 104
aggaggcctc ctatgaccca

20

<210> 105
<211> 20
<212> DNA
<213> Homo sapiens

<400> 105
tgtgaagacg cacggtgcca

20

<210> 106
<211> 20
<212> DNA
<213> Homo sapiens

<400> 106
ccgccctggg tcatgtgccg

20

<210> 107
<211> 20
<212> DNA
<213> Homo sapiens

<400> 107
aagacctggt ggaagaggag

20

<210> 108
<211> 20
<212> DNA
<213> Homo sapiens

<400> 108
agtcaaagtt ctcatgggtca

20

<210> 109
<211> 20
<212> DNA
<213> Homo sapiens

<400> 109
gagaactcct acgtgtccag

20

<210> 110

<211> 20
<212> DNA
<213> Homo sapiens

<400> 110
gaactcctac gtgtccagca

20

<210> 111
<211> 20
<212> DNA
<213> Homo sapiens

<400> 111
cctgcccgcac agaagatggt

20

<210> 112
<211> 20
<212> DNA
<213> Homo sapiens

<400> 112
caccagagc acactgcaag

20

<210> 113
<211> 20
<212> DNA
<213> Homo sapiens

<400> 113
gaggtggagc agctgtccag

20

<210> 114
<211> 20
<212> DNA
<213> Homo sapiens

<400> 114
caaaagtagc ccagggctgt

20

<210> 115
<211> 20
<212> DNA
<213> Homo sapiens

<400> 115
cagagtggaa ccctgcctcc

20

<210> 116
<211> 20
<212> DNA
<213> Homo sapiens

<400> 116
tgcaagcagg tctggctgca

20

<210> 117
<211> 20
<212> DNA
<213> Homo sapiens

<400> 117
cagaggggcc actacccaag

20

<210> 118
<211> 20
<212> DNA
<213> Homo sapiens

<400> 118
cagccgtgga aggactggcc

20

<210> 119
<211> 20
<212> DNA
<213> Homo sapiens

<400> 119
tgctggctac tgtgctcaga

20

<210> 120
<211> 20
<212> DNA
<213> Homo sapiens

<400> 120
acgcacctgc agctgctccg

20

<210> 121
<211> 20
<212> DNA
<213> Homo sapiens

<400> 121
cctgggtcca agccctgctt

20

<210> 122
<211> 20
<212> DNA
<213> Homo sapiens

<400> 122
ctcggaggag ctcaagatcg

20

<210> 123
<211> 20
<212> DNA
<213> Homo sapiens

<400> 123
agagcttcct gaccgaggtg

20

<210> 124
<211> 20
<212> DNA
<213> Homo sapiens

<400> 124
gcctggtgta cggcttcctg

20

<210> 125
<211> 20
<212> DNA
<213> Homo sapiens

<400> 125
gtggcccgga cacagacagt

20

<210> 126
<211> 20
<212> DNA
<213> Homo sapiens

<400> 126
tgctgcctgc accgccgggc

20

<210> 127
<211> 20
<212> DNA
<213> Homo sapiens

<400> 127
gtacgagagg ctagagaagc

20

<210> 128
<211> 20
<212> DNA
<213> Homo sapiens

<400> 128
ccaggcagca gagcagctgc

20

<210> 129
<211> 20
<212> DNA
<213> Homo sapiens

<400> 129
agagcctagg cggcctctct

20

<210> 130
<211> 20
<212> DNA
<213> Homo sapiens

<400> 130
atggtccaga agctggccct

20

<210> 131
<211> 20
<212> DNA
<213> Homo sapiens

<400> 131
ccaggcctct ggcagcagct

20

<210> 132
<211> 20
<212> DNA
<213> Homo sapiens

<400> 132
aaagtgaagt atggctgtaa

20

<210> 133
<211> 20
<212> DNA
<213> Homo sapiens

<400> 133
cctagcaaga agcgagaatt

20

<210> 134
<211> 20
<212> DNA
<213> Homo sapiens

<400> 134
tggggacctg cgagctggcc

20

<210> 135
<211> 20
<212> DNA
<213> Homo sapiens

<400> 135
agcatggcag acaggggaagg

20

<210> 136
<211> 20
<212> DNA
<213> Homo sapiens

<400> 136
aaccgagtgt cctcttgct

20

<210> 137
<211> 20
<212> DNA
<213> Homo sapiens

<400> 137
cagtgat ttt gtgttcagcc

20

<210> 138
<211> 20
<212> DNA
<213> Homo sapiens

<400> 138
ttgtgttcag ccgtgagtc

20

<210> 139
<211> 20
<212> DNA
<213> Homo sapiens

<400> 139
cttgagtaat aaaaacgtat

20

<210> 140
<211> 20
<212> DNA
<213> Homo sapiens

<400> 140
tgtcttcaag tgggctctcc

20

<210> 141
<211> 20
<212> DNA
<213> Homo sapiens

<400> 141

attccaggcc ttgctctgta

20

<210> 142
<211> 20
<212> DNA
<213> Homo sapiens

<400> 142
ccttcacata gagagaagga

20

<210> 143
<211> 20
<212> DNA
<213> Homo sapiens

<400> 143
ccgccatctc cagcctgggt

20

INTERNATIONAL SEARCH REPORT

International Application No

PCT/03/18003

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/11

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, SEQUENCE SEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GUO FUKUN ET AL: "Antisense IRAK-1 oligonucleotide blocks activation of NF-kappaB and AP-1 induced by IL-18" IMMUNOPHARMACOLOGY, vol. 49, no. 3, September 2000 (2000-09), pages 241-246, XP002257993 ISSN: 0162-3109 cited in the application page 242-244; figure 1 -----	1-20

☐ Further documents are listed in the continuation of box C.☐ Patent family members are listed in annex

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- * & * document member of the same patent family

Date of the actual completion of the international search

16 October 2003

Date of mailing of the international search report

03/11/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Hillenbrand, G

INTERNATIONAL SEARCH REPORT

International Application No. ...
PCT/US 03/18003

B x I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 15-20 are directed to a method of treatment of the animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-4, 10-20

A compound 8-80 nucleobases in length targeted to a nucleic acid molecule encoding IL-1 receptor-associated kinase-1, wherein said compound specifically hybridizes with said nucleic acid molecule encoding IL-1 receptor-associated kinase-1 and inhibits the expression of IL-1 receptor-associated kinase-1 (claim 1), wherein the compound is an antisense oligonucleotide which comprises at least one modified internucleoside linkage which is a phosphorothioate linkage, a composition comprising the compound of claim 1, a method for inhibiting the expression of IL-1 receptor-associated kinase-1 with the compound of claim 1, and a method of treating an animal with the compound of claim 1.

2. Claims: 1-2, 5-6

A compound 8-80 nucleobases in length targeted to a nucleic acid molecule encoding IL-1 receptor-associated kinase-1, wherein said compound specifically hybridizes with said nucleic acid molecule encoding IL-1 receptor-associated kinase-1 and inhibits the expression of IL-1 receptor-associated kinase-1 (claim 1), wherein the compound is an antisense oligonucleotide which comprises at least one modified sugar moiety.

3. Claims: 1-2, 7-8

A compound 8-80 nucleobases in length targeted to a nucleic acid molecule encoding IL-1 receptor-associated kinase-1, wherein said compound specifically hybridizes with said nucleic acid molecule encoding IL-1 receptor-associated kinase-1 and inhibits the expression of IL-1 receptor-associated kinase-1 (claim 1), wherein the compound is an antisense oligonucleotide which comprises at least one one modified nucleobase.

The attention of the applicant is directed to the fact that no search has been carried out for the multiplicity of different oligonucleotides listed in Table 1 of the description. Said structurally different sequences do not represent a common single inventive concept.